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Summary
The development of a vaccine against some strains of the human papillomavirus (HPV)
has led to many interesting public health questions [1]. We address some of these ques-
tions in the following work. We develop a compartmental mathematical model and
examine the effect of waning immunity, vaccinating individuals prior to their becom-
ing sexually active and the current government policy of vaccinating only females [2].
We calculate parameters based on data. We consider both time-dependent and age-
dependent ODE models and an age- and time-dependent PDE model and compare
the results. We find the “effective” R0 value, R
e
0, for the time-dependent models. We
introduce optimal control to both the time-dependent and age-dependent ODE models
to assess the most cost-effective method for introducing the vaccine into a population.
We find that the duration of protection offered by the vaccine can influence whether
it is possible to eradicate infection from the population. We find the critical proportion
to vaccinate to eradicate the disease. We see that introducing male vaccination would
lead to a greater proportion of individuals to be vaccinated if the disease is to be
eradicated. The PDE model shows that the proportion of females vaccinated has a
large impact on the proportion of females infected. We show that it is cost-effective to
vaccinate males and females. Our results support current government policy for age of
vaccination [2].
We conclude that potential waning immunity will impact the success of the vaccine.
We broadly support government policy for vaccination but recommend including male
vaccination to most cost-effectively eradicate the disease.
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Chapter 1
Introduction and Literature
Review
The aim of this thesis is to consider the effect that the implementation of a new health-
care policy has on the spread of an infectious disease in a population. More specifically,
we consider the introduction of a vaccination programme, targeted at a specific group
of individuals, for a sexually transmitted disease. We consider the implications of vac-
cinating individuals before they become sexually active and the possibility of waning
immunity from the vaccination. We model this mathematically, using compartmen-
tal, population-level models, represented by systems of differential equations. We also
assess the cost-effectiveness of the vaccination strategy using optimal control.
This research is motivated by the introduction of a national vaccination programme
against certain sexually transmitted strains of the human papillomavirus (HPV). This
vaccine is not the first against a sexually transmitted disease - vaccines exist both for
hepatitis B and herpes simplex type-2 (HSV-2) [9] - but neither of these are routinely
offered in the UK for adolescents [4]. In the UK, vaccination against HPV strains -16
and -18 is targeted at 12-13 year old females, with a ‘catch-up’ vaccination programme
being offered up to the age of 18 [5]. This vaccination policy means that the majority
of females are vaccinated before they become sexually active. Two questions naturally
arise; What happens if immunity provided by the vaccine wanes? If it does, how will the
interaction between waning immunity and many individuals being non-sexually active
when vaccinated impact on the potential success of vaccination? These questions are
addressed in the following work.
The second part of the research presented is concerned with the cost-effectiveness
of the vaccine. Unlike previous studies for the HPV vaccine, we consider this issue
by using optimal control to determine the most cost-effective method for vaccinating
10
individuals. We also consider whether male vaccination can be cost-effective, as current
policy is to only vaccinate females [2]. This research gives an interesting counterpoint
to the economic cost-effectiveness analyses that have so far been carried out [10, 11, 12].
1.1 Human Papillomavirus: Biological and Background
Information
A virus that is a causal factor in the development of cervical cancer, sexually transmit-
ted strains of the human papillomavirus (HPV) are thought to affect about 80% of the
sexually active female population at some point during their lives [13]. Of these, about
10-20% have a persistent infection (the definition of this differs greatly in the literature,
but most sources put it as somewhere between 6 months and 2 or more years), say an
infection lasting 2 or more years [14]. The likelihood of developing pre-cancerous lesions
increases with long-term infection; for type HPV-16, there is a 40% chance of cervical
intraepithelial neoplasia (CIN) after infection lasting 5 or more years [15].
Of over 120 different strains of HPV which have been identified, only about 40
are thought to infect the anogenital area, of which two strains, -6 and -11, cause 90%
of genital warts [16]. Further to that, only 13-18 of these strains are thought to be
carcinogenic [17]. The connection between HPV and cervical cancer has been suspected
since the 1970s, a discovery that was aided by the knowledge that papillomaviruses
cause cancer in animals [18]. Studies showed that HPV could be found in 99.7%
of cervical cancer tumours, leading the International Agency for Research on Cancer
(IARC) in 1995 to classify types HPV-16 and HPV-18 as carcinogenic [19]. Further
studies led to HPV types -31, -33, -35, -45 also being classified as carcinogenic [20], but
it is types -16 and -18 that are considered to be the most prevalent of the carcinogenic
types throughout the world, causing about 70% of all cervical cancer [17]. Since HPV
has been identified as a factor in cervical cancer (and now in some other genital and
anal cancers as well [17]), investigations have been under way to try and find a way of
preventing it. This is important because worldwide, cervical cancer is the second most
common form of cancer, with 493,000 deaths attributed to it in 2002. At present, 80%
of deaths occur in developing countries, with the proportion expected to rise to 90%
by the year 2020 [21]. It is one of the biggest causes of number of years of life lost [14].
Current processes for prevention and cure of cervical cancer and HPV rely mainly
on screening. In the UK, Pap smears are used to test for abnormalities in the cells at
the cervix, as this could be an indication of pre-cancerous lesions. Women are advised
to be tested at regular intervals, the intervals differing depending on age [6]. This
has been a successful policy - since the introduction of Pap smears 50 years ago, cases
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of cervical cancer have been reduced by approximately 50% [14]. However, there are
flaws in the system. Screening does not always reveal the presence of HPV-DNA, and
while there are tests that will do this more effectively, they are then less effective at
identifying pre-cancerous cells [22]. Also, not all women will be screened; the rate of
screening seems to be falling in the population as a whole, and some sectors of the
community traditionally have a poor uptake rate [15].
Two prophylactic vaccines have been developed that protect against some strains of
HPV, with a view to dramatically reducing the cases of cervical cancer. The vaccines
have been produced by Merck and GlaxoSmithKline; the Merck vaccine protects against
strains -6, -11, -16, -18, and the GlaxoSmithKline vaccine protects against strains -16
and -18 [15]. These vaccines are widely welcomed, as in testing they have shown close
to 100% efficacy against these strains of HPV [23]. As they are so new, it is not clear
how long they are expected to remain effective. Current trials show that they are still
effective after 5 years, but the true duration of protection will only become evident in
the next 10-20 years [18]. By preventing strains -16 and -18, these vaccines could play
a major part in reducing cervical cancer, but there are other factors to be considered.
Firstly, the cost of the vaccine is very high, and will almost certainly be prohibitive for
some countries; for the UK, vaccine cost has been estimated (without administration
costs) at approximately £60 per dose [10]. Secondly, the vaccine is a course of three
injections at 0, 2 and 6 months so there is a question about uptake. If an individual
does not complete the course, they will need to start the course from the beginning
again to be protected, which would be costly. However, the cost of screening and
treatment (if necessary) is also expensive, as is the treatment of genital warts. From a
cost-effectiveness viewpoint, questions also need to be raised about who should receive
the vaccine (Dushyant Mital, personal communication).
As evidence begins to emerge about a connection between HPV and other genital
cancers [17], it may indicate that males should also be vaccinated. Another consider-
ation is whether the vaccine could have a negative effect on the cervical cancer rates;
as HPV strains -16 and -18 only cause about 70% of all cervical cancer, there is some
concern that other carcinogenic strains will take their place. Also, some studies have
suggested that strains -6 and -11 can offer some protection against other, more car-
cinogenic strains, so reducing the rates of these may not be beneficial [24]. Studies into
whether an HPV-16/18 vaccine provides cross-protection against other strains have
been conducted, and some suggest that there is a high level of cross-protection against
HPV-31 and -45. The protection against -45 seems much higher, with 94% of vacci-
nated women also being protected against it, whereas 54% of vaccinated women were
protected against -31 [15]. Another concern is that women will assume they are fully
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protected once they have been vaccinated and so no longer need smears, although it
will still be crucial that women are screened [24]. Hildesheim et al. (2006) [1] gave the
issues still to be addressed, which included duration of protection, the optimal age for
vaccination, and how to implement the vaccine. These ideas provide a starting point
for developing a model to address some of the pertinent questions surrounding the HPV
vaccine.
Prior to building a model, it is important to understand how the human papillo-
mavirus works, and also how the vaccine works. One of the difficulties facing researchers
is that very little is known about this virus. It is not clear for example whether the
virus ever leaves the system once infected, or whether it enters a latent period [25]. It
is also not clear why some people and not others have a persistent infection, although
it is suspected this is due in part to the strain of the virus and in part to the host’s
susceptibility to the disease [25]. Another problem is that if a woman presents with
an HPV infection at two or three consecutive screening sessions, it is very difficult to
know whether it is the same infection each time or a different infection [25]. However,
as not all women with persistent HPV infections go on to develop cancer, questions
also remain as to why some women are susceptible when others are not. There are
some opinions on this; other risk factors such as smoking and the number of full-term
pregnancies are thought to play a part [19]. Also, is it not clear whether an individual
can develop natural immunity to the virus once infected [17]. The immune response
to HPV is not completely understood; it has been noticed that in some women with
skin warts there was a serum Immunoglobulin G (IgG) response (this is a response
that occurs towards the end of a first, or primary, immune response) to the virus. This
response only seems to occur in women who have had a previous infection, implying
that some memory of the virus remains in the body [20]. Man (1998) [26] suggests
that natural infection does not induce a strong antibody response and that the vaccine
will need to induce a strong response for prophylaxis to occur, and a study done in
Costa Rica found no evidence of protective immunity, and suggested that the immune
response from natural infection may not be strong enough to provide immunity [27].
Other issues arise, for example the majority of HPV infections are asymptomatic, so
people do not seek treatment, and therefore the true scale of the disease may never be
known. The strains that can display symptoms - namely, strains such as -6 and -11 that
cause genital warts - are not considered to be carcinogenic, so it is the more dangerous
strains that may be undetected. However, even if detected, much uncertainty remains.
For example, will the patient go on to develop cervical cancer? How long will it take for
pre-cancerous lesions (which may or may not lead to cancer) to manifest? This has been
measured at anything from a few months to several years [17]. If lesions do develop,
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what is the likelihood that they will progress to the more serious pre-cancerous stages,
or indeed, to cancer itself? These are currently all unknown quantities, and need to
be taken into account when developing a model. Studies have been undertaken to try
and determine more accurately the answers to these questions, but the results tend to
vary wildly, leaving us without a clear picture.
It is not yet fully understood what causes an HPV infection to progress to cervical
cancer. The length of time it takes for any lesions that develop to progress to cancer,
if indeed they do at all, is very variable; they can take anything from a few months
to several years. It is also thought the Human Leukocyte Antigens may play a part
in a person’s susceptibility to cancer. There are risk factors involved; a person’s age
and sexual history (number of lifetime partners, recent partners) are considered strong
indicators of the likelihood of contracting cervical cancer [17]. Other factors that could
increase the risk of developing cervical cancer are viral load, other sexually transmitted
infections (STIs), circumcision (may help reduce transmissibility), and condom use.
However, the evidence is not always particularly strong, and at times is contradictory.
Issues that still need to be explored are the natural history of the virus, and the viral
load pattern [28]. It is also not clear what can cause an HPV infection to become
persistent, or lead to cervical cancer, other than the HPV type and its variant. It
is thought that the host’s immune system probably plays a part. If reinfection does
occur, it is not clear whether this has anything to do with developing into a persistent
infection. While most women with HPV recover and do not develop cervical cancer,
an individual is 13 times more likely to develop a high-grade squamous intraepithelial
lesion (HSIL) from a persistent infection. From here, 13 to
2
3 of women with HSIL will
go on to develop cervical cancer if the HSIL is not treated [25].
1.2 Human Papillomavirus: Mathematical Modelling In-
formation
Mathematical modelling of biological situations has been done for centuries, with ev-
idence from as early as the 11th and 12th centuries confirming that attempts were
made to describe a biological situation in mathematical terms [29, 30]. From these
early days, the use of mathematics in aiding our biological understanding has grown
tremendously. One area in which mathematical modelling has proved very useful is
that of epidemiology, modelling the spread of a disease through a population. It has
been used to great effect in many situations and can be used in both a descriptive and
predictive role [31]. In particular, sexually transmitted infections (STIs) have generally
been of modelling interest - they have some very specific characteristics that need to
14
be considered, such as separation of genders, or contact structure. These ideas have
been widely used, for example, in modelling human immunodeficiency virus (HIV) in
populations, and comparing this to the effect of introducing an (as yet hypothetical)
vaccine into the population. These ideas can also be applied to the situation with HPV,
as described above.
Models relating to the transmission of HPV and the success of the vaccine are the
subject of this section. Hughes et al. (2002) [32] comprises two models:- one examines
the transmission of HPV in a population, the development into cancer (this is an
ODE model), and the effect of the vaccine; the other looks at the effect of reducing
cervical intraepithelial neoplasia (CIN) and (cervical) cancer through the use of the
vaccine, which is an ODE/PDE model. They employ the use of different sexual activity
groups as a means of dividing the population, a concept that other models also use.
Whether the vaccine reduces susceptibility, transmissibility of disease or mean duration
of infectiousness is considered. The models assume an arbitrary age at which people
enter the susceptible class, i.e. an arbitrary age at which they become sexually active.
They find that if the vaccine protects against -16 and -18, other high-risk types will fill
the gap and so cancers caused by them will increase. They assume a mean immunity
of 10 years with a vaccine that is 75% effective. The conclusion is that vaccinating
women is about 75% as effective as vaccinating men and women, but this again may
need to be checked against what is now known about the vaccine [32].
Many of the other models touch on slightly different aspects; Kohli et al. (2007) [33]
use a Markov process model to assess the impact of vaccination, carrying it through
to consider the effect on CIN and cervical cancer. The conclusions they reach suggest
that 100% coverage of pre-teenage girls could lead to around a 75% drop in deaths
from cervical cancer, but that the benefits of vaccination would decrease as the age
of vaccination increased. Goldie et al. (2003) [34] use a computer-based simulation
model to assess the effect of vaccination on the prevalence of HPV and pre-cancerous
stages. This model again uses Markov processes to model the situation. Under certain
assumptions, this model shows that a vaccine administered at age 13, even with differing
efficacy levels, could have a significant effect on the incidence of cervical cancer. They
also find that the proportion vaccinated is a key factor in the overall reduction of cervical
cancer. Barnabas et al. (2006) [35] construct a compartmental, deterministic model
dealing with infection of HPV and potential progression to cervical cancer. This model
allows for an HPV sufferer to become immune. They assume a type-specific lifelong
immunity once an individual has recovered, but allow for a ‘gradual loss of a detectable
antibody response’, as tests may not be sensitive enough to detect very low levels of
antibodies, and this assumption therefore allows for a comparison with test results. The
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model also divides the population into age groups with a 5 year spread (i.e. 0-4yrs,
5-9yrs etc), and also into sexual activity groups (four groups relating to the rate at
which an individual changes their sexual partner). The model is studied numerically,
as the population is divided into a large number of different classes. Their results
are similar to other conclusions, in that vaccinating men made very little difference,
and what was important was vaccinating the girls before they became sexually active
and achieving a high level of coverage. They did, however, assume the vaccine would
offer lifelong protection, or that it would be supplemented with boosters, so if this
assumption does not hold, the results could be quite different. Llamazares and Smith?
(2008) [36] is the only paper explicitly to include a compartment for non-sexually active
individuals, although it focuses on female-only vaccination, so does not mirror this with
an equivalent non-sexually active male class. They concentrate on the impact of the
efficacy and ‘take’ of the vaccine on the overall success of the vaccine.
The second part of the thesis relates to the most cost-effective way to introduce
the vaccine, and indeed whether vaccination is cost-effective. A comparison of the
current cost-effectiveness analyses suggests that the important assumptions are those
such as the effectiveness of the vaccine, smear tests and the model used for predictions.
Expansions to the models include ideas such as different options in using the vaccine
and epidemiological variables. The vaccine cannot replace screening, as types -16 and
-18 only account for about 70% of cervical cancer. In the USA there is a high cost
to screening as they use expensive testing methods and screen frequently [22], so the
vaccine along with a reduction in the screening programme may benefit them. Cost-
effectiveness analyses often include reduced quality of life as a cost, although this value
could be underestimated if aspects such as the effect the illness and treatment has on
the rest of the family are not included. Although all models produce slightly different
conclusions, the general consensus is that the vaccine is cost-effective under certain
conditions [12, 22, 37]. It is agreed that screening will still be necessary, so this is taken
into account. Most of the studies agree that there is little extra benefit in vaccinating
males as well as females, and that a catch-up programme is probably not particularly
cost-effective. Kim et al. (2007) [38] look at the effect of vaccinating males as well as
females, specifically in Brazil. This study found that, even with vaccination of males
(pre-adolescents), there was very little overall benefit. Cervical cancer rates would drop
slightly in this situation, but the drop was marginal compared to the increased cost
of vaccination. Indeed, the paper concludes that, if a choice must be made between
vaccinating boys or increasing the level of vaccination in females, the latter option
should be taken first [38]. Taira et al. (2004) [39] use decision analysis software to model
HPV transmission dynamics, then assess the cost-effectiveness of including males in the
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vaccination strategy. They also found that, although it is cost-effective to vaccinate
the females, there is little benefit in also vaccinating males. However, they did show
that under certain conditions, such as low vaccine coverage, or low vaccine efficacy,
vaccinating males would be cost-effective [39]. Elbasha et al. (2007) [40] develop
a dynamic model to consider cost-effectiveness and find that the inclusion of male
vaccination would be cost-effective. Jit et al. (2008) [10] conduct a comprehensive
economic evaluation, including many different scenarios, into introducing the HPV
vaccine in the UK. They find that vaccination of 12 year old females is cost-effective
under certain conditions, with a catch-up vaccination programme for females up to
18 years old initially. They do not find male vaccination to be cost-effective. These
models were developed in the last few years, and include parameter assumptions that
may not now be true. None of them employ optimal control as a means of judging
cost-effectiveness; they mostly use decision analysis or stochastic processes.
From a study of the literature, we feel that a new approach would be to build a
model that includes waning immunity and separate compartments for sexually active
and non-sexually active individuals. We want to be able to consider the vaccination
for both males and females, so our model allows for the inclusion of a protected male
class. Following many other models [41], we model the disease as an SIS model as
there are conflicting opinions about natural immunity. If protective natural immunity
exists, its role is unclear (length of protection provided, proportion of individuals that
develop immunity unknown) [41], so we also extend this to an SIRS model to consider
both cases.
1.3 Background Information: Age-structured Models
Developing age-structured models for infectious diseases is discussed at length in [31]. It
often adds another level of accuracy to a model as behaviours (e.g. contact structures)
and transmissibility of a disease can change as an individual ages. Age is usually
introduced into a model as a variable, and is often combined with time as a variable
to create a set of partial differential equations, as in [35, 42]. The inclusion of age as a
variable allows many parameters, that would otherwise be constant in a time-dependent
model, to be age-dependent. The models in [35, 42] also stratify their population into
age groups, and calculate forces of infection that are dependent on these age groups.
Age-structured models are of particular use in modelling sexually transmitted dis-
eases - sexual activity often varies significantly by age [3], and individuals usually
contact others of a similar age [43]. We develop an age- and time-dependent system of
PDEs in Chapter 6 to allow for the inclusion of age-dependent parameters, based on
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data, that more accurately reflect the situation within society [3].
1.4 Background Information: Optimal Control
We use optimal control to assess the most cost-effective method of introducing the
vaccination, both for the case of female-only vaccination and when both males and
females are vaccinated. Optimal control is a useful mathematical tool which has pre-
viously been used to determine optimal vaccination strategies, although not for HPV.
Lenhart and Workman (2007) [44] present many different biological situations which
can be modelled using optimal control, including an epidemic model in a population.
They also explain Pontryagin’s Maximum Principle, which we use in Chapters 7 and
8 when developing our optimal control model. An explanation of this principle can be
found in Chapter 7. Other authors [45, 46, 47, 48, 49, 50, 51, 52] have used optimal
control in modelling epidemics, although only [52] use two control functions (something
we introduce in Chapter 7). The types of control functions used in the cost function, or
objective functional, vary between linear (‘bang-bang’) controls (in this scenario, the
control is either at maximum or minimum, and can switch between the two states) and
more complex functions, usually quadratic expressions. Quadratic expressions in the
objective functional are commonly used, and we follow this trend in our formulation of
the objective functional.
Behncke (2000) [46] considers general SIR and SEIR models with different con-
trol strategies (e.g. vaccination/quarantine/screening). He uses a ‘bang-bang’ form of
control and shows that the optimal solution (when considering vaccination) is to have
maximum vaccination at early time. Sethi and Staats (1978) [47] analytically solve
three different control scenarios using compartment models. They use the concepts
of Pontryagin’s Maximum Principle to characterise the optimal control solution, using
‘bang-bang’ controls. In doing this, they define the optimal control problems for three
different types of intervention in compartment models and provide a useful reference
when formulating a model with optimal control. Optimal control applied to an SIR
model is taken further in [49], where an optimal control problem in a structured pop-
ulation is built. This model contains four connected subgroups, with an SIR model
applied to each of them. Optimal control is applied to the model, with quadratic
terms for the control functions in the objective functional, and Pontryagin’s Maximum
Principle is used to characterise the optimal control. Their results support other re-
sults found, namely that vaccination is highest at initial time, after which it decreases
to very low levels. Gaff and Schaefer (2009) [50] use optimal control with different
compartmental models (e.g. SIR, SIRS, SEIR) to discover whether the type of com-
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partmental model used has an effect on the optimal strategy for minimising the number
of infected individuals. They include both treatment and vaccination and vary the form
of the objective functional. They show that the form of the compartmental model leads
to only slight differences in the optimal strategy. They also find that vaccination is
almost always indicated as part of any strategy. Zaman et al. (2008) [51] consider
an SIR model with lifelong immunity for their optimal control problem and carry out
stability analysis. Their work presents an optimal control problem where they seek to
minimise the number of infected and susceptible individuals through vaccination, using
a quadratic term for their control function in the objective functional. They use Pon-
tryagin’s Maximum Principle and show that, as in previous work, vaccination should be
introduced at maximum levels, before decreasing over time. By introducing vaccination
in this way, they show that the numbers of susceptibles and infecteds decrease to very
low levels over a period of 90 days. Yan and Zou (2008) [52] apply optimal control to a
compartmental model for Severe Acute Respiratory Syndrome (SARS). They consider
two different interventions - quarantine and isolation - and search for both an optimal
and sub-optimal solution (their sub-optimal solution is found by defining the form of
the control function and looking to minimise the objective functional for that particular
form). Their results for the control functions agree with the work discussed above -
both the optimal and sub-optimal forms should be introduced at their maximums and
decreased over time, which can greatly reduce the number of infected individuals. They
also set both control functions as constants in their model and compare the results. In
doing this, they found that there are a much greater number of infected individuals
under the constant control model, with a much greater cost associated with this model.
In applying optimal control to our model, we considered the issues discussed in
previous work. We decided to use optimal control to minimise the cost of vaccination,
using two control functions (as in [52]). We also compared our optimal control solutions
to the results generated from a constant control model, as in [52]. A precise explanation
of our model can be seen in Chapters 7 and 8.
Optimal control as applied to PDEs is discussed in [44]. It is generally more com-
plicated to apply optimal control to a PDE rather than an ODE, but it is possible to
follow the ideas of Pontryagin’s Maximum Principle provided an extra set of equations
(the sensitivity equations) are also calculated. An example of this process takes place
in Appendix A.
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1.5 Thesis Structure
Chapter 2 introduces a simple model, divided into genders, that specifically looks at
the impact of waning immunity from the vaccination. We consider the steady states of
this system and compute numerical solutions. We also linearise the system, considering
initial behaviour and what this can tell us about the full model.
Chapter 3 provides a description of the different parameters that will be used in
subsequent Chapters. We discuss the data used to estimate these parameters and
provide ranges for each parameter.
Chapters 4 and 5 introduce a model that incorporates both waning immunity and
a non-sexually active class. Combining these with vaccination of non-sexually active
individuals gives a more accurate picture of the impact of the vaccine. Chapter 4
presents this model as gender-free, a simplified version of the gender-present model
presented in Chapter 5, that allows us to carry out further analysis. In both Chapters
we find steady states and their stability, consider R0 and the “effective” R0 value
(denoted here as Re0) and show numerical solutions to the system. In Chapter 5 we
extend our SIS model to an SIRS model to assess the effect any potential natural
immunity has on the results.
Chapter 6 develops an age- and time-dependent PDE system for a very similar
model to that presented in Chapter 5. In Chapter 6 we first consider this system at
temporal equilibrium (so use a system of age-dependent ODEs), before progressing to
the full PDE system. We consider how using a different force of infection impacts the
results for the ODE and compare the results to the PDE.
Chapters 7 and 8 introduce optimal control. Chapter 7 uses a very similar model
to that in Chapter 5 and applies optimal control to find the most cost-effective method
of vaccination. Pontryagin’s Maximum Principle is used to characterise the optimal
control and numerical solutions are found. Chapter 8 shows optimal control applied
to an age-dependent ODE model very similar to that seen in Chapter 6. For the ODE
system of equations we characterise the optimal control and find numerical solutions.
We refer to optimal control applied to a PDE model - the characterisation of optimal
control functions subject to a PDE model can be seen in Appendix A.
For all numerical solutions presented we use Matlab. In Chapters 2, 4 and 5 we
use the ODE solver provided by Matlab; numerical code used in Chapters 6, 7 and 8
is given in Appendix B.
Finally, we draw conclusions from this thesis and assess what new insights this work
gives to the body of knowledge on prophylactic vaccination with waning immunity.
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Chapter 2
Introductory HPV Model
2.1 Introduction
Mathematical modelling of infectious diseases can be done in many different ways.
Throughout this thesis we consider our population as divided into ‘compartments’,
with each compartment representing a different stage in the disease. Individuals move
between different compartments at different rates and subject to various constraints
(for example, females cannot move into compartments for male individuals). We are
using this type of modelling at the population-level and as such it is the between-host
dynamics that we are considering.
A basic model, first suggested by Kermack and McKendrick [53, 54, 55], is the
SIR model and from this model, many other compartmental models can be derived.
A common example is the S → I → S model, which divides a population into two
classes, susceptible and infected.
?
6
I
S
βSIγI
Figure 2-1: Schematic of a basic SIS system.
Individuals begin in (or enter the model through) the susceptible class (S). From
there, they can move to the infected class (I) based on the ‘force of infection’, which is
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calculated by multiplying the contact rate between susceptibles and infecteds, β, by I.
Finally, individuals return from the infected class to the susceptible class with rate γ,
the recovery rate. From this model (see Figure 2-1 for schematic) we can build a pair
of differential equations to model the rate of change of each of the classes over time.
The model equations are
dS
dt
= −βSI + γI, (2.1)
dI
dt
= βSI − γI.
In the first case, we assume that the duration of infection is very short compared to
an individual’s lifespan and so birth/ death rates are not included. As we can see
from (2.1), these equations are modelling a closed population - if we set N = S + I,
dN
dt =
d(S+I)
dt = 0, which implies N is a constant. Once we have obtained this system
(2.1), we can calculate the basic reproductive ratio R0, which is defined as the
“average number of secondary infections produced when one infected individual is
introduced into a host population where everyone is susceptible.” (taken from [31],
p.17)
For the disease to survive, and remain within a population, we require R0 > 1 [31].
For R0 < 1, the disease will die out [30]. For (2.1), R0 =
βN
γ . For more complicated
models, it is appropriate to define the “effective” R0 value (R
e
0); this is defined as the
reproductive value for the system when factors exist that reduce the pool of susceptibles.
It is possible to find the steady states of (2.1). We calculate the steady states by
allowing t→∞, so that dSdt = 0 and dIdt = 0. We then solve these equations for S∗ and
I∗, the steady states of the susceptibles and infecteds respectively. We find that there
are two steady states - the first is the disease-free steady state (S∗, I∗) = (N, 0). The
second steady state is the disease-present steady state and is (S∗, I∗) = ( γβ , N − γβ ).
Once the steady states are determined, we can determine when they are stable
using the Jacobian matrix. In this case, if the trace of the Jacobian is negative and the
determinant is positive then the steady state in question is locally stable [30]. If both
the trace and the determinant are zero, we consider the eigenvalues of the Jacobian to
determine the stability of the steady state. We define dSdt = f(S, I) and
dI
dt = g(S, I),
then the Jacobian matrix is
J =
(
fS fI
gS gI
)
. (2.2)
Calculating the Jacobian for (2.1) gives
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J =
(
−βI γ − βS
βI βS − γ
)
. (2.3)
At steady state (S∗, I∗) = (N, 0), the trace and determinant of (2.3) are zero, so
we consider the eigenvalues. These are 0 and βN − γ, so we know that the disease-free
steady state is stable for R0 < 1 and unstable for R0 > 1 (where R0 =
βN
γ ). For the
disease-present steady state (S∗, I∗) = ( γβ , N − γβ ), the same analysis shows that it is
stable for R0 > 1. This steady state does not exist for R0 < 1. This analysis gives us
some insights into the behaviour of the system - for R0 < 1 the system will tend to
the disease-free steady state, but for R0 > 1 the disease-free steady state is unstable
and so the system will tend to the disease-present steady state, which is stable when
it exists in the positive quadrant.
Calculating and using the Jacobian matrix is a method of linearisation. Linearisa-
tion is used to simplify a model about a certain point (often a steady state) to allow
for greater levels of analysis [30]. Comparing the linearised system to the full system
can also indicate any underlying behaviours in the model that are maintained when
the system is linearised.
Another aspect for consideration is the disease transmission: should it be frequency-
dependent or density-dependent? The answer to this question will usually depend on
the exact nature of the biological situation being modelled; here we are discussing a
sexually transmitted infection, which suggests a frequency-dependent disease transmis-
sion [56]. For the models above, this would mean (in the simplest case) that instead of
using βSI, we would use βSIN .
All of the above analysis can offer insights into different aspects of the model and
can allow us to make predictions based on the results - for example, we can predict
whether or not an epidemic is likely and also estimate the final size of any possible
epidemic. However, it is also important to note that the analysis will not always be
straightforward, or even possible. We saw with the system above that it was not easy
to find the stability of the steady states, and this system is one of the more basic. When
building our model, there are further compartments we will need to include. As we are
modelling a sexually transmitted disease, we will want to include both genders. We
are interested in the effect of vaccination on the spread of the disease, and so we will
need to include at least one protected class (dependent on whether we are vaccinating
both males and females, or just females). As discussed above, the inclusion of further
classes will mean that the use of Re0 will be essential when considering the predictions
of the model.
This chapter applies the above techniques to a five compartment model and as-
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sesses the results. As mentioned, we include vaccination (with a vaccine with limited
duration of protection) in our model and so we are considering the effect of waning
immunity. We vary some of the model parameters to establish their influence on the
model, especially the proportion of individuals vaccinated. We will concentrate on in-
troducing many of the ideas and techniques we will employ throughout the thesis. We
will introduce a deterministic, compartmental, population-level model for a sexually
transmitted disease (in this case HPV) and analyse it to study its behaviour. We also
study the effects of different parameters on the model to determine which ones have the
greatest influence on the overall behaviour of the system. We reduce our five-equation
system to a linearised two-equation system to consider the initial, underlying dynamics
of the model.
2.2 Setting up the Model
Here we present a compartmental, deterministic model designed to represent a sexually
active population (divided into males and females) with a protected female class (i.e.
those females who have been vaccinated and so are immune at time t = 0). We include
waning immunity in the model, so females who slowly lose their immunity join the
susceptible class. Initially we are interested in the impact of a single vaccination event
at time t = 0, which corresponds to monitoring a single population cohort of which
a fraction are initially vaccinated. We are only considering a heterosexual population
here. A schematic of the model can be seen in Fig. 2-2.
For the model, we assume a closed population with a 50:50 sex ratio, so N =
IF + SF + PF = IM + SM gives our population size as 2N . One parameter that
shows a significant degree of variation is the average length of infection. From the
literature [17, 28], we find this to be between 6 months and two years. As we are
taking our time units to be in years, (with γi = 1/(average length of infection)) we
set 0.5 ≤ γi ≤ 2, where i = F,M (females, males). It could be argued that this
range deals mainly with the more persistent infections, but many of the studies do not
test females more frequently than every six months so we cannot really use a lower
value. The average number of contacts per unit time is zi. We vary this between 2
and 3 in our numerical solutions [3]. Finally, we assume αF ≈ 0.1 is the rate at which
protection is lost (corresponding to a 10 year efficacy for the vaccine). We also assume
that transmission rates differ between males and females, so we take βMF ≈ 0.6 to be
the transmission from males to females, and βFM ≤ 0.6 to be the transmission rate
from females to males. These values come from estimates found in the literature that
suggest transmission rates vary between 0.4 and 0.8 [28, 35, 40, 57]. We take our initial
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Figure 2-2: Schematic of the system. Note that λF = βMF zFSF
IM
N and λM =
βFMzMSM
IF
N .
conditions to be SM (0) = S
0
m, IM (0) = I
0
m = N − S0m, IF (0) = I0f , PF (0) = pN and
SF (0) = (1− p)N − I0f , where p is proportion vaccinated. With these parameters and
initial conditions, our model becomes
dPF
dt
= −αFPF , (2.4a)
dSF
dt
= −βMF zFSF IM
N
+ γF IF + αFPF , (2.4b)
dIF
dt
= βMF zFSF
IM
N
− γF IF , (2.4c)
dSM
dt
= −βFMzMSM IF
N
+ γMIM , (2.4d)
dIM
dt
= βFMzMSM
IF
N
− γMIM . (2.4e)
2.2.1 R0
From here we can easily calculate the R0 value of the system. We need to establish the
number of secondary infections in females caused by the introduction of one infected
female into a completely susceptible population (or similarly for males). For a female
to be infected by another female, a male must be infected as an intermediate stage
(as the infection needs to pass from a female to a male, and then to another female).
We assume that one generation of infection is measured as female infection to female
infection. As such, R0 for this system is
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R0 =
βMF zF
γF
βFMzM
γM
. (2.5)
For R0 < 1, this means that βMF zFβFMzM < γFγM .
2.3 Analysis
2.3.1 Reducing the System
As (2.4) is a closed system, we can reduce it to 3, or even 2, equations to make it easier
to analyse. In doing so, our system of equations becomes
dPF
dt
= −αFPF , (2.6a)
dIF
dt
= βMF zF
(N − IF − PF )IM
N
− γF IF , (2.6b)
dIM
dt
= βFMzM
(N − IM )IF
N
− γMIM . (2.6c)
We can now analyse the model as follows:- firstly we solve (2.6a) and then look at the
stability of the steady states from the remaining two equations ((2.6b) and (2.6c)), and
secondly we linearise the system, turning it into a vector equation of the form x˙ = Ax,
making it easier to solve.
2.3.2 Steady States and their Stability
We can look at the steady states of the three-equation system (2.6) and see what
information these give. We can see that P ∗F = 0, so that leaves us with the two
equilibrium equations for I∗F and I
∗
M . These are
βMF zF (N − I∗F )
I∗M
N
− γF I∗F = 0, (2.7a)
βFMzM (N − I∗M )
I∗F
N
− γMI∗M = 0. (2.7b)
These lead to two steady states - either the disease-free steady state (I∗F , I
∗
M ) = (0, 0),
or the disease-present steady state, which is
(I∗F , I
∗
M ) =
(
N(βMFβFMzMzF − γMγF )
βFMzM (βMF zF + γF )
,
N(βMFβFMzMzF − γMγF )
βMF zF (βFMzM + γM )
)
. (2.8)
For the disease-present steady state to be realistic it must be positive, and we can see
from (2.8) that it is positive when R0 > 1.
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We can calculate the stability of the steady states from the Jacobian; this is
J =
(
−(βMF zF I∗MN + γF ) βMF zF (1−
I∗F
N )
βFMzM (1− I
∗
M
N ) −(
βFMzM I
∗
F
N + γM )
)
, (2.9)
which at (0, 0) tells us that the disease-free steady state is stable if
γMγF > βMFβFMzF zM . (2.10)
The Jacobian tells us that the disease-free steady state is stable (i.e. det(J) > 0
and tr(J) < 0) as long as the disease-present steady state does not exist (i.e. that
R0 < 1) but while the disease-present steady state exists, the disease-free steady state
is unstable. We see that the disease-present steady state is stable as long as R0 > 1, i.e.
as long as it exists there is a transcritical bifurcation as R0 increases through R0 = 1.
2.3.3 Linearising the System
Our second attempt at analysing the system (2.4) is to linearise the system about
the initial conditions for the case αF = 0 and consider the model initially to assess
its behaviour. We assume that IF (0) and IM (0) are very small, and therefore that
SF (0) = (1 − p)N and SM (0) = N . We substitute these values for SF (0) and SM (0)
into (2.4c) and (2.4e). As neither of these equations contain PF , we do not need to
include (2.4a) in the system. We are left with a pair of coupled ODEs to solve,
dIF
dt
= −γF IF + (1− p)βMF zF IM , (2.11a)
dIM
dt
= βFMzMIF − γMIM . (2.11b)
We can write this as x˙ = Ax, with x = (IF IM )
T and
A =
(
−γF (1− p)βMF zF
βFMzM −γM
)
. (2.12)
“Effective” R0 Value and Critical Parameter Values
We can use (2.12) to determine to which steady state the system will tend. As described
in Section 2.1, if tr(A) < 0 and det(A) > 0 then IF and IM will tend to the disease-free
steady state. For det(A) > 0, we require
γFγM > (1− p)βMFβFMzMzF , (2.13)
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As R0 relates to the number of secondary infections in an entirely susceptible popu-
lation, taking p into the equation gives us an updated condition on R0. That is, we
require 1 > (1− p)R0 for the system to tend to the disease-free steady state. This now
takes into account that some of our population are vaccinated and provides us with an
“effective” R0 value, R
e
0, as described in the introduction. In this case, we can rewrite
(2.13) as 1 > R0(1− p), giving us
Re0 = (1− p)R0. (2.14)
From (2.14) we can find a critical value of p when Re0 = 1. For the disease to be
removed from the population, we require
p > pcrit := 1− 1
R0
. (2.15)
Both (2.14) and (2.15) are not new; they are established results that are widely used
[31]. Condition (2.15) tells us the critical proportion of individuals that need to be
vaccinated for the system to tend to the disease-free steady state. The basic reproduc-
tive value is very important here; for R0 < 1, the system will tend to the disease-free
steady state regardless of the value of p; but when R0 > 1, the value of p will influence
whether or not the disease can be eradicated from the population.
Solving the System
We can now determine IF and IM by finding the eigenvalues and eigenvectors of A.
The eigenvalues are (k = 1, 2)
λk =
−(γF + γM )±
√
(γF − γM )2 + 4(1− p)βMFβFMzMzF
2
, (2.16)
leading to corresponding eigenvectors
xk =
(
(γF − γM )∓
√
(γF − γM )2 + 4(1− p)βMFβFMzMzF
−2βFMzM
)
(2.17)
From these, we know that our solution is
x = c1x1e
λ1t + c2x2e
λ2t, (2.18)
where c1, c2 are constants to be determined from the initial conditions (IF (0) = IM (0) =
1, or x(0) = 1). On using the initial conditions, we find that
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c1 =
−1
4βFMzM
− ( (γF − γM ) + 2βFMzM
4βFMzM
√
(γF − γM )2 + 4(1− p)βMFβFMzF zM
), (2.19)
and that
c2 =
−1
4βFMzM
+ (
(γF − γM ) + 2βFMzM
4βFMzM
√
(γF − γM )2 + 4(1− p)βMFβFMzF zM
). (2.20)
This gives us the solutions for IF (t) and IM (t) when αF = 0;
IF = c1x
1
1e
λ1t + c2x
1
2e
λ2t, (2.21)
and
IM = c1x
2
1e
λ1t + c2x
2
2e
λ2t. (2.22)
2.4 Numerical Solutions
We solve numerically (2.21) and (2.22) and try to establish whether the numerical
solutions can show any interesting behaviours demonstrated by the system. We look
at the effect varying some of the parameter values has on the profile of IF . Fig. 2-3
shows the effects of varying p on the size of IF . We see that the greater the value of p,
the smaller the proportion of infected female individuals.
Figure 2-4 shows the linearised system (2.11) for varying values of p. It shows that
for certain values of p, the infected female class initially decreases, then increases whilst
the infected male class initially increases. To consider this analytically, we solve
dIF (0)
dt
< 0, (2.23a)
dIM (0)
dt
> 0, (2.23b)
to find a condition for p. We find that the conditions that need to be satisfied are
βFMzM > γM and
p > (1− γF
βMF zF
). (2.24)
We also solve (2.6) numerically. The aim of the numerical solutions is two-fold.
We want to assess the effect of different parameter values on the model’s behaviour
and we also want to compare the reduced system (2.6) to the linearised system (2.11),
to identify whether (2.11) accurately describes the system’s behaviour. We vary p
to see the effect that this has on the behaviour of the system, as with such a high
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Figure 2-3: A graph showing the change in IF as p varies. In this case we let γF = 1.5,
γM = 1, βMW = 0.6, βWM = 0.4, zF = 2, zM = 2.
transmission rate we would expect (for this model) to need very high coverage levels.
However, the analysis above tells us that the important parameters (based on R0) are
βij , γi, zi (where i, j =M,F ). So even with low coverage levels, if the other parameters
force R0 < 1, the system tends to the disease-free steady state, whereas when R0 > 1,
we require the further condition of 1 > (1 − p)R0, or p > 1 − 1/R0 for the system to
tend to the disease-free steady state.
This model can produce some interesting results. Figure 2-5 shows the varying class
profiles when p is set at either 0.75 or 0.95 (high coverage levels), but with differing
values of zi and γi. In changing the values of γi, we also changed their relationship,
so that in four of the graphs γF > γM , whereas in the other four, γF < γM . We see
that zi influences the size of the infected classes (R0 > 1 for both zi = 2 and zi = 3,
so we would not expect that varying this value alone would lead to eradication of the
disease), as does varying γi. The change in γi leads to another change in behaviour, as
the infected classes are much slower to increase for larger γi values.
Fig 2-6 shows the initial path of the Ii profiles from (2.6) when p > (1−γF /βMF zF ),
which shows the IM profile first increasing, then decreasing, and then finally increasing
again. The IF profile, meanwhile, decreases then increases. This is a solution of the
reduced system, using the initial conditions [PF (0), IF (0), IM (0)] = [pN, 50, 50]. We
use Ii(0) = 50 as this shows the initial behaviour of the Ii classes more clearly than
when Ii(0) = 1. The parameter values were chosen from within the ranges discussed
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Figure 2-4: Plots of the linearised system as p increases. In all plots βMF = 0.6,
βFM = 0.4, zF = zM = 3, γM = 1, γF = 1.5 and the initial conditions are [1, 1].
above to ensure that p satisfied the condition p > (1− γF /βMF zF ).
Figure 2-7 shows both the reduced system (2.6) and the linearised system (2.11)
for small time, to compare their behaviours initially. We can see that, for t ≥ 10, the
two systems are not very similar, but that the two systems are very similar for t ≤ 1.
2.5 Conclusions
We see fairly standard behaviour from the steady states and their stability, in that
we have one disease-free steady state and one steady state where disease is present,
with the disease-present steady state being stable as long as it exists. We see that it is
possible to calculate a critical value of p for which the disease dies out, based on other
parameters. In Chapter 3 we investigate parameter estimates based on available data,
but by varying parameters in this model we are able to assess the amount of influence
different parameters have on the overall behaviour of the model.
Figure 2-3 shows the numerical solutions for the solution of IF found from (2.21).
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It shows that increasing the proportion of individuals vaccinated will decrease the
proportion of infected individuals.
Figure 2-4 shows the linearised system for varying values of p and we see that, for
particular values of p, the initial profile of the male infected class increases, then de-
creases and initial female infected class decreases then increases. We find the condition
on p for the female class to decrease initially and we see that when this is not satisfied,
both classes increase initially. Satisfying (2.24) may mean that infection appears to be
dying out initially, but will need to be monitored as it may increase at a later date.
Figure 2-5 shows the reduced system for a variety of parameter values. We see that
both zi and γi affect the eventual size of the infected classes and that the value of p only
affects when the numbers of infected individuals begins to increase. A combination of
small zi values and large γi and p values shows the disease can be eradicated.
Figure 2-6 shows the reduced system initially. Although the initial conditions are
different to those used for Figure 2-4d, the initial behaviour of the Ii classes in both
Figures is the same. We suspect that we see this at small time because the initial
behaviour of both the profiles is governed by satisfying (2.24) (so IM increases and
IF decreases). However, the R0 value for the system is greater than 1, so beyond the
initial behaviour the infected classes start increasing.
We can now compare the results from the linearised system and the reduced system
of three equations. The value of R0 is the same in both systems. Equally, initial
behaviour is the same for both systems. Figure 2-7 shows the two systems on the
same graph to give us a direct comparison between the two. We can see that in both
cases there is good agreement between the systems for 0 ≤ t ≤ 1, but after that the
two systems diverge and show quite different behaviour. Changing the values of the
parameters did not affect the agreement between the two systems. As the linearised
system is really only representative of the main system initially, this is an expected
result.
This model has been able to give some idea of how HPV would behave in the
population from a very simplistic viewpoint. There are several limitations with the
model; it does not include age-dependence, and in this type of situation, age-dependence
could give more accurate results. We do not differentiate between sexually active and
non-sexually active members of the population; this may play a role in determining the
cost-effectiveness of the vaccine, and also the optimal age for the vaccine.
Nonetheless, we are able to draw some conclusions from this work. We can see that,
under certain conditions, the vaccine will reduce the infective classes. In the linearised
system, we can see that, even for low values of p, the vaccine will make a difference
in the overall spread of infection (depending also on the value of R0). The results for
32
the linearised system are true for the case αF = 0, but for αF 6= 0 and αF t << 1,
the inclusion of α would not have a dominant effect and so the similar conclusions
would still hold. In the main system, we see that the emphasis is on the transmission
probabilities, the average length of infection and the average number of contacts per
unit time. The level of vaccination plays very little part here, although you may expect
it to slow the epidemic, as it basically delays a proportion of the population becoming
susceptible and therefore (potentially) infected. The level of the effect the vaccine can
have will depend on the exact value of αF ; we know αF < 0.2 [18]. This value will
determine the rate at which females lose their immunity and join the susceptible class.
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Figure 2-5: Eight graphs showing the effect of varying model parameters, with βMF =
0.6, βFM = 0.4 and αF = 0.1. Figures 2-5a, 2-5b, 2-5c and 2-5d have zi = 3, with zi = 2
in Figures 2-5e, 2-5f, 2-5g and 2-5h. In Figures 2-5a, 2-5b, 2-5e and 2-5f, γF = 0.7,
γM = 0.8. In Figures 2-5c, 2-5d, 2-5g and 2-5h, γF = 1.5 and γM = 1. Initial conditions
are (pN, 50, 50).
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Figure 2-6: Showing the initial paths of the Ii profiles of the reduced system for p = 0.1,
βFM = βMF = 0.6, zi = 2, γi = 1.1, αF = 0.1 so that p satisfies p > (1− γF /βMF zF ).
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Figure 2-7: Comparing the reduced system and linearised system initially; the solid
lines are the reduced system and the dashed lines are the linearised system. In all
graphs βFM = βMF = 0.6, zi = 2, α = 0.1. In Figures 2-7a and 2-7b γi = 0.7 and
p = 0.45. In Figures 2-7c and 2-7d γi = 1.1 and p = 0.1. In both pairs the right-hand
graph is an enlargement of the left-hand graph. PF (t) is much larger than Ii(t) initially
and so is not shown.
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Chapter 3
Determining the Parameter
Values
In this Chapter we develop estimates, from data, of the parameters that we will use in
subsequent chapters. In the following Chapters we develop compartmental, determin-
istic models that consist of a number of classes. A schematic of the model considered
in Chapter 5 is given in Figure 3-1. This model contains all of the parameters that will
be used in this thesis. The model here consists of seven classes, with males and females
represented separately; female classes and parameters are denoted by a subscript ‘F’
and male classes and parameters by a subscript ‘M’. The classes are: the protected
(vaccinated) female class PF , the non-sexually active classes Ji (i = F,M), the suscep-
tible (sexually active) classes Si and the infected classes Ii. The force of infection, λi
is defined as
λi =
zβIk
(Nk − Jk) , i, k = F,M, i 6= k. (3.1)
The definition of each of the parameters used in the model is given below. To
estimate the different parameters we use data from various sources, making extensive
use of the National Survey of Sexual Attitudes and Lifestyles II (NATSAL II), [3],
carried out between 2000 and 2001 by the National Centre for Social Research. Many
areas are covered in this survey, for example age at first intercourse, age of first partner,
number of sexual partners in the last year. The parameters that need to be estimated
are as follows:
• α(a)−1: Average length of vaccine protection.
• ηi(a)−1: Average length of time spent in the non-sexually active class from the
onset of the model (i = F,M).
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Figure 3-1: Schematic of model researched in Chapter 5. See text for further details.
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• q(α): Proportion of protected class not sexually active when vaccine wears off.
• γ−1i : Average duration of infection.
• zi(a): Average number of sexual partners at age a per year.
• β(a, a′): Probability that someone of age a′ infects someone of age a.
• ji: Proportion of susceptible, non-sexually active at age a0.
• p: Proportion of population to be vaccinated.
• µ(a)−1: Average lifespan.
• HPV incidence/prevalence in the UK (used for estimating the initial conditions
for the age-dependent models).
3.1 α(a)−1: Average Length of Protection
It is difficult to determine an accurate estimate for this parameter, as the vaccines are
so new that it is not yet known how long they will last. The latest information shows
that vaccination provides protection after 5-6 years [58], so that α ≤ 0.2. The hope is
that it will last at least 10 years, in which case α = 0.1, but this will not be known
for some time. We wish to predict α(a), assuming a linear relationship; assuming a
vaccine with an average duration of 10 years,
α(a) = 0.003a. (3.2)
3.2 ηi(a): Rate of becoming Sexually Active
To estimate ηi(a), we calculated the rate at which individuals became sexually active
using data from the NATSAL II survey [3]. When we do not include age-dependence,
we estimated ηi = 0.1 (as 0.005 ≤ ηi ≤ 0.23) [3].
To calculate ηi(a), we first consider the steady state and assume (for the females)
there is no vaccination. This gives (with Ji as given at the beginning of this Chapter)
dJi
da
= −ηi(a)Ji. (3.3)
The solution is calculated as
J(a) = J(a0)exp{−
∫ a
a0
ηi(a˜)da˜}. (3.4)
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From the data, we can find the value of
xik :=
J(a)
J(a0)
= exp{−
∫ ak+1
ak
η(a˜)da˜}, (3.5)
k = 0, ..., n, i = F,M . If we take our integral limits to be consecutive years, and take
ηik to be constant in each of these intervals, then we can say that − log(xik) = ηik. We
plotted ηi(a) (calculated using NATSAL II data [3]), as can be seen in Figs. 3-2 and
3-3. It was possible to calculate the proportion that were sexually active at each age
group from the database. For the youngest age group, ηi is the negative of the natural
log of (1-proportion sexually active), but for all subsequent ages ηi was calculated by
taking the negative of the natural log of (1-difference between the proportion sexually
active for consecutive ages).
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Figure 3-2: A graph showing the ηF (a) data points against age.
From the distribution of the data, a normal distribution seems to be a potential
fit, although only until the age a ≈ 19. Beyond this, the data indicate that a normal
distribution would not be the best fit, so we instead use piecewise continuous functions
for both the ηi(a). For a0 ≤ a ≤ 19, we use a normal distribution for both ηF (a) and
ηM (a). In both cases, the standard deviation used for the normal distribution is the
standard deviation of the data, and the mean is estimated from the data. Once past
a ≈ 19, we set ηi = 0.06. Putting these together, our estimates for ηF (a) and ηM (a)
are as follows:
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Figure 3-3: A graph showing the ηM (a) data points against age.
ηF =
{
1
1.33
√
2π
exp(− (x−16.95)2
2(1.33)2
) a ≤ 19
0.06 19 < a
(3.6)
ηM =
{
1
1.14
√
2π
exp(− (x−16.58)2
2(1.14)2
) a ≤ 19
0.06 19 < a
(3.7)
3.3 q(α): Proportion of Protected who are Non-Sexually
Active after Loss of Protection
Exactly what value q(α) takes will depend on the duration of induced protection. It
can be estimated from looking at the data used for ηF (a) (NATSAL II) [3], to see
what percentage of females are non-sexually active at different ages. In Fig. 3-4,
the proportion of sexually active girls is shown at each age, which was calculated by
dividing the cumulative number of sexually active girls at age a by the total number
of respondents at age a to the survey minus any girls of age less than a who were not
sexually active. This is because those girls at age a1 < a may be sexually active by the
time they reach age a and so should not be included.
From the data we see that the average value of q(α) over all ages settles down to
q(α) ≈ 0.1, so we assume the area under q(α) = q = 0.1 (for 0 ≤ α ≤ 0.2) to be the
same as the area under q(α) for 0 ≤ α ≤ 0.2. We assume q(α) to be a function of the
form
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Figure 3-4: A plot of sexually active females against age.
q(α) ≈ mα+ 0.05
1 + α
. (3.8)
Using these assumptions and available data, we find that
q(α) ≈ 0.616α+ 0.05
1 + α
. (3.9)
3.4 γ−1i : Average Duration of Infection
The average duration of an infection is hard to determine with any accuracy, as testing
methods mean that it may not be clear from one test to the next whether it is the same
infection being detected or a different one [17]. However, in most situations infection
duration is cited as being between 6 months and 2 years [17, 28]. These tests are mainly
carried out on women but we assume a similar average duration of infection for males
[28]. This puts 12 ≤ γi ≤ 2. In the following Chapters, we take γi ≈ 1.
3.5 zi(a): Average Number of Sexual Partners at Age a
per Year
This parameter is estimated using data from NATSAL II [3]. The average values fall
in the range 0.6 ≤ zi ≤ 2.9, and we use the estimate zi = 2. For the age-dependent
parameters when a ≥ 16, we find a linear relationship from [3]. For a < 16, we
calculate a linear relationship based on zi(0) = 0 and the estimated values (from the
linear relationship calculated using [3]) of zi(a) when a = 16. For simplicity in the
age-dependent work, we assumed zF (a) = zM (a); putting these assumptions together
gives the function for zi(a) as
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zi(a) =


0.1411a, a ≤ 16
2.93− 0.042a, 16 < a ≤ 69
0. a > 69
(3.10)
3.6 β(a, a′): Probability Someone of Age a′ Infects Some-
one of Age a
This can be divided up into βA, where β is the constant probability of transmission,
and A is the contact structure between people of different ages [42]. Many papers refer
to the transmission probability β. Most do not differentiate between male-female and
female-male transmission, but all put 0.4 ≤ β ≤ 0.8 [28, 35, 40, 32]. The most common
estimate seems to be β = 0.6.
There are some papers that look at the sexual contact structure by age (A). Both
of the references we have found are related to the United States [43, 59] and as there
does not seem to be any data from the UK, these may provide the best information.
Based on the information given in these papers, we see that the majority of individuals
have partners very close to their own age. We therefore estimate
A =


0.5 0.25 0.25 0 0 0 . . . 0
0.25 0.5 0.125 0.125 0 0 . . . 0
0.125 0.125 0.5 0.125 0.125 0 . . . 0
...
...
0 . . . 0 0.125 0.125 0.5 0.125 0.125
0 . . . 0 0 0.125 0.125 0.5 0.25
0 . . . 0 0 0 0.25 0.25 0.5


. (3.11)
The entries in the matrix are the estimated probabilities of contact between individuals
of age a and age a
′
.
3.7 ji: Proportion of Susceptible, Non-Sexually Active at
Age a0
This is a parameter that is only applicable in the time-dependent ODEs - it does not
appear in the age-dependent ODE. That said, its value will depend on the age set as
a0, the age at which individuals enter the model. It can be estimated from the same
data used for estimating q(α) and ηi(a) [3].
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Figure 3-5: Plots of sexually active individuals against age. Figure 3-5a shows sexually
active females and Figure 3-5b shows sexually active males.
In Figure 3-5 we have plotted the data as the sexually active proportion of the
age group. The sexually active proportion was calculated by dividing the cumulative
number of sexually active at age a by (total number of respondents at age a minus
number not sexually active at age a − a1), for all a > a1. To give the non-sexually
active proportion we can just take the sexually active proportion away from 1. From
this information, we estimate ji = 0.9 for a ≈ 12.
3.8 p: Proportion Vaccinated
This is not a parameter to estimate, as we wish to investigate the effects of changing p
on our model. That said, one would hope to achieve p ≈ 0.7 in a vaccination programme
[60].
3.9 µ(a)−1: Average Lifespan
From [61], we see that a Gompertz function is a good approximation for the death rate
in England. From this article,
µF (a) = 0.0000189e
0.1a, (3.12)
and
µM (a) = 0.0000347e
0.098a (3.13)
Where we do not include µi as an age-dependent parameter, we set µi = 1/φ (i = F,M),
with φ ≈ 65 being the average lifespan of an individual from age 12 [7].
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Age Manchester Cohort Edinburgh and Lothian Cohort
<25 23.0 42.0
25-35 13.1 22.6
35-45 5.4 13.0
45-55 4.0 9.1
>55 1.8 5.4
Table 3.1: A comparison by age of percentages of women who are HPV positive. Data
taken from [63] and [64].
3.10 HPV Incidence/Prevalence in the UK
This information is important to estimate the initial conditions for all our classes. There
are three papers currently available that deal with HPV prevalence in the UK, looking
at South Wales, Manchester and Edinburgh. All three studies show high prevalence in
the younger age groups (15-24), with prevalence declining as age increases [62, 63, 64].
The results vary quite significantly. Here we will just discuss the Manchester and
Edinburgh studies [63, 64].
As mentioned, there is significant difference between the two references. The
Manchester cohort [63] has an HPV prevalence of ≈ 23% for women aged under 25,
whereas the Edinburgh and Lothian cohort returns a percentage of 42% for the under
25s. The Edinburgh and Lothian study [64] starts at a slightly older age (16.5 years)
and has a higher maximum age (78 years) than the Manchester study (15 years and 69
years), but even allowing for this it is a big discrepancy. Both studies show a decline
in HPV prevalence as age increases, although the percentages from the Edinburgh and
Lothian cohort are still much larger than those from the Manchester cohort. These
percentages can be seen in table 3.1. The Manchester study actually looked at the
percentages over a 5 year age spread, but we have recalculated to bring them in line
with those from the Edinburgh and Lothian cohort.
Using the Manchester cohort for our estimate we find that, over all ages, the average
percentage of females infected is 7%, which we use in our initial conditions for our time-
dependent ODEs. We fit a curve to the Manchester data to give initial conditions for
the infected classes in our age- and time-dependent PDE model, the equation for which
is given in Chapter 6.
A table of a standard set of parameter values, which we use in many of the following
Chapters, is given in Table 3.2.
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Parameter Symbol Value Range
Rate of losing protection α α ≈ 0.1
α(a) α ≈ 0.003a
Rate of becoming sexually ηi ηi ≈ 0.1
active ηM (a) ηM (a) ={
1
1.14
√
2π
exp(− (x−16.58)2
2(1.14)2
) a ≤ 19
0.06 19 < a
ηF (a) ηF (a) ={
1
1.33
√
2π
exp(− (x−16.95)2
2(1.33)2
) a ≤ 19
0.06 19 < a
Proportion of protected q(α) q(α) ≈ 0.616α+0.051+α
class not sexually active when
vaccine wears off
Average duration of infection γ−1i γi ≈ 1
Average number of sexual zi zi ≈ 2
partners per year zi(a) zi(a) =


0.1411a a ≤ 16
2.93− 0.042a 16 < a ≤ 69
0 69 < a
Probability of transmission of β β ≈ 0.6
infection per sexual partner
Proportion of the average ji ji ≈ 0.9
population in one year that
enters the ‘juvenile’ class
Proportion of the average p 0 ≤ p ≤ 1
population in one year that
is vaccinated
Average lifespan (µi)
−1 µi = 1/φ, φ ≈ 65
µM (a) µM (a) = 0.0000347e
0.098a
µF (a) µF (a) = 0.0000189e
0.1a
Table 3.2: Table of standard parameter values.
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Chapter 4
Time-dependent Gender-free
ODE Model
4.1 Introduction
Chapter 2 was an investigation into the spread of a disease through a population when
vaccination was present. We initially introduced vaccination to a given proportion of
the population and modelled its effects. However, a more realistic approach would be
to consider a model that allows the population to renew itself. We therefore consider a
model as shown in Figure 4-1, and look to answer certain questions. We are interested
in the behaviour of this model - its steady states and R0 value. We wish to know the
effect of varying different parameters (behavioural or vaccination) as this can provide
suggestions as to how to amend public health policy to best combat the disease. There
have been several models suggested for HPV [35, 39, 65, 66]; a key element in ours is
the introduction of a non-sexually active compartment which manifests itself through
parameters such as the rate at which individuals become sexually active and the effect
a non-sexually active class has on disease transmission.
The aim of this Chapter is to extend the work done in Chapter 2 with a more
complex model. In the following chapter, Chapter 5, we present a model with genders,
but for our initial study we do not include genders to reduce the complexity. We study
the steady states and stability and discuss the “effective” R0 value, R
e
0. A gender-free
model in this situation can also be seen as modelling a population with both male and
female vaccination, where there is both homosexual and heterosexual mixing.
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4.2 Model
We build a compartmental model of a population, the schematic of which can be seen
in Figure 4-1. It is a deterministic model, with parameters estimated as average values
using age-dependent data (see Chapter 3). As the transmission probability, β, is so
high, we follow [65] and assume homogeneous mixing. We do not account for het-
erogeneity in individual behaviour beyond classifying individuals as sexually active or
inactive. In particular there is no sexual contact or age structure, neither do we distin-
guish genders. Although age structure is not included, behavioural parameter values
were estimated from an age-dependent database (NATSAL II) [3]. Such simplifications
allow us to highlight key parameter groupings such as the basic reproductive value
R0 and the “effective” reproductive value R
e
0 from which the behaviour of HPV in a
population with vaccination can be explored.
Vaccination takes place as individuals enter the model. We include a non-sexually
active (juvenile) class, to allow us to consider the interplay between waning protec-
tion and onset of sexual activity. We present an SIS (susceptible-infected-susceptible)
model, as in [34, 39, 67]. This produces a model with four classes; protected individ-
uals P , juvenile individuals J , susceptible individuals (or susceptibles) S and infected
individuals I. We assume that none of the cohort entering the model are infected, thus
there is no external input into the I class. The parameters are as in Table 3.2 with
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µ = 1φ and the frequency-dependent force of infection λ is set as
λ =
zβI
(N − J) . (4.1)
Whilst the model here does not explicitly monitor the age of individuals, several
parameters are directly linked to the age of vaccination. The proportion of individu-
als, q(α), who are not sexually active when the vaccination protection wears off and
the proportion of unvaccinated individuals, j, who are not sexually active are both
estimated using the NATSAL II database [3]. The parameter q(α) is taken to be an
increasing function of α and was also estimated using data from [3]. Taking all of these
factors into account, our model equations are
dP
dt
=
pN
φ
− (α+ 1
φ
)P, (4.2a)
dJ
dt
=
(1− p)jN
φ
− (η + 1
φ
)J + q(α)αP, (4.2b)
dS
dt
=
(1− p)(1− j)N
φ
+ (1− q(α))αP + ηJ − zβ
N − J SI + γI −
1
φ
S, (4.2c)
dI
dt
=
zβ
N − J SI − (γ +
1
φ
)I. (4.2d)
We determine R0 for the system to be
R0 =
zβ
(γ + 1/φ)
. (4.3)
The initial conditions for this model are P (0) = 0, J(0) = 25000, S(0) = 90750 and
I(0) = 9250, which are estimated using available data.
4.3 Analysis
4.3.1 Solving the Equations
We can solve (4.2a) and (4.2b) to give
P =
pN
φ(α+ 1φ)
(1− e−(α+1/φ)t), (4.4a)
J =
C
η + 1φ
− De
−(α+1/φ)t
η − α + Ee
−(η+1/φ)t, η 6= α, (4.4b)
J =
C
η + 1φ
−Dte−(η+1/φ)t + E˜e−(η+1/φ)t, η = α, (4.4c)
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where
C =
N
φ
[(1− p)j + q(α)αp
α+ 1φ
],
D =
q(α)αpN
φ(α+ 1φ)
,
E =
−C
η + 1φ
+
D
η − α + J(0),
E˜ =
−C
η + 1/φ
+ J(0).
The corresponding steady states are
P ∗ =
pN
φ(α+ 1/φ)
, (4.5)
and
J∗ =
((1− p)(α+ 1/φ)j + q(α)αp)N
φ(α+ 1/φ)(η + 1/φ)
. (4.6)
These expressions (4.4) then feed into the nonlinear system for S and I;
dS
dt
= (1− p)(1− j)N
φ
+ (1− q(α))αP+ (4.7a)
ηJ − zβ
N − J SI + γI −
1
φ
S,
dI
dt
=
zβ
N − J SI − (γ +
1
φ
)I. (4.7b)
4.3.2 Steady States and Stability
From (4.7), we can find the two steady states (S∗, I∗). We know the values of P ∗ and
J∗ from above, so we set S∗ = N − P ∗ − J∗ − I∗ and hence solve
dI
dt =
zβ
N−J∗ (N − P ∗ − J∗ − I∗)I∗ − (γ + 1φ)I∗ = 0, giving (S∗, I∗) = (N − P ∗ − J∗, 0)
(disease-free steady state) or (S∗, I∗)=(N−J
∗
R0
, (1− 1R0 )(N − J∗)−P ∗) (disease-present
steady state).
We can calculate the Jacobian for this system and use it to determine conditions for
stability of the steady states. In particular, for a steady state to be stable, we require
tr(A) < 0 and det(A) > 0. For the disease-free steady state the Jacobian is
B :=
(
− 1φ −zβ(N−P
∗−J∗)
N−J∗ + γ
0 zβ(N−P
∗−J∗)
N−J∗ − (γ + 1φ)
)
. (4.8)
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If
zβ(N − P ∗ − J∗)
N − J∗ − (γ +
1
φ
) < 0 (4.9)
then the disease-free steady state will be stable. Rearranging this condition we find
R0(1− P
∗
N − J∗ ) < 1. (4.10)
Substituting for P ∗ and J∗, we find that the condition to be satisfied is
R0(1− p(η + 1/φ)
φ(η + 1/φ)(α+ 1/φ)− ((1− p)(α+ 1/φ)j + q(α)αp)) < 1. (4.11)
The Jacobian for the disease-present steady state of the system (4.7) is
B :=
(
zβP ∗
N−J∗ − zβ(1− 1R0 )− 1φ −
zβP ∗
N−J∗ + zβ(1− 1R0 )
− 1φ 0
)
. (4.12)
In this case, the disease-present steady state is stable if the condition given in (4.11)
is not satisfied. This is also the condition that needs to be met for the disease-present
steady state to exist, so we can say that as long as the disease-present steady state
exists, it is stable. Furthermore, the disease-free steady state is only stable as long
as the disease-present steady state does not exist; otherwise, it is unstable. This is a
transcritical bifurcation.
We now plot part of the phase plane of this system about the steady states, using
parameter estimates as detailed in Chapter 3 (see Table 3.2), which can be seen in
Figure 4-2. It shows the situation when the disease-present steady state exists and we
can see that in this scenario, the disease-free steady state is a saddle point and the
disease-present steady state is a stable node.
4.3.3 “Effective” R0 and Critical Values
Results presented above give us expressions for Re0, the “effective” R0, as defined in
Chapter 2. It is such that, for Re0 < 1, the disease-free steady state is stable and
vaccination can eradicate infection from the population.
We have
Re0 = R0(1−
p(η + 1/φ)
φ(η + 1/φ)(α+ 1/φ)− ((1− p)(α+ 1/φ)j + q(α)αp)).
Without a non-sexually active class, but with vaccination providing lifelong protection
in a model, we would expect that Re0 = (1 − p)R0 [30]. If we allow j, q(α) = 0 (as
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Figure 4-2: Phase plane of the system, using the standard parameter set as given in
Table 3.2.
these are the parameters that relate to the non-sexually active class), but keep our
assumption of waning immunity, we find that (as shown in [68])
Re0 = R0(1−
1
φ(α+ 1/φ)
p). (4.13)
The extra term in front of p relates to our assumption of waning immunity. If we
assume protection is lifelong (i.e. set α = 0) then Re0 = R0(1 − p), thereby agreeing
with previous work, as discussed in [30].
Corresponding to Re0 = 1, we can derive critical values for η and α for eradication
of infection; these are
ηcrit =
(1− 1R0 )((1− p)(α+ 1/φ)j + q(α)αp)
φ(α+ 1/φ)(1− 1R0 )− p
− 1
φ
,
and
αcrit =
p(η + 1/φ)− (1− 1R0 )(η + 1φ −
(1−p)j
φ )
(1− 1R0 )(φ(η + 1/φ)− (1− p)j)− q(αcrit)p
.
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With q(α) = 0.616α+0.051+α , we obtain a quadratic for α
crit;
(φ(η +
1
φ
)− (1− p)j − 0.616p
(1− 1/R0))(α
crit)2
+ ((φ(η +
1
φ
)− (1− p)j)(1 + 1
φ
)−
(p(η + 1φ + 0.05))
(1− 1R0 )
)αcrit
− (
p(η + 1φ)
(1− 1R0 )
− (η + 1− (1− p)j
φ
)) = 0, (4.14)
which has solutions
αcrit =
−k ±
√
k2 + 4(φ(η + 1φ)− (1− p)j − 0.616p(1−1/R0))(
p(η+ 1
φ
)
(1− 1
R0
)
− (η + 1−(1−p)jφ ))
2(φ(η + 1φ)− (1− p)j − 0.616p(1−1/R0))
,
(4.15)
where k = ((φ(η + 1φ)− (1− p)j)(1 + 1φ)−
(p(η+ 1
φ
+0.05))
(1− 1
R0
)
)). We now let
m = (φ(η + 1φ) − (1 − p)j − 0.616p(1−1/R0)) and n = (
p(η+ 1
φ
)
(1− 1
R0
)
− (η + 1−(1−p)jφ )). If m > 0,
n > 0 and k < 0, either solution given in (4.15) is positive. If αcrit < 0, it means that
the disease could be eradicated regardless of the duration of protection offered by the
vaccine. For our standard parameter set, this is not the case and αcrit ≈ 0.06.
We can do the same to find a critical value for p, namely
pcrit =
[φ(α+ 1/φ)(1− 1/R0)(η + (1− j)/φ)]
(η + 1/φ+ (1− 1/R0)(α(q(α)− j)− j/φ)) . (4.16)
For Re0 < 1, we require p > p
crit. This value ties in with the concept of “herd
immunity” - i.e. that it is not necessary to vaccinate every individual in a population to
eradicate a disease from that population [31]. This critical value of p is that proportion
of individuals that it is necessary to vaccinate so that the disease dies out in the
population. From the equation (4.16) we can see that, for R0 < 1, p
crit < 0 - i.e.
that there is no minimum level of vaccination required to eradicate the disease. When
R0 > 1, p
crit > 0 provided (η + 1/φ)( R0R0−1) > (α(j − q(α)) + j/φ). This gives us a
relationship between the behavioural parameters (left hand side) and the vaccination
parameters (right hand side).
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4.4 Numerical Solutions
As an exploration of the model, we used Matlab to solve (4.2). We tested it both with
and without protection, to show the impact vaccination would have over time. Figure
4-3 demonstrates this; Figure 4-3a shows the numerical solution for the population
when there is no vaccination taking place in the population. Figure 4-3b shows the
case when P (0) = 0, but the proportion of individuals vaccinated is p = 0.7, and
shows the infection being maintained in the population. Figure 4-4 shows the same
set of graphs as in Figure 4-3, with the difference that z = 1.7. For this value of z,
infection is at very low levels in the population without vaccination, and dies out when
vaccination is present.
We also consider numerically the change in Re0 when different parameters are varied.
Figure 4-5 shows Re0 against η for different values of α, so we are investigating how
the duration of protection and the rate at which individuals become sexually active
influences whether or not the disease dies out. Figure 4-5 shows that α has a much
greater effect on Re0 than η, and that we require α ≤ 0.04 for all values of η for Re0 < 1.
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Figure 4-3: Numerical solutions to the gender-free, time-dependent ODE. All parameter
values are the standard values given in Chapter 3.
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Figure 4-4: Numerical solutions to the gender-free, time-dependent ODE. All parameter
values are the standard values given in Chapter 3 barring z, which is set to z = 1.7.
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Figure 4-5: A graph showing the effect of varying η and α on the value of Re0. All other
parameters are standard, as given in Table 3.2.
4.5 Conclusions
This time-dependent ODE model, with its non-sexually active class, better reflects
the vaccination strategy (vaccination for a sexually transmitted infection occurs at a
relatively young age) than the model presented in Chapter 2. We explore the model
analytically, considering the steady states and their stability, and the influence of var-
ious parameters on the “effective” R0 value, R
e
0. In presenting numerical solutions,
we can, using our estimated parameter values, consider the behaviour of the model in
different circumstances. We find that there are two steady states, with the value of Re0
telling us which steady state the system will tend towards.
Changing the value of z from 2 to 1.7 gives different results, with Figure 4-4 showing
that with no protection present, the disease remains in the population. Once protection
is introduced, the model tends to the disease-free steady state. It demonstrates the
influence that z has on the model (expected, as z is a dominant parameter in R0).
Figure 4-5 shows how Re0 varies based on changing values of α and η and demon-
strates that a vaccine offering close to lifelong protection (α ∈ [0, 0.04]) may well mean
that the disease can be removed from the population, regardless of the value of η.
This Chapter has provided some insights into the behaviour of a gender-free model
with vaccination. It shows the steady states and how different parameters influence
which steady state the model will tend towards. It gives an excellent starting point
for the following Chapter, when we will introduce genders to this model and assess the
difference that this makes.
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Chapter 5
Time-dependent ODE with
Genders
5.1 Introduction
In this Chapter we introduce a compartmental, population-level, time-dependent ODE
model with genders. As before, we find the “effective” reproductive value for HPV, Re0.
We are interested in using Re0 to assess the interplay of behavioural and vaccination
parameters, and how these affect the potential success of the vaccine. We also use Re0
to judge the impact of including male vaccination in the vaccination policy.
This complements previous work ([65, 66, 68], for example) and by using a simple
structure, highlights key parameter groupings. These parameter groupings are criti-
cal in understanding how HPV could be contained in a population, by a vaccination
strategy aimed either at females only prior to their sexual debut, or at both males and
females.
The aim of this Chapter is to extend the work presented in Chapter 4 by including
genders in the population model. The introduction of genders into a model is common
when a sexually transmitted infection is being considered [31], as it is helpful to be able
to model contact between genders and parameter values are often gender-dependent.
The introduction of genders also allows us to consider female-only vaccination, which is
the current policy for HPV [2]. We present an investigation into the influence the var-
ious behavioural and vaccination parameters have on our model, infection prevalence,
and in particular on the value of Re0. We introduce male vaccination and compare this
to the situation of female-only vaccination, looking at how the introduction of male
vaccination affects the total number of individuals that need to be vaccinated in order
to control the spread of the disease.
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Figure 5-1: Schematic of model. See Table 3.2 for parameter definitions and text for
further details.
5.2 Model
The model presented here is a continuation of the model presented in Chapter 4, as
we now introduce genders to the model. The schematic of this model can be seen in
Figure 5-1. A description of the parameters can be found in Chapters 3 and 4.
Considering HPV as a sexually transmitted infection (STI), we introduce two gen-
ders and study the heterosexual case. Initially we assume that only females are vacci-
nated, as this is current UK policy [2], and that vaccination takes place as individuals
enter the model. As in Chapter 4, we include a non-sexually active (juvenile) class, to
allow us to consider the interplay between waning protection and onset of sexual activ-
ity. We present an SIS (susceptible-infected-susceptible) model for the infection, as in
[34, 39, 67]. This produces a model with seven classes; protected females PF , juvenile
individuals Ji, susceptible individuals (or susceptibles) Si and infected individuals Ii.
We assume that none of the cohort entering the model are infected, thus there is no
external input into the Ii classes. Here i = F,M represents females and males. The
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parameters are as in Table 3.2; these estimates have a variety of published sources.
The frequency-dependent force of infection λi is set as
λi =
zβIk
(Nk − Jk) , i, k = F,M, i 6= k. (5.1)
Age-related gender differences are included by assuming that the rate of becoming
sexually active is greater for males than females (ηM ≥ ηF ) and that more males are
sexually active than females when vaccination is administered (jM ≤ jF ). Taking all
of these factors into account, our model equations are
dPF
dt
= p
NF
φ
− (α+ 1
φ
)PF , (5.2a)
dJF
dt
= (1− p)jF NF
φ
− (ηF + 1
φ
)JF + q(α)αPF , (5.2b)
dSF
dt
= (1− jF )(1− p)NF
φ
+ (1− q(α))αPF + ηFJF (5.2c)
− zβ
NM − JM IMSF + γF IF −
1
φ
SF ,
dIF
dt
=
zβ
NM − JM IMSF − (γF +
1
φ
)IF , (5.2d)
dJM
dt
= jM
NM
φ
− (ηM + 1
φ
)JM , (5.2e)
dSM
dt
= (1− jM )NM
φ
+ ηMJM − zβ
NF − JF IFSM + γMIM −
1
φ
SM , (5.2f)
dIM
dt
=
zβ
NF − JF IFSM − (γM +
1
φ
)IM . (5.2g)
Assuming that one generation of the infection is measured as female infection to
female infection we calculate R0 as
R0 =
(zβ)2
(γF + 1/φ)(γM + 1/φ)
. (5.3)
For standard parameters from Table 3.2 (z = 2, β = 0.6, φ = 65, γF = γM = 1),
we estimate R0 ≈ 1.4.
5.2.1 Introducing Male Vaccination
Following analysis of the female-only vaccination strategy, we include male vaccination
in the model by including a protected male class (PM ) that has the same parameters
(q(α), α) as the female protected class. A proportion pM of individuals enters the PM
class, with a corresponding female proportion, pF , entering the female protected class.
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5.3 Analysis
5.3.1 Solving the PF and Ji Equations
We can solve the equations for PF , JF and JM , as they can be uncoupled from the
system. The solutions of these equations are
PF =
pNF
φ(α+ 1/φ)
(1− e−(α+1/φ)t), (5.4)
which leads us to
JF =
B
ηF + 1/φ
− Ce
−(α+1/φ)t
ηF − α +De
−(ηF+1/φ)t, η 6= α, (5.5a)
JF =
B
ηF +
1
φ
− Cte−(ηF+1/φ)t + D˜e−(ηF+1/φ)t, η = α, (5.5b)
where
B = [
jf (1− p)
φ
+
q(α)αp
φ(α+ 1/φ)
]NF , (5.6a)
C =
q(α)αp
φ(α+ 1/φ)
NF , (5.6b)
D = [
J0F
NF
+
q(α)αp
φ(ηF − α)(α+ 1/φ) −
jF (1− p)(α+ 1/φ) + q(α)αp
φ(ηF + 1/φ)(α+ 1/φ)
]NF , (5.6c)
D˜ = J0F −
B
ηF + 1/φ
. (5.6d)
The solution to JM is
JM =
jMNM
φ(ηM + 1/φ)
+ J0Me
−(ηM+1/φ)t. (5.7)
It is also possible to find the steady states for these classes; they are
P ∗F =
pNF
φ(α+ 1/φ)
,
J∗F =
(1− p)(α+ 1/φ)jFNF + q(α)αpNF
φ(ηF + 1/φ)(α+ 1/φ)
,
and
J∗M =
jMNM
φ(ηM + 1/φ)
.
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5.3.2 Steady States and their Stability
We can find the steady states of the system; those for PF and Ji are given above and
the remaining classes at steady state are
I∗F = 0 and I
∗
M = 0 or
I∗F = (zβ)
((1− 1R0 )(NF − J∗F )− P ∗F )
(zβ + γF + 1/φ)
,
and
I∗M =
(zβ)(NM − J∗M )((1− 1R0 )(NF − J∗F )− P ∗F )
zβ(NF − P ∗F − J∗F ) + (γM + 1/φ)(NF − J∗F )
.
Substituting all other steady state values into the equations for Ni gives the steady
state values of Si (S
∗
F = N
∗
F − P ∗F − J∗F − I∗F , S∗M = N∗M − J∗M − I∗M ).
Analysis of the full model system (5.2) can be reduced to explore the behaviours
of an equivalent 2-D system in the following way. The governing equations for PF , JF
and JM are uncoupled from the remainder of the system and hence stability of their
steady states can also be determined separately from the full system. Since we are
assuming a constant population size for each of the males and females, the dimension
of the infection system (SF , IF , SM , IM ) can further be reduced to consider the two
dimensional system for (IF , IM ):
dIF
dt
=
zβ
NM − JM IM (NF − PF − JF − IF )− (γF +
1
φ
)IF , (5.8a)
dIM
dt
=
zβ
NF − JF IF (NM − JM − IM )− (γM +
1
φ
)IM , (5.8b)
where JF (t), PF (t) and JM (t) are determined from the full system; see the previous
subsection. Behaviour of the full system can then be inferred from the behaviour of the
2-D system. We calculate the stability of the disease-free steady state (I∗F = I
∗
M = 0)
using the Jacobian of (5.8) evaluated at that point. This gives
B =

 −(γF + 1φ) zβ(NF−P ∗F−J∗F )NM−J∗M
zβ(NM−J∗M )
NF−J∗F
−(γM + 1φ)

 . (5.9)
Stability of this steady state requires that tr(J) < 0 and det(J) > 0. Since tr(J) < 0
for all parameter combinations, stability of the disease-free steady state requires that
(γF +
1
φ
)(γM +
1
φ
) >
(zβ)2(NF − P ∗F − J∗F )
NF − J∗F
, (5.10)
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i.e.
R0(NF − P ∗F − J∗F )
NF − J∗F
< 1. (5.11)
For
R0(NF−P ∗F−J∗F )
NF−J∗F
< 1 the disease-free steady state is stable, and is the only steady
state of the system. For
R0(NF−P ∗F−J∗F )
NF−J∗F
> 1, the disease-present steady state exists and
the disease-free steady state is unstable (this is an example of a transcritical bifurca-
tion).
5.3.3 “Effective” R0, R
e
0
Using (5.11), we see that Re0 =
R0(NF−P ∗F−J∗F )
NF−J∗F
= R0(1− f(p)) where
f(p) =
p(ηF + 1/φ)
φ(ηF + 1/φ)(α+ 1/φ)− ((1− p)(α+ 1/φ)jF + q(α)αp) . (5.12)
Eradication of infection in the population is only possible if Re0 < 1, which corre-
sponds to
f(p) > 1− 1
R0
. (5.13)
With the introduction of male vaccination, Re0 is modified to
Re0 = R0(1− fF (p))(1− fM (p)), where
fi(p) =
p(ηi + 1/φ)
φ(ηi + 1/φ)(α+ 1/φ)− ((1− p)(α+ 1/φ)ji + q(α)αp) . (5.14)
Initially we specify all gender specific parameters to be the same, which means that
Re0 = R0(1− f(p))2, and then infection can only be eradicated for the condition
f(p) > 1− 1√
R0
. (5.15)
We use (5.12)-(5.15) to explore the interplay between key behavioural parameters
ji and ηi, and vaccination parameters p and α in predicting conditions under which
HPV could be eradicated by an appropriate vaccination strategy. The dependence of
f(p) on these parameters in the case of female-only vaccination is shown in Figures
5-2a, 5-2c and 5-2e, from which we see that f(p) is an increasing function of p but a
decreasing function of both α and ηF , with variation in α causing the greatest variation
in f(p). According to (5.13) and (5.15), eradication of infection can only occur if f(p)
is sufficiently large - we see from Figure 5-2 that this will only happen if either p is
sufficiently large or if ηF or α is sufficiently small, with small α giving the largest change
in f(p).
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5.3.4 Vaccination in a Population already Sexually Active
Setting q(α) = ji = 0, we consider a vaccination strategy aimed at a population of
sexually active individuals. This is analogous to previous work presented in [68] and
gives the following results:
• For female-only vaccination
Re0 = R0(1−
p
φ(α+ 1/φ)
). (5.16)
• With female and male vaccination
Re0 = R0(1−
p
φ(α+ 1/φ)
)2. (5.17)
In both cases, as α decreases the period of vaccine efficacy increases and the pro-
portion of the population that should be vaccinated to eradicate HPV is reduced; this
reduction is more pronounced when both males and females are vaccinated. For ex-
ample, the value of p required when α is essentially lifelong (α = 1/φ) is less than half
of that required for p when the vaccine lasts for 20 years (all other parameters being
equal) for both female-only vaccination and for vaccination of both sexes, although in
the case of vaccination of both sexes, Re0 can be driven below 1 for a lower p value.
5.3.5 Female-only Vaccination
Figure 5-3 shows how Re0, for female-only vaccination as given by (5.16), varies with
the key model parameters. Using parameters from Table 3.2 we see that changes to
ηF are not able to drive infection from the population for any level of vaccination. By
contrast, provided that the vaccination is sufficiently long-lasting (α small) then if p is
large enough infection may be eradicated. For example, a vaccine lasting for at least 20
years (α = 0.05) in a population averaging 2 partners per year (z = 2), with coverage
of at least 70% of the female population (p ≥ 0.7), can drive Re0 < 1. Whilst changes
in ηF do not have a great impact on R
e
0, another behavioural parameter, z, does. In
particular, a reduction of z by less than 25% (z reduced from 2 to z = 1.6) results in
Re0 < 1 for a range of parameters.
5.3.6 Female and Male Vaccination
In Figure 5-2 we compare conditions (5.13) and (5.15), from which we see that the
addition of male vaccination makes eradication of infection possible for a wider range
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of parameter values. Where eradication is not possible, male vaccination allows the
system to have a lower Re0.
5.3.7 Critical Values
Corresponding to Re0 = 1 for the case with female-only vaccination, we can derive
critical values for ηF and α;
ηcritF =
(1− 1R0 )((1− p)(α+ 1/φ)jF + q(α)αp)
φ(α+ 1/φ)(1− 1R0 )− p
− 1
φ
.
As q = q(α), we can analytically define αcrit in terms of q(α) as
αcrit =
p(ηF + 1/φ)− (1− 1R0 )(ηF + 1φ −
(1−p)jF
φ )
(1− 1R0 )(φ(ηF + 1/φ)− (1− p)jF )− q(αcrit)p
.
With q(α) = 0.616α+0.051+α , we obtain a quadratic for α
crit;
(φ(ηF +
1
φ
)− (1− p)jF − 0.616p
(1− 1/R0))(α
crit)2
+ ((φ(ηF +
1
φ
)− (1− p)jF )(1 + 1
φ
)−
(p(ηF +
1
φ + 0.05))
(1− 1R0 )
)αcrit
− (
p(ηF +
1
φ)
(1− 1R0 )
− (ηF + 1− (1− p)jF
φ
)) = 0. (5.18)
The solutions of (5.18) are
αcrit =
−k ±
√
k2 + 4(φ(ηF +
1
φ)− (1− p)jF − 0.616p(1−1/R0))(
p(ηF+
1
φ
)
(1− 1
R0
)
− (ηF + 1−(1−p)jFφ ))
2(φ(ηF +
1
φ)− (1− p)jF − 0.616p(1−1/R0))
.
(5.19)
where k = ((φ(ηF +
1
φ)− (1− p)jF )(1 + 1φ)−
(p(ηF+
1
φ
+0.05))
(1− 1
R0
)
)). We now let
m = (φ(ηF +
1
φ)− (1−p)jF − 0.616p(1−1/R0)) and n = (
p(ηF+
1
φ
)
(1− 1
R0
)
− (ηF + 1−(1−p)jFφ )). If m > 0,
n > 0 and k < 0, either solution given in (5.19) is positive. If αcrit < 0, it means that
the disease could be eradicated regardless of the duration of protection offered by the
vaccine. For our standard parameter set, m > 0, k > 0 and n < 0, giving αcrit ≈ 0.023.
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Figure 5-2: Graphs showing how varying different parameters affects the point at which
Re0 = 1, for the cases both with and without male vaccination. Figures 5-2a, 5-2c and
5-2e show the case when there is no male vaccination. The other graphs represent the
situation with male vaccination. All parameters used are given as estimates in Table
3.2.
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Figure 5-3: Two graphs showing the effect on Re0 of varying two parameters. Figure
5-3a shows the change in Re0 against α and p, whereas 5-3b shows R
e
0 against ηF and
p. All other parameters are standard, taken from Table 3.2.
We can do the same to find a critical value for p, pcrit. This gives us
pcrit =
[φ(α+ 1/φ)(1− 1/R0)(ηF + (1− jF )/φ)]
(ηF + 1/φ+ (1− 1/R0)(α(q(α)− jF )− jF /φ)) . (5.20)
For Re0 < 1, we require p > p
crit. From the equation (5.20) we can see that, for R0 <
1, pcrit < 0 - i.e. that there is no minimum level of vaccination required to eradicate the
disease. When R0 > 1, p
crit > 0 provided (ηF + 1/φ)(
R0
R0−1) > (α(jF − q(α)) + jF /φ).
5.4 Numerical Solutions
We numerically solve the model both with and without male vaccination. Figure 5-4
shows infection prevalence for females and males corresponding to the Re0 values shown
in Figure 5-3, for the case of female-only vaccination. This highlights the heterogeneity
in infection prevalence between the two sexes as a result of a female-only vaccination
strategy. The initial conditions used are Pi(0) = 0, Ji(0) = 25000, Si(0) = 90750 and
Ii(0) = 9250, which are estimated using available data.
Figure 5-5 is analogous to Figure 5-4 and highlights two changes which arise with
the inclusion of male vaccination:
1. Infection prevalence in both sexes is the same when varying α and p since the
vaccination is the same for both sexes.
2. There is a wider range of parameter values for which infection can be removed
from the population.
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Figure 5-4: Four graphs showing the effect on the female and male infected steady
states as different parameters are varied. Figures 5-4a and 5-4b show the female and
male infected steady states as α and p are varied; 5-4c and 5-4d show the steady states
as ηF and p vary. All parameters come from the estimated values given in Table 3.2.
68
To directly compare the two vaccination strategies (female-only versus both sexes),
we compare values of f(p) required to achieve Re0 = 1 in (5.13) and (5.15) respectively.
The proportional reduction in f(p) when male vaccination is added to female-only
vaccination is given as
Λ =
f(p)|female-only − f(p)|female and male
f(p)|female-only
, (5.21)
i.e.
Λ =
√
R0 − 1
R0 − 1 . (5.22)
With R0 ≈ 1.4, male vaccination leads to around 45% reduction in the proportion
that should be vaccinated, although the population is now doubled to NF +NM . This
means that a greater number of individuals must be vaccinated than under female-only
vaccination. In fact, (5.22) shows that the percentage reduction will only be greater
than 50% when R0 < 1.
Figure 5-6 shows the time profiles for each compartment of the population for
the model with and without male vaccination, and surface plots for the number of
individuals in the protected and infected classes as the proportion of females vaccinated
(pF ) and males vaccinated (pM ) varies. The class profiles show that male vaccination,
when implemented at the same level as female vaccination, does not alter the path of
the profiles. The surface plots suggest that there is a symmetry between pF and pM ,
although the exact values show that there is a slight decrease in the total number of
infecteds when male vaccination is included, compared to female-only vaccination. It
does show that it is possible to halve the value of p so that the same total number of
individuals are vaccinated and not see an increase in infection prevalence.
5.5 Adding Natural Immunity
As a comparison to the SIS model presented thus far, we now introduce a recovered
class to consider an SIRS model as shown in Fig 5-7. Both SIS and SIR models
have previously been considered in relation to this topic [33, 39, 57] and as such it is
of interest to consider the different results produced when a (naturally) immune class
is introduced. As we can see from the schematic, the recovery can be permanent or
temporary, depending on the value of the parameter ǫi, and the proportion of indi-
viduals that develop natural immunity can be varied by varying σi. On studying this
system, the values of P ∗F , J
∗
F and J
∗
M are unchanged from the system without natural
immunity. We can once again solve for S∗i by using S
∗
F = NF − P ∗F − J∗F − I∗F − R∗F
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Figure 5-5: Four graphs showing the effect on the female and male infected steady
states as different parameters are varied for vaccination of both sexes. Figures 5-5a
and 5-5b show the female and male infected steady states as α and p are varied; 5-5c
and 5-5d show the steady states as ηF and p vary. All parameters come from the
estimated values given in Table 3.2.
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Figure 5-6: Graphs showing the class profiles for the model without male vaccination
(Figure 5-6a) and the model with male vaccination (Figure 5-6b; the female class
profiles lie under the the male ones). The second set of figures (Figures 5-6c, 5-6d
and 5-6e) show the total numbers of individuals in each type of class (Infected classes,
Infected female class, Protected classes) for the model as the proportion of both female
vaccinated (pF ) and male vaccinated (pM ) varies. The parameter values are all taken
from the standard set as seen in Table 3.2.
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and S∗M = NM − J∗M − I∗M −R∗M , where the equations for the Ri classes are
dRi
dt
= (1− σi)γiIi − (ǫi + µ)Ri, (5.23)
giving
R∗i =
(1− σi)γi
ǫi + µ
I∗i . (5.24)
The disease-present steady states for I∗i are affected by the existence of the Ri
classes, and become
I∗F = (zβ)
((1− 1R0 )(NF − J∗F )− P ∗F )
(zβ(1 + (1−σF )γFǫF+1/φ ) + (γF + 1/φ)(1 +
(1−σM )γM
ǫM+1/φ
))
,
and
I∗M =
(zβ)(NM − J∗M )((1− 1R0 )(NF − J∗F )− P ∗F )
zβ(1 + (1−σM )γMǫM+1/φ )(NF − P ∗F − J∗F ) + (γM + 1/φ)(1 +
(1−σF )γF
ǫF+1/φ
)(NF − J∗F )
.
The denominators are clearly positive, and so for these steady states to exist, we require
the numerators to be positive. These are exactly the same as those given in the system
without natural immunity. Equally, steady state analysis is the same with or without
natural immunity, so the work shown on Re0 for the SIS model above is also applicable
here.
Figure 5-8 shows a plot of the class profiles over time when natural immunity is
included in the model. Comparing it to Figure 5-6a shows that the introduction of
natural immunity does not qualitatively affect the outcome; infection is still present in
the model both with and without protection.
5.6 Conclusions
The results of this model show that, under certain circumstances, it is possible to
force Re0 under 1, and thus it may be possible to eradicate HPV from the population.
We assessed the effect that different behavioural and vaccination parameters have on
the value of Re0. Figures 5-2a, 5-2c and 5-2e show that by increasing the proportion
vaccinated, the value of Re0 will decrease. We see the opposite effect with α and ηF ,
as an increase in either of these parameters will cause Re0 to increase. These are all
as we would expect, and we note that there is close to a linear relationship between
p and f(p), but a nonlinear relationship exists between both α and f(p) and between
ηF and f(p). We also see that changing the value of α has the greatest effect on f(p),
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Figure 5-8: A graph of the class profiles over time when natural immunity is included in
the model. In the Figure 5-8a, vaccination is included; in 5-8b, there is no vaccination
present and the female classes lie underneath the male classes. All parameters and
initial conditions are as before (see Table 3.2); σi = 0.5, ǫi = 0.2.
suggesting that the duration of vaccine protection will have an important effect on the
final outcome.
Figure 5-2 shows how varying certain parameters can affect whether Re0 < 1 or not,
and we find that only for a long duration of protection is it possible to force Re0 < 1.
However, the duration of protection needed for this to happen is decreased when male
vaccination is included, suggesting that male vaccination may come into play if the
vaccination is shown to last less than 40 years.
The impact of α is confirmed in Figure 5-3, where we see plots of Re0 against different
parameters. For a value of α = 0.1, varying ηF and p cannot force R
e
0 under 1, but for
a value of ηF = 0.1, varying α and p shows that, for α < 0.04 and p > 0.7, it is possible
to push Re0 < 1 (for p = 0.7, α = 0.023 is the critical point for R
e
0 = 1).
Figure 5-4 shows how the values of different parameters affects the infected steady
states directly. This again supports the hypothesis that α has a much greater impact
than ηF , especially at higher values of p. Figures 5-4a and 5-4b show that, for a low
value of α, it is possible to reach the disease-free steady state (in both genders), but
that the disease-free steady state cannot be reached for α = 0.1 and varying ηF and p.
Figure 5-5 shows plots of infection prevalence (as in Figure 5-4), but for a model
containing both male and female vaccination. As expected, including vaccination on
both sexes increases the range of values of α and ηF for which prevalence is very low,
although this occurs for a wider range of values when varying α and p than when varying
ηF and p - which matches the results gained from the case of female-only vaccination.
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We also saw that the inclusion of male vaccination (at the same rate as for females)
led to a decrease of 45% in the percentage of individuals that needed to be vaccinated.
However, as these individuals came from both the male and female classes, this actually
leads to an increase in the total number of individuals that need to be vaccinated. We
found that it would only be possible to vaccinate fewer individuals when R0 < 1 and
vaccination may not be appropriate in this case anyway.
Figure 5-6 shows the benefit of including male vaccination. The values found when
including male vaccination indicate that vaccinating the same number of individuals
(both males and females) as would be vaccinated in the female-only vaccination strategy
leads to a slight decrease in the total prevalence of infection at steady state compared
to female-only vaccination. This is positive in itself, but holds further benefits if HPV
becomes recognised as a significant factor in other genital cancers.
Figure 5-8 shows the class profiles when the SIS model introduced at the start
of the Chapter is adapted to an SIRS format. The SIRS model (with the same set
of parameter values and initial conditions as for the SIS model) indicates that, with
or without a protected class, the results are qualitatively similar to the results from
the SIS model. Indeed, varying the σi and ǫi values suggested that the disease would
only be eradicated in the population when almost all (σi ≈ 0) individuals became
(permanently - ǫi ≈ 0) naturally immune.
These results show the importance of considering a range of different factors when
assessing the potential success of the vaccine. We see that the most important vac-
cination parameter of those we considered was α. From the behavioural parameters
considered, it is clear that the value of z will also have an important effect, as we find
it is possible to force Re0 < 1 by varying z, where other behavioural parameters (e.g.
the rate at which individuals become sexually active) cannot.
The inclusion of a non-sexually active class is a key difference between the work
presented here and most previous work, although [36] do introduce this idea for females.
Coupled with the inclusion of waning immunity, having this class allows us to explicitly
consider the effect of vaccination for a sexually transmitted infection in a group that
is (largely) not yet sexually active. We also consider male vaccination, and the effect
this has, specifically the impact of male vaccination on values such as Re0.
The importance of interplay between vaccination, epidemiological and behavioural
parameters is clearly demonstrated here. Of these, epidemiological parameters are
essentially fixed but vaccination parameters may be adjusted via public health strategy
(p) and further pharmaceutical developments (α). Modifying behavioural parameters
(ji, ηi, z) to assist the effectiveness of the vaccination programme is a more challenging
problem, which might only be addressed by educational programmes. Whether the
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significance of altering behaviours can be made clear through such a programme remains
to be seen.
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Chapter 6
The PDE model
6.1 Introduction
Sexually transmitted infections often lend themselves to age-structured models for sev-
eral reasons. Sexual mixing occurs mainly between individuals of a similar age [43, 59];
transmission probabilities can vary dependent on age [31] and sexual behaviour often
changes with age [3]. In our case, vaccination is targeted at a specific age group [2].
All of these factors indicate that an age-structured model may give us more accurate
results.
The aim of this Chapter is to build a model that is both age- and time-dependent.
We first consider an age-dependent ODE, then go on to study an age- and time-
dependent PDE, generating numerical solutions and comparing the results to both
the age-dependent ODE and the time-dependent model presented in Chapter 5.
We consider the model discussed in previous chapters as a system of PDE equa-
tions, dependent on age (a) and time (t). The inclusion of age as well as time allows
us to include age-dependence in key behavioural parameters. A discussion of these
parameters, and the age-dependent functions used, is given in Chapter 3.
6.2 ODE Model
We commence this Chapter by considering the age-dependent ODE model that is com-
parable to the time-dependent ODE models shown in Chapters 4 and 5. The key dif-
ference to the time-dependent ODE models is that our parameters can be represented
by age-dependent functions (given in Chapter 3); for completeness we also consider the
model with constant parameters. The schematic from which the ODE model is derived
is shown in Figure 6-1, and we consider the classes as only age-dependent.
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Figure 6-1: A schematic of the system.
From the schematic and considering only the temporally stable case, the ODE
model is
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dPF
da
= −(α(a) + µF (a))PF , (6.1a)
dJF
da
= −(ηF (a) + µF (a))JF + q(α)α(a)PF , (6.1b)
dSF
da
= −(λF (a) + µF (a))SF + (1− q(α))α(a)PF + ηF (a)JF + γF IF , (6.1c)
dIF
da
= −(γF + µF (a))IF + λF (a)SF , (6.1d)
dJM
da
= −(ηM (a) + µM (a))JM , (6.1e)
dSM
da
= −(λM (a) + µM (a))SM + ηM (a)JM + γMIM , (6.1f)
dIM
da
= −(γM + µM (a))IM + λM (a)SM , (6.1g)
dNF
da
= −µF (a)NF , (6.1h)
dNM
da
= −µM (a)NM . (6.1i)
All parameters are as discussed in Chapter 3. In the work that follows, we use two
different definitions for λi (i = F,M). In the first case we assume homogeneous mixing,
and so use a version of λi, λ
l
i, which is defined as
λli(a) = zi(a)β
∫ amax
a0
Ik(a
′)
Nk(a′)− Jk(a′) da
′, (6.2)
i, k = F,M , i 6= k, zi(a) and β are as defined in Chapter 3 [31].
However, for an age-dependent model, this does not take into account any hetero-
geneity of relationships occurring between individuals of different ages. To allow for
this, we assume heterogeneous mixing; the definition of this λi, λ
h
i , is
λhi (a) = zi(a)
∫ amax
a0
β(a, a′)
Ik(a
′)
Nk(a′)− Jk(a′) da
′, (6.3)
[31]. As described in Chapter 3, we set β(a, a′) = βA, where β is the constant probabil-
ity of transmission and A is a contact matrix, giving the probability of contact between
individuals of age a and a′.
To complete the model, we set the boundary conditions at age a0. These were
estimated as PF (a0) = 0.7NF (a0), JF (a0) = 0.225NF (a0), SF (a0) = 0.025NF (a0),
IF (a0) = 0.05NF (a0), JM (a0) = 0.855NM (a0), SM (a0) = 0.095NM (a, 0) and
IM (a0) = 0.05NM (a0).
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6.3 Solving the Equations
We can solve (6.1a), (6.1b), (6.1e), (6.1h) and (6.1i) analytically, giving the solutions
PF (a) = PF (a0)e
−
∫ a
a0
(α(s)+µF (s)) ds, (6.4)
JF (a) = JF (a0) + PF (a0)e
−
∫ a
a0
(ηF (s)+µF (s)) ds
∫ a
a0
α(w)q(α)e
−
∫ w
a0
(ηF (s)−α(s)) ds dw,
(6.5)
JM (a) = JM (a0)e
−
∫ a
a0
(ηM (s)+µM (s)) ds, (6.6)
and
Ni(a) = Ni(a0)e
−
∫ a
a0
µ(s) ds
, (6.7)
with i = F,M .
6.4 Numerical Solutions
From this model, we considered four different situations. We used either the ‘homoge-
neous mixing’ form of λi (6.2) or the more complicated form (6.3), and in each case we
used either constant or age-dependent parameters. The sections that follow consider
each of these cases and show the different results. We use a fourth order Runge-Kutta
numerical scheme to solve the equations. To find the values of λi, we use an iterative
method. We solve the model equations for the initial conditions and calculate the value
of λi. We repeat this, updating the values of λi after each iteration, until each of the
model equations and λi values converge to a solution. The Matlab code is given in
Appendix B.
6.4.1 Model with Constant Parameters, λli
This takes (6.1) and uses the constant parameter values given in Table 3.2 and (6.2)
(λli) as described above. Using Matlab to solve this numerically gives the class profiles
as shown in Figure 6-2, both with and without protection. In this case, we see that
infection persists in the model when a protected class exists, but that the proportion
of infected individuals is decreased by the presence of a vaccine.
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Figure 6-2: A graph showing all classes of the model with constant parameter values
and the λli. The parameter values and initial conditions are as described in Table 3.2
and in this Chapter, with γi = 1. Figure 6-2a shows the system when there is no
protected class (here the female classes lie underneath the male classes) and Figure
6-2b shows the system with a protected class and an average duration of immunity
from vaccination of 10 years.
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6.4.2 Model with Age-dependent Parameters, λli
This model uses the age-dependent set of parameters described in Chapter 3, but keeps
(6.2) as the force of infection. We also reduce γi to γi = 0.8 as the introduction of age-
dependent parameters reduces infection to very low levels. The numerical solution is
given in Figure 6-3. As in the previous subsection, we can see that infection persists
even when vaccination is included. We find that the peak of the proportion of infected
individuals is halved when vaccination is introduced. In contrast to Figure 6-2, the
population remains very close to 1 until a ≈ 40, when it starts to decrease slowly. The
survivorship curve shown in Figure 6-2 is more appropriate for ‘Type II’ survival [31].
Survival in Western countries tends to follow a ‘Type I’ survivorship curve, which is
approximated in Figure 6-3.
6.4.3 Model with Constant Parameters, λhi
We next move to the case of constant parameters and λhi , given in (6.3). The class
profiles are shown in Figure 6-4, again both with and without a protected class. Once
more we see that infection is present in both situations, although there is a higher
proportion of infected individuals when there is no protection. We also see that when
protection is included, the ‘take-off’ of infection is delayed and occurs only when the
protected class is very small. The biggest contrast between this case and Figure 6-3
is the survival curve - here, as in Figure 6-2, the shape of the survival curve is more
suited to ‘Type II’ survival [31].
6.4.4 Model with Age-dependent Parameters, λhi
We next move to the case of age-dependent parameters and λhi , given in (6.3). The
class profiles are shown in Figure 6-5 for the cases with and without protection. We see
that the introduction of vaccination has a dramatic impact in this case, as it virtually
eradicates infection. In comparison to the previous cases, Figure 6-5 shows a clear peak
in infection when no protection is present. The juvenile classes decrease more slowly
than with constant parameters. We use a smaller value of γi in this scenario, γi = 0.8,
as the combination of age-dependent parameters and λhi reduces the infected classes to
an extremely low proportion even without infection.
A consideration of the proportion of infected individuals present in the model when
there is a non-zero PF class and when PF (a) = 0 is shown in Figure 6-6. This shows
that without protection, there is a peak in the proportion infected between the ages
of 20 and 30, but the introduction of vaccination pushes the proportion of infected
individuals (both male and female) to very low levels.
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Figure 6-3: A graph showing all classes of the model with age-dependent parameter
values and λli. The parameter values and initial conditions are as described in Table
3.2 and in this Chapter, with γi = 0.8. Figure 6-3a shows the system when there is no
protected class and Figure 6-3b shows the system with a protected class and an average
duration of immunity from vaccination of 10 years.
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Figure 6-4: A graph showing all classes of the model with constant parameter values
and λhi . The parameter values and initial conditions are as described in Table 3.2 and
in this Chapter, with γi = 1. Figure 6-4a shows the system when there is no protected
class (here the female classes lie underneath the male classes) and Figure 6-4b shows the
system with a protected class and an average duration of immunity from vaccination
of 10 years.
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Figure 6-5: A graph showing all classes of the model with age-dependent parameter
values and λhi . The parameter values and initial conditions are as described in Table
3.2 and in this Chapter, with γi = 0.8. Figure 6-5a shows the system when there is no
protected class and Figure 6-5b shows the system with a protected class and an average
duration of immunity from vaccination of 10 years.
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Figure 6-6: A graph showing the infected classes of the model with age-dependent
parameter values and λhi , both when a protected class exists and when there is no
protected class. The parameter values and initial conditions are as described in Table
3.2 and in this chapter with γi = 0.8.
86
6.5 The PDE Model
We present a system incorporating age-dependence. This model takes age a0 as its
initial age, and divides the population into three or four classes, depending on whether
they are male or female (M or F ). In the male population, every individual is either
classified as susceptible, ‘juvenile’ (i.e. non-sexually active) or infected at age a. In the
female population a fourth class is added; that of protected individuals, who have been
vaccinated. A schematic of this can be seen in Fig. 6-1.
6.5.1 The Model
Using the age-dependent parameter functions as outlined in Chapter 3, the model
becomes
∂PF
∂t
+
∂PF
∂a
=− (α(a) + µF (a))PF (a, t), (6.8a)
∂JF
∂t
+
∂JF
∂a
=q(α)α(a)PF (a, t)− (ηF (a) + µF (a))JF (a, t), (6.8b)
∂SF
∂t
+
∂SF
∂a
=(1− q(α))α(a)PF (a, t) + ηF (a)JF (a, t) (6.8c)
+ γF IF (a, t)− (λF (a, t) + µF (a))SF (a, t),
∂IF
∂t
+
∂IF
∂a
=λF (a, t)SF (a, t)− (γF + µF (a))IF (a, t), (6.8d)
∂JM
∂t
+
∂JM
∂a
=− (ηM (a) + µM (a))JM (a, t), (6.8e)
∂SM
∂t
+
∂SM
∂a
=ηM (a)JM (a, t) + γMIM (a, t)− (λM (a, t)− µM (a))SM (a, t), (6.8f)
∂IM
∂t
+
∂IM
∂a
=λM (a, t)SM (a, t)− (γM + µM (a))IM (a, t), (6.8g)
∂NF
∂t
+
∂NF
∂a
=− µF (a)NF , (6.8h)
∂NM
∂t
+
∂NM
∂a
=− µM (a)NM . (6.8i)
As our model is age- as well as time-dependent, we cannot define a single R0 value;
rather we can define a series of R0 values based on the age of the initial infected
individual in an otherwise susceptible population [31]. Assuming the age of the initial
infected individual is a
′
, R0 for our model is,
R0,a′ =
z(a
′
)2
(γF + 1/φ)(γM + 1/φ)
[∫ amax
a0
β(a
′
, a)da
]2
. (6.9)
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All classes are as defined in previous Chapters and we set
λi(a, t) = zi(a)
∫ amax
a0
β(a, a′)Ik(a′, t)
Nk(a′, t)− Jk(a′, t) da
′. (6.10)
Note that i, k = M,F and i 6= k. As for the ODE model above, β(a, a′) = βA with β
and A given in Chapter 3.
6.5.2 PDE Boundary Conditions
We assume here that a0 ≤ a ≤ amax, where amax ≈ 77 and a0 ≈ 12. The boundary
conditions are the values for each of the classes at a = a0 and are as follows (p, ji as
defined in Chapter 3):
• PF (a0, t) = pNF (a0, t),
• JF (a0, t) = (1− p)jFNF (a0, t),
• SF (a0, t) = (1− p)(1− jF )NF (a0, t),
• IF (a0, t) = 0,
• JM (a0, t) = jMNM (a0, t),
• SM (a0, t) = (1− jM )NM (a0, t),
• IM (a0, t) = 0,
• Ni(a0, t) = Nia0.
Here, p is the proportion of girls that have been vaccinated by age a0, and (1 − p)jF
and jM represent the proportion of the population that are in the non-sexually active
female or male class at age a0 respectively.
6.5.3 Initial Conditions
We assume, at t = 0, that vaccination only takes place at a = a0. To calculate
the initial conditions for the Ji (i = F,M) classes we neglect death rate and (since
PF (a, 0) = 0, a 6= a0) any connection to the protected class. We leave Ji(a, 0) as
differential equations with respect to age, giving us dJida = −ηi(a)Ji. As we also assume
no transfer of infection at the instant t = 0, we take dSida = ηi(a)Ji. We define Ii(a, 0)
as I0i (a) - we not do not define it further at present, but will estimate it from the
data when calculating numerical solutions. The initial conditions for the Ni classes are
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estimated to be Gompertz functions in [31]; the exact values as given below are from
[61]. The initial conditions are listed below.
• PF (a, 0) = 0, a 6= a0,
• dJFda = −ηF (a)JF ,
• dSFda = ηF (a)JF ,
• IF (a, 0) = I0F (a),
• dJMda = −ηM (a)JM ,
• dSMda = ηM (a)JM ,
• IM (a, 0) = I0M (a),
• NF (a, 0) = e−(0.000189e0.1a),
• NM (a, 0) = e−(0.000354e0.098a).
It is also important that the boundary conditions for t = 0 are equal to the initial
conditions at a = a0.
6.6 Analysis
6.6.1 Characteristic Equations
Using the Method of Characteristics as shown in [69] and parametrising about a variable
s we can calculate the characteristics. We first arrange (6.8) into the form
∂Hi
∂t
+
∂Hi
∂a
+ µiHi = Gk(Hi), (6.11)
where i = F,M and k = 1, ..., 7, in order to calculate the characteristics and Hi
represents the different classes (the Gk are functions).
We set
dHi(s+ a− t, s)
ds
=
∂Hi(s+ a− t, s)
∂t
+
∂Hi(s+ a− t, s)
∂a
, (6.12)
giving
dHi(s+ a− t, s)
ds
+ µi(s+ a− t)Hi(s+ a− t, s) = Gk(Hi). (6.13)
Using an integrating factor, we can then solve the equations for a < t and a ≥ t. On
doing this, and setting Hi(a, 0) = H
0
i , the characteristics are
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PF =


e−
∫ t
0 µF (τ+a−t)dτP 0F (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (−α(s+ a− t)PF (s+ a− t, s)) ds a ≥ t
PF (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (−α(s)PF (s, s+ t− a)) ds a < t
(6.14)
JF =


e−
∫ t
0 µF (τ+a−t)dτJ0F (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (q(α)α(s+ a− t)PF (s+ a− t, s)) ds
− ∫ t0 e− ∫ ts µF (τ+a−t)dτηF (s+ a− t)JF (s+ a− t, s) ds a ≥ t
JF (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (q(α)α(s)PF (s, s+ t− a)) ds
− ∫ aa0 e− ∫ as µF (τ)dτηF (s)JF (s, s+ t− a) ds a < t
(6.15)
SF =


e−
∫ t
0 µF (τ+a−t)dτS0F (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ ((1− q(α))α(s+ a− t)PF (s+ a− t, s)) ds
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (ηF (s+ a− t)JF (s+ a− t, s)) ds
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτγF IF (s+ a− t, s) ds
− ∫ t0 e− ∫ ts µF (τ+a−t)dτ (λF (s+ a− t, s)SF (s+ a− t, s)) ds a ≥ t
SF (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ ((1− q(α))α(s)PF (s, s+ t− a)) ds
+
∫ a
a0
e−
∫ a
s
µF (τ)dτηF (s)JF (s, s+ t− a)) ds
+
∫ a
a0
e−
∫ a
s
µF (τ)dτγF IF (s, s+ t− a) ds
− ∫ aa0 e− ∫ as µF (τ)dτ (λF (s, s+ t− a)SF (s, s+ t− a)) ds a < t
(6.16)
IF =


e−
∫ t
0 µF (τ+a−t)dτI0F (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (λF (s+ a− t, s)SF (s+ a− t, s)) ds
− ∫ t0 e− ∫ ts µF (τ+a−t)dτ (γF IF (s+ a− t, s)) ds a ≥ t
IF (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (λF (s, s+ t− a)SF (s, s+ t− a)) ds
− ∫ aa0 e− ∫ as µF (τ)dτ (γF IF (s, s+ t− a)) ds a < t
(6.17)
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JM =


e−
∫ t
0 µF (τ+a−t)dτJ0M (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (−ηM (s+ a− t)JM (s+ a− t, s)) ds a ≥ t
JM (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (−ηM (s)JM (s, s+ t− a)) ds a < t
(6.18)
SM =


e−
∫ t
0 µF (τ+a−t)dτS0M (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (ηM (s+ a− t)JM (s+ a− t, s)) ds
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (γMIM (s+ a− t, s)) ds
− ∫ t0 e− ∫ ts µF (τ+a−t)dτ (λM (s+ a− t, s)SM (s+ a− t, s)) ds a ≥ t
SM (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (ηM (s)JM (s+ t− a, s)) ds
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (γMIM (s+ t− a, s)) ds
− ∫ aa0 e− ∫ as µF (τ)dτλM (s+ t− a, s)SM (s+ t− a, s)) ds a < t
(6.19)
IM =


e−
∫ t
0 µF (τ+a−t)dτI0M (a− t)
+
∫ t
0 e
−
∫ t
s
µF (τ+a−t)dτ (λM (s+ a− t, s)SM (s+ a− t, s)) ds
− ∫ t0 e− ∫ ts µF (τ+a−t)dτ (γMIM (s+ a− t, s)) ds a ≥ t
IM (a0, (a0 − a) + t)e−
∫ a
a0
µF (τ)dτ
+
∫ a
a0
e−
∫ a
s
µF (τ)dτ (λM (s, s+ t− a)SM (s, s+ t− a)) ds
− ∫ aa0 e− ∫ as µF (τ)dτ (γMIM (s, s+ t− a)) ds a < t
(6.20)
6.6.2 Numerical Solutions
In order to retrieve numerical solutions, we estimate the initial and boundary conditions
from available data. PF (a, 0) is a smoothed approximation for current government
policy [2]; Si(a, 0) and Ji(a, 0) are estimated using [3], Ii(a, 0) is estimated using data
given in [63], and Ni(a, 0) are estimated in [61]. The initial conditions are therefore
estimated to be
• NF (a, 0) = e−(0.0000189e0.1(a)),
• NM (a, 0) = e−(0.0000354e0.098(a)),
• PF (a, 0) =
{
pNF (a, 0)(1− 0.9(1+exp(16.3−a)))cos(πl)3 a < 21
0 a ≥ 21.
where l = 4736(a−12)76657 ,
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• JF (a, 0) = ((1− 0.9(1+exp(16.3−a)))NF (a, 0)− PF (a, 0)),
• IF (a, 0) = (0.23e−(
(a−21.8)
12.5
)2)( 0.9(1+exp(16.3−a)))NF (a, 0),
• SF (a, 0) = (1− 0.23e−(
(a−21.8)
12.5
)2)( 0.9(1+exp(16.3−a)))NF (a, 0),
• SM (a, 0) = (1− 0.23e−(
(a−21.8)
12.5
)2)( 0.9(1+exp(13.3−0.8a)))NM (a, 0),
• JM (a, 0) = (1− 0.9(1+exp(13.3−0.8a)))NM (a, 0),
• IM (a, 0) = (0.23e−(
(a−21.8)
12.5
)2)( 0.9(1+exp(13.3−0.8a)))NM (a, 0).
Analysis of the PDE is difficult, as we see in the previous subsection, but it is
possible to generate numerical solutions for the PDE. We numerically solve (6.8) using
a finite difference scheme given in Appendix B (using [70]) to predict the distribution
of each class. Figure 6-7 shows three graphs, the first (6-7a) showing the initial class
distributions, 6-7b showing the distributions after 25 years and 6-7c showing the dis-
tributions after 40 years. They show that vaccination at 70% for the initial age class
can virtually eradicate the disease in both males and females over a 40 year period.
Figure 6-8 shows the female infection class profile after 25 and 50 years for varying
values of α(a). After 25 years the greatest difference is between the profile when there is
an average of 5 years protection and the other profiles. After 50 years, that difference is
much more pronounced and we also see a larger difference between the infection profile
with a 10 year vaccine and the infection profiles with 20 and 40 year vaccines. With
the latter two, female infection is almost eradicated after 50 years.
Figure 6-9 shows the varying female infection profiles after 25 years when we vary
the value of p. This figure shows that the value of p has a large impact on the infection
profile, with the higher values of p leading to much lower peaks in the infection profile
after 25 years.
6.7 Conclusions
In this Chapter we have introduced age-dependence to our system. We initially studied
an age-dependent ODE model, in a variety of situations. We were able to partially
analyse this model and found expressions for the PF (a), Ji(a) and Ni(a) classes.
Figures 6-2 - 6-5 show the age-dependent ODE in a number of ways, varying both
the choice of λi and the functions used for the parameters. In all cases, infection
was shown to persist (albeit potentially at very low levels) despite the introduction of
vaccination, although the infected class profiles are particular to each situation. From
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Figure 6-7: Numerical solutions of the PDE model initially (Figure 6-7a), after 25 years
(Figure 6-7b) and after 40 years (Figure 6-7c). The initial conditions and parameter
values are described in Chapter 3, with γi = 0.8.
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Figure 6-8: Graphs of IF as α varies after 25 (Figure 6-8a) and 50 (Figure 6-8b)
years. All other parameters and initial and boundary conditions are as described in
this Chapter and Chapter 3, with γi = 0.8.
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Figure 6-9: A graph of IF as p varies after 25 years. All other parameters and initial
and boundary conditions are as described in this chapter and Chapter 3.
a modelling perspective, these results show that it is possible to generate very different
outcomes from the same model, dependent on the form of the parameters and force
of infection. The case illustrated by Fig 6-5 is the most accurate of the four ODE
cases studied, and the results found most closely emulate those shown when the PDE
is solved numerically. In drawing a conclusion, these results show the choice of model
and model parameters can influence any predictions. Our conclusions from Figure 6-
5 suggest that the introduction of vaccination means that it is possible to virtually
eradicate the disease.
We were able to find the characteristics for the PDE using the Method of Charac-
teristics. We were able to describe the forms of the characteristics, using the method
presented in [69]; defining the characteristics in this way means that further analytical
work may be more straightforward.
The numerical solutions in Figure 6-7 for the PDE show that, over time, the intro-
duction of a protected class has the ability to eradicate the infection from the popu-
lation. The initial conditions for this system can be seen in Figure 6-7a and show the
profile for the infected classes as vaccination is introduced. Figure 6-7c suggests that,
40 years after the introduction of the vaccine, the disease has almost been eradicated.
This result is supported by the results from the age-dependent ODE with age-dependent
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parameters and λhi , and can also be matched to the time-dependent ODE presented in
Chapter 5 for a non-standard parameter set (i.e. when z = 1.7). These results suggest
that current vaccination policy may be sufficient to virtually eradicate HPV from the
population in 40 years. Figures 6-8 and 6-9 show the influence α and p have on the
female infection profile over time. We see that, contrary to the time-dependent ODE
case, over 25 years p has a larger impact than α. Over a 50 year time span, we see that
α has a large effect, with the smaller values of α able to drive female infection almost
to eradication. We probably only see this difference after 50 years as the true impact
of the longer-lasting vaccines will only become apparent over a longer time period. The
following Chapters will now assess the cost-effectiveness of that vaccination strategy,
and whether there is a more cost-effective way to deliver the vaccine.
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Chapter 7
Optimal Control applied to an
ODE Model
7.1 Introduction
The introduction of the HPV vaccine generated much debate about its value for money,
and the most cost-effective way to deliver it. This is discussed in some detail in Chapter
1. Several analyses of the cost-effectiveness of the HPV vaccine have been carried out;
the models all produce slightly different results dependent upon the assumptions made
in each model, but almost all agree that female-only vaccination is more cost-effective
than vaccinating both males and females [12, 22, 37]. Here we take a different approach
to previous models - we explore the solution of an optimal control problem in which
we minimise the costs associated with both treatment of infecteds and the vaccination
programme, subject to the underlying infection dynamics.
We present a detailed description of previous optimal control work in Chapter 1.
Optimal control has been applied to infectious disease problems in the past, and is
a good method for determining how best to control a disease. Sethi and Staats [47]
and [46] both provide an overview of optimal control as applied to some deterministic
models, including a situation with vaccination. O¨gren and Martin [49] apply optimal
control to structured SIR models to determine the optimal vaccination policy for pop-
ulations that are very mobile, making their minimisation problem one that considers
both the proportion who fall ill and the cost of the vaccine. Lenhart and Workman [44]
introduce many examples of optimal control applied to different problems, including
an infectious disease problem.
The notation we use to develop an optimal control model follows that given in [44],
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in that we define the differential equation (state equation) to be
x
′
(t) = g(t, x(t), u(t)), (7.1)
with control u(t) acting on it (x(t) and u(t) can either be single variables or vectors of
variables [y1, ..., yn]). The objective functional is defined to be
J(u) :=
∫ t1
t0
f(t, x(t), u(t))dt. (7.2)
We are interested in either minimising or maximising (depending on the exact problem
being considered) the objective functional subject to (7.1) - i.e. in finding the optimal
functions u∗(t) and x∗(t) such that (7.2) is either maximised or minimised. We can do
this by using Pontryagin’s Maximum Principle. As stated in [44], this is
Theorem 1 If u∗(t) and x∗(t) are optimal for
max
u
∫ t1
t0
f(t, x(t), u(t)) dt
subject to
x
′
(t) = g(t, x(t), u(t))
x(t0) = x0 and x(t1) free.
then there exists a piecewise differentiable adjoint variable λ(t) such that
H(t, x∗(t), u(t), λ(t)) ≤ H(t, x∗(t), u∗(t), λ(t))
for all controls u at each time t, where the Hamiltonian H is
H = f(t, x(t), u(t)) + λ(t)g(t, x(t), u(t)),
and
λ
′
(t) = −∂H(t, x
∗(t), u∗(t), λ(t))
∂x
λ(t1) = 0.
By defining the Hamiltonian as in the Theorem above, we can find u∗(t) through
differentiation; ∂H∂u = 0 at u
∗(t). This will generally depend on the adjoint equation,
which we can find as described in the Theorem. Once we have found u∗(t), we can
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substitute it into the state equation (7.1) to find x∗(t).
Returning to the problem described above in (7.1) and (7.2) and following Pontrya-
gin’s Maximum Principle as stated above, we find the Hamiltonian to be
H(t, x, u, λ) := f(t, x, u) + λg(t, x, u).
From here we can deduce the optimality condition, the adjoint equation and the
transversality condition, all of which will be used in determining the optimal control,
u∗(t). The optimality condition is
∂H
∂u
|u∗ = 0 ⇒ fu + λgu |u∗ = 0,
(note that the problem is a minimisation problem if H is convex, i.e. if ∂
2H
∂u2
> 0 and a
maximisation problem if H is concave, i.e. if ∂
2H
∂u2
< 0 [44]), with adjoint equation
λ
′
= −∂H
∂x
⇒ λ′ = −(fx + λgx),
and transversality condition
λ(t1) = 0.
Finally, the state equation can also be described as
x
′
(t) = g(t, x, u) =
∂H
∂λ
, x(t0) = x0.
From the optimality equation we can find u∗, thus giving us the form of the optimal
control function.
We present a model which allows for vaccination of both an adolescent female
population and a catch-up programme for vaccination of females in their late teens.
Parameters linked to costs and underlying infection dynamics are estimated from a
range of published sources. We compare our results to a system with constant control,
and one allowing for male vaccination, to show how these alternative scenarios impact
on the optimal control solution.
7.2 Model
We construct an optimal control problem, for which the objective functional which
we wish to minimise is the total cost associated with HPV infection within a closed
population and the related vaccination programme. This functional is constrained by
the underlying infection dynamics within the population, which are represented by a
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Figure 7-1: Schematic of the model system. It shows the basic dynamics of the model
and the controls ujf (t) and usf (t) which move individuals from the non-sexually active
female class to the protected female class and from the sexually active female class to
the protected female class respectively. The force of infection is λi = zβIk/(Nk − Jk)
(z, β defined in Table 3.2, i, k = F,M, i 6= k).
compartmental model in which the individuals are classified according to gender and
infection status, as for our model of infection dynamics in Chapter 5.
We present a slightly different model to previous Chapters, although we include the
same classes as in Chapter 5. In this case, individuals enter the model either through
the non-sexually active class or the susceptible class. Individuals then leave these
classes and enter the protected class at a rate ujf (t) or usf (t) - these are the controls
acting on the non-sexually active and sexually active female classes respectively.
The model schematic is given in Figure 7-1. All parameters used in the model
are defined, and their ranges given, in Table 3.2. The rates of vaccination of the
non-sexually active and the sexually active classes are ujf (t) and usf (t) respectively.
Combining these assumptions produces the following model system for HPV infection:
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dJF
dt
=
jFNF
φ
+ αq(α)PF − (ujf (t) + ηF + 1
φ
)JF , (7.3a)
dSF
dt
=
(1− jF )NF
φ
+ ηFJF − λFSF + γF IF − (usf (t) + 1
φ
)SF + (1− q(α))αPF ,
(7.3b)
dPF
dt
= ujf (t)JF + usf (t)SF − (α+ 1
φ
)PF , (7.3c)
dIF
dt
= λFSF − (γF + 1
φ
)IF , (7.3d)
dJM
dt
=
jmNM
φ
− (ηM + 1
φ
)JM , (7.3e)
dSM
dt
=
(1− jM )NM
φ
+ ηMJM − λMSM + γMIM − 1
φ
SM , (7.3f)
dIM
dt
= λMSM − (γM + 1
φ
)IM . (7.3g)
To completely specify the problem, we include initial conditions (JF (0) = 12500,
SF (0) = 103325, PF (0) = 0, IF (0) = 9175, JM (0) = 12500, SM (0) = 103325,
IM (0) = 9175) which are based on data estimates of prevalence and sexual activity
from a population prior to vaccination [3, 63].
In the absence of any control, R0 is given as
R0 =
(zβ)2
(γF + 1/φ)(γM + 1/φ)
. (7.4)
7.2.1 Adding Optimal Control
We include optimal control in the model through the rates of vaccination, ujf (t) and
usf (t), which act on the non-sexually active (JF (t)) and the sexually active (SF (t))
female classes respectively. These controls (ujf (t) and usf (t)) represent the proportion
of each class that is vaccinated per unit time (year). We set a maximum for both
ujf (t) and usf (t) that equates to 90% coverage, as this is a reasonable estimate for
the maximum coverage that can be realistically achieved. The model parameters ujf
and usf are annual rates and hence 90% coverage corresponds to max(un) = 2.3,
n = jf, sf . We calculate this by considering that the only way for individuals to leave
(e.g.) the non-sexually active class is by vaccination, giving JF (t) = JF (0)e
−ujf t. For a
90% annual vaccination rate, we therefore need to solve 0.1JF (0) = JF (0)e
−ujf , giving
ujf = 2.3.
The costs associated with vaccination appear as quadratic terms in the objective
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functional. A quadratic term is chosen to describe the nonlinear behaviour of the
cost of implementing a vaccination programme; per unit vaccinated it becomes more
expensive to vaccinate once a higher proportion of the population is targeted [50]. The
form of the objective functional follows previous applications of optimal control to the
management of infectious diseases [44, 51, 52], as discussed in Chapter 1.
Combining the factors described above we obtain the optimal functional
min
u
J(u) =
∫ T
0
[AIF (t) + cu
2
jf (t) + du
2
sf (t)] dt, (7.5)
u ∈ {un : 0 ≤ un ≤ 2.3} , n = jf, sf
subject to the underlying dynamics given in (7.3).
The weightings A, c and d relate to the costs of infection (A) and vaccination (c
and d). The parameter A includes the cost of screening women and the cost of further
tests and treatment in the case of a positive smear test. We include the probabilities
of progression to pre-cancerous lesions, CIN and cancer with the cost of each stage to
give an overall cost on infection, from [71]. To calculate c and d we use the cost of three
doses of the vaccine plus the administration costs. To calculate these parameters we
use data from [10] which suggests that the cost of vaccination is £60 per dose, with ≈
£3.56 pounds per dose administration costs when vaccination is administered through
the school and ≈ £10 per dose administration costs when the vaccine is administered
by a GP. We equate the cost of vaccination in schools to the cost of vaccinating non-
sexually active individuals, and the cost of vaccination at GP surgeries to the cost of
vaccinating sexually active individuals. On multiplying these costs by an estimated
number of individuals in the appropriate class (non-sexually active and sexually active
class respectively), we find the scaled estimates for these values are A = 0.0002, c = 0.1
and d = 1.
To understand the importance of using an optimal control approach, we compare
results obtained with the system above to the output of a model which assumes a
constant vaccination strategy. To do this, we replaced ujf (t) and usf (t) with the
constant p/φ, where φ is the average lifespan of individuals from the age of 12 and p is
the proportion vaccinated in their lifetime (see Table 3.2 for parameter values).
To compare the current vaccination strategy with one which allows for vaccination of
both sexes, we extend (7.3) to include two more controls ujm(t) and usm(t) - vaccination
of males in the non-sexually active and sexually active classes respectively. The revised
model is given in Section 7.2.2. Since HPV-16 and -18 are rarely treated in males in the
UK [8], we assume both that there is no cost to treating infected males (i.e. weighting
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on IM (t) in the objective functional, B, is zero) and that there is a small cost associated
to vaccinating males (B = 0.0001).
7.2.2 The Hamiltonian and Optimal Solution
Applying this theory specifically to the model presented in (7.3), we find that the
Hamiltonian takes the form
H = AIF + cu
2
jf + du
2
sf + λ1(
jFNF
φ
− (ηF + ujf (t) + 1
φ
)JF + q(α)αPF )
+ λ2(
(1− jF )NF
φ
+ ηFJF − zβSF IM
NM − JM + γF IF − (usf (t) +
1
φ
)SF + (1− q(α))αPF )
+ λ3(ujf (t)JF + usf (t)SF − (α+ 1
φ
)PF ) + λ4(
zβSF IM
NM − JM − (γF +
1
φ
)IF )
+λ5(
jMNM
φ
− (ηM + 1
φ
)JM )+λ6(
(1− jM )NM
φ
+ ηMJM − zβSMIF
NF − JF + γMIM −
1
φ
SM )
+ λ7(
zβSMIF
NF − JF − (γM +
1
φ
)IM ).
The adjoint equations follow directly from this and are given as
λ
′
1 = (ηF + ujf (t) +
1
φ
)λ1 − ηFλ2 − ujf (t)λ3 + zβSMIF
(NF − JF )2λ6 −
zβSMIF
(NF − JF )2λ7,
(7.6a)
λ
′
2 = (
zβIM
NM − JM + usf (t) +
1
φ
)λ2 − usf (t)λ3 − zβIM
NM − JM λ4, (7.6b)
λ
′
3 = −q(α)αλ1 − (1− q(α))αλ2 + (α+
1
φ
)λ3, (7.6c)
λ
′
4 = −A− γFλ2 + (γF +
1
φ
)λ4 +
zβSM
NF − JF λ6 −
zβSM
NF − JF λ7, (7.6d)
λ
′
5 =
zβSF IM
(NM − JM )2λ2 −
zβSF IM
(NM − JM )2λ4 + (ηM +
1
φ
)λ5 − ηMλ6, (7.6e)
λ
′
6 = (
zβIF
NF − JF +
1
φ
)λ6 − zβIF
NF − JF λ7, (7.6f)
λ
′
7 =
zβSF
NM − JM λ2 −
zβSF
NM − JM λ4 − γMλ6 + (γM +
1
φ
)λ7, (7.6g)
with transversality conditions λw(T ) = 0 (w = 1, ..., 7, T is the end time). Using the
Hamiltonian, we obtain the optimality conditions
u∗jf (t) =
(λ1 − λ3)JF
2c
,
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and
u∗sf (t) =
(λ2 − λ3)SF
2d
.
Including male vaccination
In order to judge whether it can be cost-effective to vaccinate males as well as females,
we compare the model described above with one that includes male vaccination. This
model includes another class, the protected male class PM (t), so the model is the same
for both the male and female genders. This means the inclusion of another two controls
on the male classes, ujm(t) and usm(t), which mimic the controls described above in the
female-only vaccination scenario. As mentioned above, the weighting on male infection
is B, with B = 0 or B = 0.0001 in the numerical solutions. The problem with a male
vaccinated class is as follows:
min
u
J(u) =
∫ T
0
[AIF (t) +BIM (t) + c(u
2
jf (t) + u
2
jm(t)) + d(u
2
sf (t) + u
2
sm(t))] dt,
u ∈ {ub : 0 ≤ ub ≤ 2.3} b = jf, sj, jm, sm,
subject to
dJF
dt
=
jFNF
φ
+ αq(α)PF − (ujf (t) + ηF + 1
φ
)JF , (7.7a)
dSF
dt
=
(1− jF )NF
φ
+ ηFJF − λFSF + γF IF − (usf (t) + 1
φ
)SF + (1− q(α))αPF ,
(7.7b)
dPF
dt
= ujf (t)JF + usf (t)SF − (α+ 1
φ
)PF , (7.7c)
dIF
dt
= λFSF − (γF + 1
φ
)IF , (7.7d)
dJM
dt
=
jMNM
φ
+ αq(α)PM − (ujm(t) + ηM + 1
φ
)JM , (7.7e)
dSM
dt
=
(1− jM )NM
φ
+ ηMJM − λMSM + γMIM − (usm(t) + 1
φ
)SM + (1− q(α))αPM ,
(7.7f)
dPM
dt
= ujm(t)JM + usm(t)SM − (α+ 1
φ
)PM , (7.7g)
dIM
dt
= λMSM − (γM + 1
φ
)IM . (7.7h)
We can generate the Hamiltonian, adjoint equations and characterise the optimal
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control as before; the adjoint equations are
λ
′
1 = (ηF + ujf (t) +
1
φ
)λ1 − ηFλ2 − ujf (t)λ3 + zβSMIF
(NF − JF )2λ6 −
zβSMIF
(NF − JF )2λ8,
(7.8a)
λ
′
2 = (
zβIM
NM − JM + usf (t) +
1
φ
)λ2 − usf (t)λ3 − zβIM
NM − JM λ4, (7.8b)
λ
′
3 = −q(α)αλ1 − (1− q(α))αλ2 + (α+
1
φ
)λ3, (7.8c)
λ
′
4 = −A− γFλ2 + (γF +
1
φ
)λ4 +
zβSM
NF − JF λ6 −
zβSM
NF − JF λ8, (7.8d)
λ
′
5 = (ηM + ujm(t) +
1
φ
)λ5 − ηMλ6 − ujm(t)λ7 + zβSF IM
(NM − JM )2λ2 −
zβSF IM
(NM − JM )2λ4,
(7.8e)
λ
′
6 = (
zβIF
NF − JF + usm(t) +
1
φ
)λ6 − usm(t)λ7 − zβIF
NF − JF λ8, (7.8f)
λ
′
7 = −q(α)αλ5 − (1− q(α))αλ6 + (α+
1
φ
)λ7, (7.8g)
λ
′
8 = −B − γMλ6 + (γM +
1
φ
)λ8 +
zβSF
NM − JM λ2 −
zβSM
NM − JM λ4, (7.8h)
with transversality conditions λq(T ) = 0 (q = 1, ..., 8, T is end time). The female
optimal control functions are characterised as
u∗jf (t) =
(λ1 − λ3)JF
2c
,
and
u∗sf (t) =
(λ2 − λ3)SF
2d
.
The male controls are
u∗jm(t) =
(λ5 − λ7)JM
2c
,
and
u∗sm(t) =
(λ6 − λ7)SM
2d
.
7.3 Numerical Solutions
We solve the optimal control problems (both with and without male vaccination), com-
prising of the model equations, the adjoint equations and the optimal control functions
using a numerical method as described in [44]. The Matlab code is given in Appendix
B.
Figure 7-2 shows the solution profiles and control functions for α = 0.05, α = 0.1 and
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α = 0.2. As the duration of protection increases (α decreasing), both controls decrease,
although ujf (t) is always less than usf (t). For shorter durations of protection (α = 0.2,
α = 0.1), over time the optimal solution is to vaccinate both the sexually active and
non-sexually active classes, but to decrease the vaccination on the non-sexually active
more rapidly (at first) than the vaccination on the sexually active (Figures 7-2b and
7-2d). For a 20 year vaccine (α = 0.05), the decrease in vaccination for the non-sexually
active females mirrors that for the sexually active class. This is because the vaccine
will still be effective when these individuals become sexually active.
To understand more about the interplay between the two control approaches (ujf (t)
and usf (t)), we solved the optimal control problem first by setting ujf (t) ≡ 0 and
looking at the resulting time profile for usf (t) and then reversing the situation to
consider ujf (t) with usf (t) ≡ 0. The numerical solution profiles which we obtained
are shown in Figure 7-3. The two scenarios differ significantly. When ujf (t) ≡ 0,
usf (t) deviates very little from the profile shown in Figure 7-2 for the corresponding α
value. However, when usf (t) ≡ 0, ujf (t) begins at the maximum level of control, and is
maintained at a higher value for longer (compared to Figure 7-2). With longer lasting
protection, vaccine coverage for the non-sexually active class increases (compared to
Figure 7-3d), which results in slightly lower infection levels (compared to Figure 7-
3c), but these levels are still much higher than with the vaccination of sexually active
individuals only (Figure 7-3a).
As the cost of catch-up vaccination for sexually active individuals increases, there
is a response through the vaccination of non-sexually active individuals. As shown
in Figure 7-4, the more costly the catch-up programme (d increasing), the higher the
vaccination of non-sexually active individuals should be.
7.3.1 Constant Control
Figure 7-5 provides a comparison between the optimal control problem and a constant
control problem for two values of the contact parameter z. In both cases infection is
reduced to very low levels, although with low z (Figures 7-5a and 7-5b), the optimal
control problem has a significantly lower protected class than the optimal control prob-
lem with a higher z value. For both values of z the constant control model has a much
larger protected class than the optimal control problem.
7.3.2 Male Vaccination
The inclusion of male vaccination produces interesting results which we present in
Figure 7-6. Despite little or no cost associated with male infection, the optimal control
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solution maintains a vaccination programme for males which, in the case of the non-
sexually active individuals, exceeds that for the females. For sexually active individuals,
control on the males shadows that for the females. When we set B = 0.0001 = A/2,
we see that the male and female controls are extremely similar in their behaviour. In
all cases, the lowest rate of vaccination is that for the non-sexually active females and
the highest rate is for sexually active females, with the male vaccination rates falling
between these two extremes.
7.4 Adding Natural Immunity
As in Chapter 5, we now add natural immunity to the model to see if this impacts on
our results. Gaff and Schaefer [50] found through their work that the exact structure of
the system (SIR/SIRS/SEIR) did not have much influence on the optimal solution.
We tested this with our model, which becomes
min
u
J(u) =
∫ T
0
[AIF (t) + cu
2
jf (t) + du
2
sf (t)] dt, (7.9)
u ∈ {un : 0 ≤ ui ≤ 2.3} , n = jf, sf
subject to
dJF
dt
=
jFNF
φ
+ αq(α)PF − (ujf (t) + ηF + 1
φ
)JF , (7.10a)
dSF
dt
=
(1− jF )NF
φ
+ ηFJF − λFSF + σFγF IF − (usf (t) + 1
φ
)SF
+ (1− q(α))αPF + ǫFRF , (7.10b)
dPF
dt
= ujf (t)JF + usf (t)SF − (α+ 1
φ
)PF , (7.10c)
dIF
dt
= λFSF − (γF + 1
φ
)IF , (7.10d)
dRF
dt
= (1− σF )γF IF − (ǫF + 1
φ
)RF , (7.10e)
dJM
dt
=
jmNM
φ
− (ηM + 1
φ
)JM , (7.10f)
dSM
dt
=
(1− jM )NM
φ
+ ηMJM − λMSM + σMγMIM + ǫMRM − 1
φ
SM , (7.10g)
dIM
dt
= λMSM − (γM + 1
φ
)IM , (7.10h)
dRM
dt
= (1− σM )γMIM − (ǫM + 1
φ
)RM . (7.10i)
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The adjoint equations are
λ
′
1 = (ηF + ujf (t) +
1
φ
)λ1 − ηFλ2 − ujf (t)λ3 + zβSMIF
(NF − JF )2λ7 −
zβSMIF
(NF − JF )2λ8,
(7.11a)
λ
′
2 = (
zβIM
NM − JM + usf (t) +
1
φ
)λ2 − usf (t)λ3 − zβIM
NM − JM λ4, (7.11b)
λ
′
3 = −q(α)αλ1 − (1− q(α))αλ2 + (α+
1
φ
)λ3, (7.11c)
λ
′
4 = −A− σFγFλ2 + (γF +
1
φ
)λ4 − (1− σF )γFλ5 + zβSM
NF − JF λ7 −
zβSM
NF − JF λ8,
(7.11d)
λ
′
5 = −ǫFλ2 + (ǫF +
1
φ
)λ5, (7.11e)
λ
′
6 =
zβSF IM
(NM − JM )2λ2 −
zβSF IM
(NM − JM )2λ4 + (ηM +
1
φ
)λ6 − ηMλ7, (7.11f)
λ
′
7 = (
zβIF
NF − JF +
1
φ
)λ7 − zβIF
NF − JF λ8, (7.11g)
λ
′
8 =
zβSF
NM − JM λ2 −
zβSF
NM − JM λ4 − σMγMλ7 + (γM +
1
φ
)λ8 − (1− σM )γMλ9,
(7.11h)
λ
′
9 = −ǫMλ7 + (ǫM +
1
φ
)λ9, (7.11i)
with transversality conditions λr(T ) = 0 (r = 1, ..., 9, T is the end time). The optimal
functions are as previously;
u∗jf (t) =
(λ1 − λ3)JF
2c
,
and
u∗sf (t) =
(λ2 − λ3)SF
2d
.
In taking σi = 0.5 and ǫi = 0.2, we find the class profiles and optimal functions as in
Figure 7-7. The results are qualitatively very similar to those found in the case without
natural immunity, with a larger proportion of sexually active individuals vaccinated.
Quantitatively, Figure 7-7 shows higher initial rates of vaccination than Figure 7-2.
7.5 Conclusions
There are several conclusions that we can draw from this study. Firstly we found
that, provided the vaccine is still effective when individuals become sexually active, the
optimal solution consists of vaccinating both sexually active and non-sexually active
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females, with sexually active females vaccinated at a higher rate, after which point
vaccination levels can be reduced (Figure 7-2). This suggests that vaccination must
continue, even at low levels, for as long as we wish to control the disease.
We found that the vaccination of sexually active individuals has a greater impact on
the optimal solution than the vaccination of non-sexually active individuals (Figure 7-
3). The function usf (t) barely changes, whether ujf (t) ≡ 0 or not, but when usf (t) ≡ 0,
ujf (t) must be maintained at a higher level (compared to Figure 7-2) for most of the
time period. This result highlights the importance of including a catch-up programme
in HPV vaccination policy if the disease is to be controlled.
We found that the relative cost of the control on the sexually active female class
influenced the behaviour of the control on the non-sexually active female class (Figure
7-4). The difference in ujf (t) as the cost on usf (t) increased is quite pronounced; as
the cost of usf (t) increased, ujf (t) was maintained at a much higher level for longer,
to make up for the deficit caused by the absence of usf (t).
The importance of considering an optimal control problem was highlighted in Figure
7-5 where very different levels of protection were shown to have the same effect. This
highlights a benefit of using optimal control - the control is able to adapt over time,
unlike a constant level of control.
The results presented in Figure 7-6 imply that it is cost-effective to vaccinate males
as well as females, even when there is no cost associated with male infection. We have
not considered the possible role of HPV in other genital cancers here, although any
added cost on the male infection would be likely to increase the case for including them
in a vaccination strategy.
Finally, Figure 7-7 shows that the inclusion of temporary natural immunity does
not significantly affect the optimal functions. This result supports [50], which found
that the form of the model system did not greatly influence the optimal solution.
The use of optimal control in assessing the cost-effectiveness of the HPV vaccine
has not previously been attempted. Cost-effectiveness studies have been done using
techniques such as decision analysis, with a variety of results [11, 39, 10]. Our results
differ with the majority of other studies in that we suggest that vaccination of males
would be cost-effective and that the catch-up programme (vaccinating older individuals)
plays a large role in controlling the disease. Of the other studies done, the conclusions
have mainly been that male vaccination would not be cost-effective, or would only be
cost-effective in specific situations. The role of the catch-up programme was generally
considered cost-effective, although [39] concluded that, if it was a choice of vaccinating
a greater number of 12 year olds or 18 year olds, it was more cost-effective to vaccinate
12 year olds.
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Figure 7-2: The time profiles and the optimal control functions for a parameter set,
initial conditions and weightings as detailed in the methods and in Table 3.2. Figures
7-2a and 7-2b show the case when α = 0.2, Figures 7-2c and 7-2d have α = 0.1 and
Figures 7-2e and 7-2f have α = 0.05.
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Figure 7-3: Time profiles and optimal vaccination strategies when one of the controls
is removed. Figures 7-3a and 7-3b show the result with ujf (t) = 0; 7-3c and 7-3d with
usf (t) = 0. All of these figures have α = 0.1. Figures 7-3e and 7-3f show the result
with usf (t) = 0 and α = 0.05. In all cases T = 20.
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Figure 7-4: A graph of the control ujf (t) as d varies. Note that the smaller the value
of d, the quicker the control tends to 0. For the largest vales of d, the control only
approaches zero near the end time. d is set at 0.1, 10 and 1000, with A and c as given
above. The parameter set and initial conditions are as for Figure 7-2c.
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Figure 7-5: A comparison of the class profiles from the optimal control and constant
control models, using the same set of parameter values and initial conditions in each
case. Figures 7-5a and 7-5b show the time profiles for the optimal control and constant
control cases respectively with z = 1. Figures 7-5c and 7-5d again show the time
profiles for the optimal control and constant control cases respectively, but now with
z = 2.
113
0 5 10 15 20
0
2
4
6
8
10
12 x 10
4
Time (years)
Po
pu
la
tio
n 
cla
ss
 p
ro
file
s
JF(t)
SF(t)
PF(t)
IF(t)
JM(t)
SM(t)
PM(t)
IM(t)
(a)
0 5 10 15 20
0
0.5
1
1.5
Time (years)
O
pt
im
al
 v
ac
cin
at
io
n 
ra
te
s
ujf(t)
u
sf(t)
ujm(t)
u
sm
(t)
(b)
0 5 10 15 20
0
2
4
6
8
10
12 x 10
4
Time (years)
Po
pu
la
tio
n 
cla
ss
 p
ro
file
s
JF(t)
SF(t)
PF(t)
IF(t)
JM(t)
SM(t)
PM(t)
IM(t)
(c)
0 5 10 15 20
0
0.5
1
1.5
Time (years)
O
pt
im
al
 v
ac
cin
at
io
n 
ra
te
s
ujf(t)
u
sf(t)
ujm(t)
u
sm
(t)
(d)
Figure 7-6: Inclusion of male vaccination. The class profiles and the optimal control
functions for a parameter set, initial conditions and weightings as detailed in the meth-
ods and in Table 3.2. In Figures 7-6a and 7-6b, weighting on male infection is B = 0.
In Figures 7-6c and 7-6d, weighting on male infection is B = 0.0001. Initial conditions
were Ji(0) = 12500, Si(0) = 103325, Pi(0) = 0, Ii(0) = 9175.
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Figure 7-7: The class profiles and optimal functions when natural immunity is included.
We set σi = 0.5 and ǫi = 0.2. All other parameters and initial conditions are as
described in the text and Table 3.2.
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Chapter 8
Optimal Control applied to an
Age-dependent Model
We can develop the work presented in the previous chapter on optimal control by
applying optimal control to an age-dependent ODE. We follow Pontryagin’s Maximum
Principle, as before, and characterise the optimal control. We are now interested in
establishing at what ages vaccination should take place. The vaccination strategy for
the HPV vaccine is unique in the UK [4]; using optimal control to assess the age-
dependent problem can show us whether this strategy is justified. Although this has
been considered in previous cost-effectiveness studies [12, 22, 37], we are using optimal
control to attempt to answer this question.
8.1 Model
We apply optimal control to the age-dependent ODE model in the same way as we
applied it to the time-dependent ODE in the previous chapter; the schematic of this
system can be seen in Figure 8-1.
We use a non-integral force of infection that assumes contact only occurs between
individuals of the same age [31],
λi(a) = zi(a)β
Ik(a)
Nk(a)− Jk(a) . (8.1)
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The system (from Figure 8-1) is
dJF
da
= −(ηF (a) + µF (a) + ujf (a))JF + q(α)α(a)PF , (8.2a)
dSF
da
= −(λ(a) + µF (a) + usf (a))SF + (1− q(α))α(a)PF + ηF (a)JF + γF IF , (8.2b)
dPF
da
= −(α(a) + µF (a))PF + ujf (a)JF + usf (a)SF , (8.2c)
dIF
da
= −(γF + µF (a))IF + λF (a)SF , (8.2d)
dJM
da
= −(ηM (a) + µM (a))JM , (8.2e)
dSM
da
= −(λM (a) + µM (a))SM + ηM (a)JM + γMIM , (8.2f)
dIM
da
= −(γM + µM (a))IM + λM (a)SM , (8.2g)
dNF
da
= −µF (a)NF , (8.2h)
dNM
da
= −µM (a)NM . (8.2i)
8.2 Adding Optimal Control
We add optimal control to the model in the same way as in Chapter 7. Our two controls
are ujf (a) and usf (a), which represent the proportion of either the JF (a) or SF (a) class
(respectively) that is vaccinated for each age. We set the objective functional to be
min
u
J(u) =
∫ amax
a0
[AIF (a) + cu
2
jf (a) + du
2
sf (a)] da, (8.3)
u ∈ {un : 0 ≤ un ≤ 2.3} , n = jf, sf
subject to the underlying infection dynamics. As in Chapter 7, we need to define
the Hamiltonian and adjoint equations, and so characterise the optimal control. The
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Hamiltonian is
H = AIF + cu
2
jf + du
2
sf + λ1(−(ηF (a) + µF (a) + ujf (a))JF + q(α)α(a)PF )
+ λ2(ηF (a)JF − zF (a)βSF IM
NM − JM + γF IF − (usf (a) + µF (a))SF + (1− q(α))α(a)PF )
+ λ3(ujf (a)JF + usf (a)SF − (α(a) + µF (a))PF ) + λ4(zF (a)βSF IM
NM − JM − (γF + µF (a))IF )
+ λ5(−(ηM (a) + µM (a))JM ) + λ6(ηM (a)JM − zM (a)βSMIF
NF − JF + γMIM − µM (a)SM )
+ λ7(
zM (a)βSMIF
NF − JF − (γM + µM (a))IM ) + λ8(−µF (a)NF ) + λ9(−µM (a)NM ),
with the adjoint equations as
λ
′
1 = (ηF (a) + µF (a) + ujf (a))λ1 − ηF (a)λ2 − ujf (a)λ3 +
zM (a)βSMIF
(NF − JF )2 λ6 (8.4a)
− zM (a)βSMIF
(NF − JF )2 λ7,
λ
′
2 = (
zF (a)βIM
NM − JM + usf (a) + µF (a))λ2 − usf (a)λ3 −
zF (a)βIM
NM − JM λ4, (8.4b)
λ
′
3 = −q(α)α(a)λ1 − (1− q(α))α(a)λ2 + (α(a) + µF (a))λ3, (8.4c)
λ
′
4 = −A− γFλ2 + (γF + µF (a))λ4 +
zM (a)βSM
NF − JF λ6 −
zM (a)βSM
NF − JF λ7, (8.4d)
λ
′
5 =
zF (a)βSF IM
(NM − JM )2 λ2 −
zF (a)βSF IM
(NM − JM )2 λ4 + (ηM (a) + µM (a))λ5 − ηM (a)λ6, (8.4e)
λ
′
6 = (
zM (a)βIF
NF − JF + µM (a))λ6 −
zM (a)βIF
NF − JF λ7, (8.4f)
λ
′
7 =
zF (a)βSF
NM − JM λ2 −
zF (a)βSF
NM − JM λ4 − γMλ6 + (γM + µM (a))λ7, (8.4g)
λ8
′ =
−zM (a)βIFSM
(NF − JF )2 λ6 +
zM (a)βIFSM
(NF − JF )2 λ7 + µF (a)λ8, (8.4h)
λ9
′ =
−zF (a)βIMSF
(NM − JM )2 λ2 +
zF (a)βIMSF
(NM − JM )2 λ4 + µM (a)λ9. (8.4i)
The transversality conditions are λv(amax) = 0 (v = 1, ..., 9, amax is the end age).
Finally, the characterisation of the optimal control functions is
u∗jf (a) =
(λ1 − λ3)JF
2c
,
and
u∗sf (a) =
(λ2 − λ3)SF
2d
.
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This optimal control problem can be compared to a constant control model, where
ujf (a) = usf (a) = p, a constant. We consider this model in our numerical solutions
and compare the results.
8.2.1 Including Male Vaccination
We extend (8.2) by including male vaccination in our model. As in Chapter 7, we
introduce two controls on the male classes, ujm(a) and usm(a), which are included for
males in the same way as the controls described above in the female-only vaccination
scenario. The weighting on male infection is B, with B = 0 or B = 0.0001 in the
numerical solutions. The problem with a male vaccinated class is as follows:
min
u
J(u) =
∫ amax
a0
[AIF (a) +BIM (a) + c(u
2
jf (a) + u
2
jm(a)) + d(u
2
sf (a) + u
2
sm(a))] da,
u ∈ {un : 0 ≤ un ≤ 2.3} , n = jf, sf
subject to
dJF
da
= −(ujf (a) + ηF (a) + µF (a))JF + α(a)q(α)PF , (8.5a)
dSF
da
= ηF (a)JF − λFSF + γF IF − (usf (a) + µF (a))SF + (1− q(α))α(a)PF , (8.5b)
dPF
da
= ujf (a)JF + usf (a)SF − (α(a) + µF (a))PF , (8.5c)
dIF
da
= λFSF − (γF + µF (a))IF , (8.5d)
dJM
da
= −(ujm(a) + ηM (a) + µM (a))JM + α(a)q(α)PM , (8.5e)
dSM
da
= ηM (a)JM − λMSM + γMIM − (usm(a) + µM (a))SM + (1− q(α))α(a)PM ,
(8.5f)
dPM
da
= ujm(a)JM + usm(a)SM − (α(a) + µM (a))PM , (8.5g)
dIM
da
= λMSM − (γM + µM (a))IM , (8.5h)
dNF
da
= −µF (a)NF , (8.5i)
dNM
da
= −µM (a)NM . (8.5j)
We can generate the Hamiltonian, adjoint equations and characterise the optimal
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control as before; the adjoint equations are
λ
′
1 = (ηF (a) + ujf (a) + µF (a))λ1 − ηF (a)λ2 − ujf (a)λ3 +
zM (a)βSMIF
(NF − JF )2 λ6 (8.6a)
− zM (a)βSMIF
(NF − JF )2 λ8,
λ
′
2 = (
zF (a)βIM
NM − JM + usf (a) + µF (a))λ2 − usf (a)λ3 −
zF (a)βIM
NM − JM λ4, (8.6b)
λ
′
3 = −q(α)α(a)λ1 − (1− q(α))α(a)λ2 + (α(a) + µF (a))λ3, (8.6c)
λ
′
4 = −A− γFλ2 + (γF + µF (a))λ4 +
zM (a)βSM
NF − JF λ6 −
zM (a)βSM
NF − JF λ8, (8.6d)
λ
′
5 = (ηM (a) + ujm(a) + µM (a))λ5 − ηM (a)λ6 − ujm(a)λ7 +
zF (a)βSF IM
(NM − JM )2 λ2 (8.6e)
− zF (a)βSF IM
(NM − JM )2 λ4,
λ
′
6 = (
zM (a)βIF
NF − JF + usm(a) + µM (a))λ6 − usm(a)λ7 −
zM (a)βIF
NF − JF λ8, (8.6f)
λ
′
7 = −q(α)α(a)λ5 − (1− q(α))α(a)λ6 + (α(a) + µM (a))λ7, (8.6g)
λ
′
8 = −B − γMλ6 + (γM + µM (a))λ8 +
zF (a)βSF
NM − JM λ2 −
zM (a)βSM
NM − JM λ4, (8.6h)
λ9
′ =
−zM (a)βIFSM
(NF − JF )2 λ6 +
zM (a)βIFSM
(NF − JF )2 λ8 + µF (a)λ9, (8.6i)
λ10
′ =
−zF (a)βIMSF
(NM − JM )2 λ2 +
zF (a)βIMSF
(NM − JM )2 λ4 + µM (a)λ10, (8.6j)
with transversality conditions λg(T ) = 0 (g = 1, ..., 10, T is end time). The female
optimal control functions are characterised as
u∗jf (a) =
(λ1 − λ3)JF
2c
,
and
u∗sf (a) =
(λ2 − λ3)SF
2d
.
The male controls are
u∗jm(a) =
(λ5 − λ7)JF
2c
,
and
u∗sm(a) =
(λ6 − λ7)SF
2d
.
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Figure 8-2: The class profiles and control functions for the age-dependent ODE.
8.3 Numerical Solutions
In the following numerical solutions, the initial conditions are Pi(a0) = 0, Ji(a0) =
0.855Ni(a0), Ii(a0) = 0.05Ni(a0) and Si(a0) = 0.095Ni(a0), with Ni(a0) = 125, 000.
The graphs are then scaled to show the proportion of the population in each class.
We run the model between the ages 12 and 32. We use age-dependent parameters as
described in Chapter 3 and set γi = 1. The weightings used for the objective functional
are A = 0.0002, c = 0.1 and d = 1 as in Chapter 7. Solving the optimal control problem
given in Section 8.2 gives the Figures shown in 8-2.
The graph shows high levels of vaccination for non-sexually active females from the
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Figure 8-3: Age profiles and optimal vaccination strategies when one of the controls
is removed. Figures 8-3a and 8-3b show the result with ujf (a) = 0. Figures 8-3c and
8-3d show the result with usf (a) = 0.
age of 12, with much lower levels of vaccination for the sexually active. As age increases,
vaccination decreases sharply and the vaccination of sexually active individuals becomes
more important, albeit at very low levels.
As in Chapter 7, we now extend our numerical solutions to consider a range of
different scenarios. Firstly, we consider the impact of setting one of the controls to
zero. This gives the graphs shown in Figure 8-3.
Unlike for the optimal control problem in Chapter 7, the control on the non-sexually
active females, ujf (a), does not change significantly if usf (a) ≡ 0. When ujf (a) ≡ 0,
the control on usf (a) initially decreases, as when ujf (a) 6= 0, but is altered by an
increase in vaccination that starts at a ≈ 15, reaching a peak at a ≈ 17.5, before
decreasing again.
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Figure 8-4: A graph of the control usf (a) as c varies. The value of c is set at 0.01, 1
and 10, with A and d as given above. The parameter set and initial conditions are as
given at the beginning of the section.
We found that, unlike in the time-dependent case, varying the value of d did not
have a strong effect on ujf (a). However, varying c led to a significant change in usf (a),
as can be seen in Figure 8-4. This shows that, for c ≥ d, the control usf (a) decreases
initially, then increases to a peak at 15 ≤ a ≤ 20, before decreasing again.
8.3.1 Constant Control
We compare the optimal solution to a constant control solution in Figure 8-5, where
un = p, a constant. We see that infection is eradicated in either case, but the level of
vaccination is much higher in the constant control situation (and therefore the expense
is greater in this case).
8.3.2 Including Male Vaccination
We now include male vaccination in our model, by including a male protected class in
the same way that the female protected class is included. The system and adjoint equa-
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Figure 8-5: The class profiles for the age-dependent optimal (8-5a) and constant (8-5b)
control problems. The constant rate of vaccination is p = 0.7.
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Figure 8-6: Inclusion of male vaccination. The class profiles and the optimal control
functions for a parameter set, initial conditions and weightings as detailed in the meth-
ods and in Table 3.2. In Figures 8-6a and 8-6b, weighting on male infection is B = 0.
In Figures 8-6c and 8-6d, weighting on male infection is B = 0.0001.
tions, and control functions, are given above. We now consider four control functions,
two pertaining to the female-only vaccination strategy and two pertaining to the male
vaccination strategy. As in Chapter 7, we consider two cases - firstly, when there is no
cost associated to male vaccination (so weighting on the males B = 0), and when there
is some cost (B = 0.0001). This presents the solutions given in Figure 8-6. We see that
the solutions suggest it is cost-effective to vaccinate both males and females and there
is a clear difference in the proportion of protected females to protected males.
We now consider ujf (a) = ujm(a) = 0 and the effect that this has on the remaining
controls. Interestingly, we find that the functions are very similar to the case for female-
only vaccination when ujf (a) = 0, but that, unlike in Figure 8-6, more vaccination is
indicated for the females rather than the males. The variation between the protected
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Figure 8-7: Inclusion of male vaccination when when ujf (a) = ujm(a) = 0 and B =
0. The class profiles and the optimal control functions for a parameter set, initial
conditions and weightings as detailed in the methods and in Table 3.2.
classes in Figures 8-6 and 8-7 is not unexpected - in both cases we see a higher propor-
tion of sexually active females vaccinated than sexually active males. This is in contrast
to vaccination of non-sexually active males, which occurs at a higher rate than vaccina-
tion of non-sexually active females. The removal of vaccination of non-sexually active
individuals therefore leads to a greater number of protected females than protected
males.
8.4 Extending the Optimal Control Problem to a PDE
Model
It is possible to build an optimal control problem based on a PDE model. We created a
PDE system based on the schematic shown above (Figure 8-1) with the boundary and
initial conditions given in Chapter 6. We applied a maximum principle, as described
in [44], and were able to characterise the optimal control. This analytical work is
presented in Appendix A. Further work would be to extend this analytical work to find
numerical solutions and compare the results to those found both in this Chapter and
in Chapter 7.
8.5 Conclusions
This Chapter has introduced optimal control for age-dependent models. We used a force
of infection that implies highly associative mixing by age. By calculating the adjoint
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equations and characterising the optimal control we were able to generate numerical
solutions. Figure 8-2 suggests that the optimal course of vaccination is to vaccinate
at high levels at a young age, with vaccination tailing off for older age groups. This
supports current policy, which is to vaccinate a high proportion of females at a young
age, and to offer catch-up vaccination to girls up to the age of 18 [2].
Figure 8-3 shows that the control on the sexually active females, usf (a), is signifi-
cantly affected when ujf (a) = 0, with an increase in vaccination from a ≈ 15. This may
be explained by the average number of sexual partners, which peaks (in our model) at
a = 16. This, combined with a reduced rate of individuals becoming sexually active
for a ≥ 19, may lead to increased vaccination for the age range 15 < a < 20.
Establishing that the function usf (a) is affected by the presence (or absence) of
ujf (a), we considered usf (a) for different values of c, the weighting attached to ujf (a)
in the objective functional. Figure 8-4 shows that, for c ≥ d the peak in usf (a)
begins to occur. We found, in plotting ujf (a) for the same (varying) values of c, that
vaccination levels for the non-sexually active become very low for c ≥ d, making usf (a)
the dominant control.
Figure 8-5 shows the contrast between the cases of optimal control and constant
control. Although both drive infection to very low levels, the proportion protected is
much greater for the constant control case, and therefore much more costly than when
following the vaccination strategy suggested by the optimal control model.
Introducing male vaccination shows that vaccination is cost effective for both males
and females, and that vaccination of non-sexually active males should be at a slightly
higher rate than for non-sexually active females, although this is reversed for vaccina-
tion of sexually active individuals (Figure 8-6). Removing vaccination of non-sexually
active individuals shows usf (a) and usm(a) taking a similar form to usf (a) for female-
only vaccination. Figure 8-7 shows a clear difference between usf (a) and usm(a), with
a higher proportion of females vaccinated, although it is still cost effective to vaccinate
both males and females.
The analytical work for the optimal control on the PDE provides all the neces-
sary background for finding numerical solutions. The characterisation of the optimal
control shows it to be equivalent to the optimal control functions in the ODE cases.
Unfortunately, the numerical solutions are very complex to program and so this falls
outside the scope of this thesis. Further work would be to develop a program to find
the numerical solutions and thus compare the results to those found with both the
time-dependent and age-dependent ODE optimal control problems.
The results from this Chapter support current vaccination policy as being cost-
effective. We show that male vaccination is also cost-effective when implemented in
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the same age groups as for female vaccination. Our results also indicate that, when
vaccinating sexually active individuals, it is most cost-effective to vaccinate high propor-
tions initially, but also to have a second vaccination drive for older teenagers (between
15 and 20 years old) to maximise the success of this vaccine. Combining the results of
this Chapter with those of Chapter 7 suggests that we can not only define vaccination
levels over time, but also determine which age groups to target to ensure the most
cost-effective strategy is employed.
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Chapter 9
Conclusions
The aim of this thesis is to introduce a model that assesses the impact of vaccinating
a largely non-sexually active group of individuals against a sexually transmitted infec-
tion. We consider several questions:- What is the effect of waning immunity? How do
behavioural parameters affect the success of the vaccine? Is it beneficial to vaccinate
males? Does introducing age-structure make a difference to the results? What is the
most cost-effective way to introduce vaccination?
In Chapter 2 we construct a simple model that includes waning immunity for a
vaccine that is introduced into a population. We calculate critical parameter values
and the model steady states and compare the full model to its linearised counterpart.
We identify certain key parameters in the model - these are the proportion of females
vaccinated per unit time, p, and the parameters within R0 - the average number of
sexual partners and the average length of infection in particular.
Chapter 3 deals with the estimation of parameter values that are used in subsequent
chapters. They are all calculated using data from a range of sources [3, 17, 28, 58, 61, 60]
to make our model predictions as realistic as possible.
Chapter 4 presents a gender-free model that includes both waning immunity and
a non-sexually active class. We find the model steady states and the “effective” R0
value, Re0. In so doing, we are able to consider the effect of vaccinating individuals
prior to their becoming sexually active and thus assess how the interaction between
the behavioural parameter η (the rate at which individuals become sexually active) and
the vaccination parameter α (the average duration of protection given by the vaccine)
impacts on the potential success of the vaccine. We find that the duration of immunity
has a greater impact on whether the disease could succeed in the population than the
average rate at which individuals became sexually active, but a reduction in both values
would have the greatest effect.
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Chapter 5 develops the work of Chapter 4 by including genders in the model. We
carry out similar analysis to that presented in Chapter 4 and identify the steady states
and Re0 value. The R
e
0 value is equivalent to the one given in Chapter 4 - the difference
between the two lies in the difference between the R0 values in each case. As previously,
we find certain critical parameter values and show that, of α and ηF , it is α that has
the greater influence on the success of the vaccine - on varying α, it is possible for
the disease to be eradicated, which is not the case for ηF . We also consider male
vaccination, which helps to reduce infection prevalence, as expected. However, we find
that we can only reduce the proportion vaccinated by ≈ 45% - meaning that overall,
a greater number of individuals need to be vaccinated (for our parameter set). We
consider whether the introduction of a (temporarily) naturally immune class affects
our results and find that there is no qualitative difference between this case and our
SIS model.
In Chapter 6 we extend the model presented in Chapter 5 to an age- and time-
dependent PDE model. We first consider the temporally stable state, giving an age-
dependent ODEmodel, and solve some of the equations. We find numerical solutions for
the ODE model with both constant and age-dependent parameters and two different
forms of the force of infection. We find that the class profiles change significantly
depending on the parameter functions and force of infection, although in all cases
infection persists in the model when vaccination is included.
The second part of Chapter 6 is related to the analysis of the PDE model. We cal-
culate the characteristics of the model and solve the system numerically. The numerical
solutions show that vaccination could virtually eradicate infection within 40 years of
introduction - a result that is very similar to that found with the age-dependent ODE.
It differs from the results found with the time-dependent ODE (with standard parame-
ter values), which suggest that infection would remain in the model at detectable levels
even with the introduction of vaccination. We vary the α(a) function and find that
it causes some variation in the female infection profile after 25 years, although after
50 years the differences are more pronounced. Varying the proportion of individuals
vaccinated also has a large impact, with greater values of p significantly reducing the
proportion of infected females after 25 years.
We consider an optimal control problem with two controls - vaccination of sexually
active individuals and vaccination of non-sexually active individuals - in Chapters 7 and
8. In Chapter 7 we present a time-dependent model and Chapter 8 contains an age-
dependent model. We use optimal control to assess the cost-effectiveness of the vaccine,
as previous Chapters demonstrated that, whilst the vaccine may not be successful at
completely eradicating the infection, it can significantly reduce the prevalence of disease
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in both males and females. In Chapter 7 we find that vaccination is cost-effective for
both sexually active and non-sexually active individuals. We find that the removal of,
or increasing the cost weighting of, the control on sexually active individuals affects
the form of the control on the non-sexually active individuals. Comparing the optimal
control model to a constant control model shows that, whilst both lead to eradication
of infection, a much greater level of protection (and therefore a greater cost) is used in
the constant control model. Male vaccination is found to be cost effective, even when
there is no cost associated with male infection, and the inclusion of temporary natural
immunity does not alter the form of the control functions (which is in agreement with
the findings of [50]).
Chapter 8 considers the age-dependent version of the model presented in Chapter
7. We carry out many of the same tests, and numerical solutions show that the most
cost-effective method for vaccinating individuals is to vaccinate a high proportion of 12
year olds, reducing the proportion vaccinated over approximately a 10 year age span.
These results support current government policy for vaccination [2]. Removing one of
the controls in this model, as in Chapter 7, shows that it is the control on sexually
active individuals that is most affected. In this case the control initially decreases,
before increasing to a peak between the ages of 15 and 20. This is probably due to the
age-dependent parameter functions, which maximise the average number of partners
and the rate at which individuals become sexually active at a ≈ 16.
We compare the optimal control problem to a constant control problem and find, as
in Chapter 7, that although both types of control are successful in subduing the disease,
the optimal control uses lower levels of vaccination and therefore is the cheaper solution.
Male vaccination is introduced and, as in the time-dependent situation, is found to be
cost-effective. On removing the controls on the non-sexually active classes the form of
the remaining controls is as in the female-only vaccination case.
We discuss extending this work to applying optimal control to a PDE model. We
include the characterisation of this optimal control in Appendix A. The optimal control
functions in this case are equivalent to those found in both the time-dependent and
age-dependent optimal control models. Further work to find numerical solutions to the
PDE optimal control problem will mean that comparisons can be drawn between it
and the ODE models presented in Chapters 7 and 8.
The work presented in this thesis aims to answer several questions, as posed in the
introduction. We wish to assess the effect of waning immunity on the overall success,
or otherwise, of the vaccine. The length of protection offered by the HPV vaccine is,
as yet, unknown [18], so we vary the value of α (the average duration of protection) in
our models to assess its affects. In the time-dependent gender model, we find that it is
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only possible to eradicate the infection for a vaccine lasting 25 years or more. In the
PDE age- and time-dependent model, a 10 year vaccine is sufficient to almost eradicate
the disease after 40 years. Varying the duration of protection in the PDE model only
has a small effect on the female infected class profile after 25 years. After 50 years, the
impact of varying α is much greater, supporting the results from the time-dependent
ODE that duration of protection from the vaccine could have a key effect on the success
of the vaccine.
We consider the effect of behavioural parameters - i.e. the rate at which individuals
become sexually active (ηi) and the average number of sexual partners (zi). We find in
the time-dependent gender case that varying ηi cannot force the model to the disease-
free steady state for our standard parameter set. The average number of sexual partners
has a much greater effect on the model and the steady state that it approaches. As zi
forms part of R0, this is expected - zi will affect the spread of the disease both with
and without vaccination present in the model.
The next question addressed is the effect of male vaccination. We consider this
both in Chapter 5 and as part of the optimal control problems in Chapters 7 and 8.
We find from Chapter 5 that the introduction of male vaccination has a positive effect,
but leads to a greater number of individuals needing to be vaccinated overall. However,
the results from Chapters 7 and 8 show that it is cost-effective to include males in a
vaccination strategy. This result is contrary to many results given in the literature,
although some previous cost-effectiveness models suggested including male vaccination
[39, 40].
We are also interested in how the model structure affects the results. We consider
the situation using both age-dependent and time-dependent ODEs, and an age- and
time- dependent PDE. We find that in both ODE scenarios, the infection cannot be
eradicated with vaccination using our standard parameter set. This is at variance with
the results from our PDE, which suggest that vaccination could virtually eradicate the
infection after 40 years. In considering the influence of the vaccination parameters, we
find that the proportion of individuals protected affects the female infected profile after
25 years, although for p ≥ 0.6 the differences are slight. The duration of protection
similarly impacts on the infection profile, especially after 50 years. This is in agreement
with the time-dependent ODE, where α makes a large difference to the disease spread
within the population.
Finally, we investigate the most cost-effective method for introducing the vaccine.
We consider this in both the time-dependent and age-dependent case and find that the
most cost-effective method over time is to start with a high proportion of individuals
vaccinated and decrease the proportion over time. When considering age of vaccination,
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the most cost-effective method is to vaccinate individuals at the highest rate at age 12,
then decrease vaccination for older individuals. However, if vaccination is only to be
applied to sexually active individuals, optimal control suggests that the highest rates of
vaccination should take place both at age 12, but with a second (lower) peak at a ≈ 17.
In both cases vaccination of both sexes is indicated to be cost effective, which goes
against much cost-effectiveness analysis that has recently been done on this vaccine
[38, 39].
This thesis has answered many questions, but much of the work done here can
be extended. More complicated functions could be formulated for some of the age-
dependent parameters; this would increase complexity in the modelling, but could
increase the accuracy of the quantitative results.
There are other factors that could be included in the model to investigate this
problem more thoroughly. We could introduce further compartments for the different
strains of the virus that are protected against by the vaccine. We could also include
parameters that allow for varying ‘take’ or efficacy of the vaccine. Developing the model
further to account for the progression to the SIL and cancer stages could indicate the
role of the vaccine in potentially decreasing cervical cancer cases. When considering
this, the inclusion of screening for women in the model would also be advisable. In the
age-dependent case presented in Chapter 6 we do not have gender-dependent values
for the number of partners an individual has, although it would be possible to include
it. If this value were to be gender- as well as age-dependent it would be important to
ensure that the number of partners balanced across the genders for the model to make
sense.
A key extension would be to continue the optimal control problem on the PDE.
Calculating numerical solutions for the PDE optimal control problem would allow com-
parison of the results from this and the ODE models presented in the thesis.
Another extension to the optimal control work would be an investigation into the
form of the objective functional. The form used in Chapters 7 and 8 is very common
[44, 52, 51], and it would be interesting to see how results generated using other forms
of the objective functional compare.
In constructing mathematical models to consider the impact of vaccination against
a sexually transmitted disease in a population, we find that, under our assumptions,
vaccination is always recommended. The level of success of the vaccine depends on
many different parameters, key amongst them the sexual behaviour of individuals and
the proportion of individuals vaccinated. We find that the model structure affects
the results, although none of our ODE models show eradication of infection with the
standard parameter set. The most cost-effective method for implementing the vaccine is
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explored and shown to support current government policy [2], although we suggest that
the inclusion of males in the vaccination strategy could also be cost effective. To achieve
the best results from the vaccine, we suggest that a combination of vaccination and
education on sexual behaviour be undertaken, so that it may be possible to eradicate
the disease from the population.
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Chapter 10
Appendix A - Optimal Control
applied to a PDE model
10.1 Optimal Control on the PDE
We apply the technique used in [44] to determine the characterisation of the optimal
control. The PDE model is
∂PF (a, t)
∂t
+
∂PF (a, t)
∂a
=− (α(a) + µF (a))PF (a, t) + uj(a, t)JF (a, t) + us(a, t)SF (a, t),
(10.1a)
∂JF (a, t)
∂t
+
∂JF (a, t)
∂a
=q(α)α(a)PF (a, t)− (ηF (a) + µF (a) + uj(a, t))JF (a, t),
(10.1b)
∂SF (a, t)
∂t
+
∂SF (a, t)
∂a
=(1− q(α))α(a)PF (a, t) + ηF (a)JF (a, t) (10.1c)
+ γF IF (a, t)− (λF (a, t) + µF (a) + us(a, t))SF (a, t),
∂IF (a, t)
∂t
+
∂IF (a, t)
∂a
=λF (a, t)SF (a, t)− (γF + µF (a))IF (a, t), (10.1d)
∂NF (a, t)
∂t
+
∂NF (a, t)
∂a
=− µF (a)NF (a, t), (10.1e)
∂JM (a, t)
∂t
+
∂JM (a, t)
∂a
=− (ηM (a) + µM (a))JM (a, t), (10.1f)
∂SM (a, t)
∂t
+
∂SM (a, t)
∂a
=ηM (a)JM (a, t) + γMIM (a, t)− (λM (a, t) + µM (a))SM (a, t),
(10.1g)
∂IM (a, t)
∂t
+
∂IM (a, t)
∂a
=λM (a, t)SM (a, t)− (γM + µM (a))IM (a, t), (10.1h)
∂NM (a, t)
∂t
+
∂NM (a, t)
∂a
=− µM (a)NM (a, t), (10.1i)
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with boundary and initial conditions as given for the PDE model in Chapter 6 and
λi(a, t) = zi(a)
∫ amax
a0
β(a, s)Ik(s, t)
Nk(s, t)− Jk(s, t) ds. (10.2)
The objective functional is
min
u
J(u) =
∫ amax
a0
∫ T
0
[AIF (a, t) + cu
2
jf (a, t) + du
2
sf (a, t)] dtda. (10.3)
10.1.1 Sensitivity Equations
Our first step is to find the sensitivity equations (sensitivities ψ1-ψ7). For our model,
these are as follows (we do not need to find sensitivity or adjoint equations for (10.1e)
and (10.1i) as the Ni are simply the sum of the other classes):
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∂ψ1(a, t)
∂t
+
∂ψ1(a, t)
∂a
+ (α(a) + µF (a))ψ1(a, t)− uj(a, t)ψ2(a, t)− us(a, t)ψ3(a, t)
= ljJF + lsSF , (10.4)
∂ψ2(a, t)
∂t
+
∂ψ2(a, t)
∂a
− q(α)α(a)ψ1(a, t) + (ηF (a) + µF (a) + uj(a, t))ψ2(a, t) = −ljJF ,
∂ψ3(a, t)
∂t
+
∂ψ3(a, t)
∂a
− (1− q(α))α(a)ψ1(a, t)− ηF (a)ψ2(a, t)− γFψ4(a, t)
+ (µF (a) + us(a, t))ψ3(a, t)
+ zF (a)ψ3(a, t)
∫ amax
a0
β(a, s)
IM (s, t)
SM (s, t) + IM (s, t)
ds
+ zF (a)SF (a, t)
∫ amax
a0
β(a, s)
ψ7(s, t)SM (s, t)− ψ6(s, t)IM (s, t)
(SM (s, t) + IM (s, t))2
ds = −lsSF ,
∂ψ4(a, t)
∂t
+
∂ψ4(a, t)
∂a
− zF (a)ψ3(a, t)
∫ amax
a0
β(a, s)
IM (s, t)
SM (s, t) + IM (s, t)
ds (10.5)
− zF (a)SF (a, t)
∫ amax
a0
β(a, s)
ψ7(s, t)SM (s, t)− ψ6(s, t)IM (s, t)
(SM (s, t) + IM (s, t))2
ds
+ (γF + µF (a))ψ4(a, t) = 0,
∂ψ5(a, t)
∂t
+
∂ψ5(a, t)
∂a
+ (ηM (a) + µM (a))ψ5(a, t) = 0,
∂ψ6(a, t)
∂t
+
∂ψ6(a, t)
∂a
+ zM (a)ψ6(a, t)
∫ amax
a0
β(a, s)
IF (s, t)
PF (s, t) + SF (s, t) + IF (s, t)
ds
+ zM (a)SM (a, t)
∫ amax
a0
β(a, s)
ψ4(s, t)(PF (s, t) + SF (s, t))
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
− zM (a)SM (a, t)
∫ amax
a0
β(a, s)
(ψ1(s, t) + ψ3(s, t))IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
− ηM (a)ψ5(a, t)− γMψ7(a, t) + µM (a))ψ6(a, t) = 0,
∂ψ7(a, t)
∂t
+
∂ψ7(a, t)
∂a
− zM (a)ψ6(a, t)
∫ amax
a0
β(a, s)
IF (s, t)
PF (s, t) + SF (s, t) + IF (s, t)
ds
− zM (a)SM (a, t)
∫ amax
a0
β(a, s)
ψ4(s, t)(PF (s, t) + SF (s, t))
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
+ zM (a)SM (a, t)
∫ amax
a0
β(a, s)
(ψ1(s, t) + ψ3(s, t))IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
+ (γM + µM (a))ψ7(a, t) = 0.
10.1.2 Adjoint Equations
As in the ODE case, we need to find the adjoint equations. In the PDE case, however,
we need to use the sensitivity equations given in the section above to calculate the
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adjoint equations. The relationship between the sensitivity equations is given below:
L


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


=


ljJF + lsSF
−ljJF
−lsSF
0
0
0
0


(10.6)
where
L


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


=
(
∂
∂t
+
∂
∂a
)


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


+M


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


+ G


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


(10.7)
M is a matrix,
M =


(α+ µF ) −uj
−qα (ηF + µF + uj)
−(1− q)α −ηF
0 0
0 0
0 0
0 0
· · ·
· · ·
−us 0
0 0(
µF (a) + us(a, t) + zF (a)
∫ amax
a0
β(a, s) IM (s,t)SM (s,t)+IM (s,t) ds
)
−γF
−zF
∫ amax
a0
β(a, s) IM (s,t)SM (s,t)+IM (s,t) ds (γF + µF )
0 0
0 0
0 0
· · ·
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· · ·
0 0 0
0 0 0
0 0 0
0 0 0
(ηM + µM ) 0 0
−ηM (zM
∫ amax
a0
β(a, s) IF (s,t)PF (s,t)+SF (s,t)+IF (s,t) ds+ µM ) −γM
0 −zM
∫ amax
a0
β(a, s) IF (s,t)PF (s,t)+SF (s,t)+IF (s,t) ds (γM + µM )


(10.8)
The final term is
G


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


=


0
0
zF (a)SF (a, t)
∫ amax
a0
β(a, s)ψ7(s,t)SM (s,t)−ψ6(s,t)IM (s,t)
(SM (s,t)+IM (s,t))2
ds
−zF (a)SF (a, t)
∫ amax
a0
β(a, s)ψ7(s,t)SM (s,t)−ψ6(s,t)IM (s,t)
(SM (s,t)+IM (s,t))2
ds
0
zM (a)SM (a, t)
∫ amax
a0
β(a, s)ψ4(s,t)(PF (s,t)+SF (s,t))−(ψ1(s,t)+ψ3(s,t))IF (s,t)
(PF (s,t)+SF (s,t)+IF (s,t))2
ds
−zM (a)SM (a, t)
∫ amax
a0
β(a, s)ψ4(s,t)(PF (s,t)+SF (s,t))−(ψ1(s,t)+ψ3(s,t))IF (s,t)
(PF (s,t)+SF (s,t)+IF (s,t))2
ds


(10.9)
Now we have expressed the sensitivity equations in this way, we can find the equa-
tions for the adjoints (p1-p7). These are related to the sensitivity equations in the
following way:
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(
p1 p2 p3 p4 p5 p6 p7
)
·L


ψ1
ψ2
ψ3
ψ4
ψ5
ψ6
ψ7


=
(
ψ1 ψ2 ψ3 ψ4 ψ5 ψ6 ψ7
)
·L ∗


p1
p2
p3
p4
p5
p6
p7


(10.10)
where
L
∗


p1
p2
p3
p4
p5
p6
p7


=


0
0
0
A
0
0
0


(10.11)
with
L
∗


p1
p2
p3
p4
p5
p6
p7


= −
(
∂
∂t
+
∂
∂a
)


p1
p2
p3
p4
p5
p6
p7


+MTranspose


p1
p2
p3
p4
p5
p6
p7


+ G ∗


p1
p2
p3
p4
p5
p6
p7


(10.12)
(A comes from the objective functional and is the weighting on IF ).
To calculate G ∗, we need to return to the operators on ψi. In the first instance (the
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nonlinear term containing ψ6 and ψ7 from the third sensitivity equation), we can look
at
∫ ∫
p3(a, t)
[
zF (a)SF (a, t)
∫
β(a, s)
ψ7(s, t)SM (s, t)
(SM (s, t) + IM (s, t))2
ds
]
dadt
−
∫ ∫
p3(a, t)
[
zF (a)SF (a, t)
∫
β(a, s)
ψ6(s, t)IM (s, t)
(SM (s, t) + IM (s, t))2
ds
]
dadt =∫ ∫
ψ7(s, t)
[
SM (s, t)
(SM (s, t) + IM (s, t))2
∫
zF (a)SF (a, t)β(a, s)p3(a, t) da
]
dsdt
−
∫ ∫
ψ6(s, t)
[
IM (s, t)
(SM (s, t) + IM (s, t))2
∫
zF (a)SF (a, t)β(a, s)p3(a, t) da
]
dsdt
(10.13)
Similarly (the term from the sixth sensitivity equation containing ψ1, ψ3 and ψ4),
∫ ∫
p6(a, t)
[
zM (a)SM (a, t)
∫ amax
a0
β(a, s)
ψ4(s, t)(PF (s, t) + SF (s, t))
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
]
dadt
−
∫ ∫
p6(a, t)
[
zM (a)SM (a, t)
∫ amax
a0
β(a, s)
ψ1(s, t)IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
]
dadt
−
∫ ∫
p6(a, t)
[
zM (a)SM (a, t)
∫ amax
a0
β(a, s)
ψ3(s, t)IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
ds
]
dadt =∫ ∫
ψ4(s, t)
[
PF (s, t) + SF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
∫ amax
a0
β(a, s)zM (a)SM (a, t)p6(a, t) da
]
dsdt
−
∫ ∫
ψ1(s, t)
[
IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
∫ amax
a0
β(a, s)zM (a)SM (a, t)p6(a, t) da
]
dsdt
−
∫ ∫
ψ3(s, t)
[
IF (s, t)
(PF (s, t) + SF (s, t) + IF (s, t))2
∫ amax
a0
β(a, s)zM (a)SM (a, t)p6(a, t) da
]
dsdt
(10.14)
Note that in the equations taken from the fourth and seventh sensitivity equations,
p3(a, t) will be replaced by p4(a, t) and p6(a, t) will be replaced by p7(a, t) in the above
equations.
Explicitly, this gives the adjoint equations as
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−
(
∂
∂t
+
∂
∂a
)
p1(a, t)+(α(a)+µF (a))p1(a, t)−q(α)α(a)p2(a, t)−(1−q(α))α(a)p3(a, t)
+
(
IF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p7(s, t) ds
)
−
(
IF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p6(s, t) ds
)
= 0,
(10.15)
−
(
∂
∂t
+
∂
∂a
)
p2(a, t)− uj(a, t)p1(a, t)
+ (ηF (a) + µF (a) + uj(a, t))p2(a, t) + ηF (a)p3(a, t) = 0, (10.16)
−
(
∂
∂t
+
∂
∂a
)
p3(a, t)− us(a, t)p1(a, t)
+
(
µF (a) + us(a, t) + zF (a)
∫ amax
a0
β(a, s)
IM (s, t)
SM (s, t) + IM (s, t)
ds
)
p3(a, t)
− zF
(∫ amax
a0
β(a, s)
IM (s, t)
SM (s, t) + IM (s, t)
ds
)
p4(a, t)
+
(
IF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p7(s, t) ds
)
−
(
IF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p6(s, t) ds
)
= 0,
(10.17)
−
(
∂
∂t
+
∂
∂a
)
p4(a, t)− γF p3(a, t) + (γF + µF (a))p4(a, t)/
+
(
PF (a, t) + SF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p6(s, t) ds
)
−
(
PF (a, t) + SF (a, t)
(PF (a, t) + SF (a, t) + IF (a, t))2
∫ amax
a0
β(s, a)zM (s)SM (s, t)p7(s, t) ds
)
= A,
(10.18)
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−
(
∂
∂t
+
∂
∂a
)
p5(a, t) + (ηM (a) + µM (a))p5(a, t)− ηM (a)p6(a, t) = 0, (10.19)
−
(
∂
∂t
+
∂
∂a
)
p6(a, t)+
(
zM
∫ amax
a0
β(a, s)
IF (s, t)
PF (s, t) + SF (s, t) + IF (s, t)
ds+ µM
)
p6(a, t)
+
(
zM
∫ amax
a0
β(a, s)
IF (s, t)
PF (s, t) + SF (s, t) + IF (s, t)
ds
)
p7(a, t)
+
(
IM (a, t)
(SM (a, t) + IM (a, t))2
∫
zF (s)SF (s, t)β(s, a)p4(s, t) ds
)
−
(
IM (a, t)
(SM (a, t) + IM (a, t))2
∫
zF (s)SF (s, t)β(s, a)p3(s, t) ds
)
= 0, (10.20)
−
(
∂
∂t
+
∂
∂a
)
p7(a, t)− γMp6(a, t) + (γM + µM (a))p7(a, t)
+
(
SM (a, t)
(SM (a, t) + IM (a, t))2
∫
zF (s)SF (s, t)β(s, a)p3(s, t) ds
)
−
(
SM (a, t)
(SM (a, t) + IM (a, t))2
∫
zF (s)SF (s, t)β(s, a)p4(s, t) ds
)
= 0. (10.21)
10.2 Characterisation of Optimal Control
This is calculated from the objective functional and uses difference quotients.
We start by taking
0 ≤ lim
ǫ→0+
J(u∗j + ǫlj , u
∗
s + ǫls)− J(u∗j , u∗s)
ǫ
, (10.22)
which gives us
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0 ≤ lim
ǫ→0+
∫ amax
a0
∫ T
0
A(
IǫF − IF
ǫ
) + c((u∗j + ǫlj)
2 − (u∗j )2) + d((u∗s + ǫls)2 − (u∗s)2) dadt,
=
∫ amax
a0
∫ T
0
Aψ4 + lj(2cu
∗
j ) + ls(2du
∗
s) dadt,
=
∫ amax
a0
∫ T
0
(
ψ1 ψ2 ψ3 ψ4 ψ5 ψ6 ψ7
)


0
0
0
A
0
0
0


+ lj(2cu
∗
j ) + ls(2du
∗
s) dtda,
(10.23)
=
∫ amax
a0
∫ T
0
(
p1 p2 p3 p4 p5 p6 p7
)


ljJF + lsSF
−ljJF
−lsSF
0
0
0
0


+ lj(2cu
∗
j ) + ls(2du
∗
s) dtda, (10.24)
=
∫ amax
a0
∫ T
0
lj(2cu
∗
j (a, t) + p1(a, t)JF (a, t)) dtda
+
∫ amax
a0
∫ T
0
ls(2du
∗
s(a, t) + p1(a, t)SF (a, t)− p3(a, t)SF (a, t)) dtda.
This implies that the optimal controls are
u∗j (a, t) =
(p2(a, t)− p1(a, t))JF (a, t)
2c
(10.25)
u∗s(a, t) =
(p3(a, t)− p1(a, t))SF (a, t)
2d
. (10.26)
To fully complete this optimal control problem, we set bounds on both controls as
0 ≤ u∗j , u∗s ≤ 2.3.
Interestingly, these optimal control functions are very similar to the optimal control
functions found for the time-dependent ODE in Chapter 7.
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Chapter 11
Appendix B - Matlab Codes
11.1 Optimal Control Code
This code is adapted from code provided with [44]; the code solves the model and
adjoint equations for the gender model used in Chapter 7.
function y = optcodegendnew4(alpha,q,p,phi,Nf,Nfo,Nm,Nmo,z,beta,jf,jm,
etaf,etam,gammaf,gammam,Pf0,Jf0,Sf0,If0,Jm0,Sm0,Im0,A,b,c,T)
% Objective functional: J(u) = \int_0^T (A I(t) + bu(t)^2 + cv(t)^2) dt
% Set up parameter values, weighting and initial conditions
[alpha,q,p,phi,Nf,Nfo,Nm,Nmo,z,beta,jf,jm,etaf,etam,gammaf,gammam]
=paramgendforoptcont;
A=0.0001; b=0.1; c=1; T=30;
Jf0=12500; Sf0=103325; Pf0=0; If0=9175;
Jm0=12500; Sm0=103325; Im0=9175;
M = 5000; %M+1 is # nodes
t=linspace(0,T,M+1);
h=T/M;
h2 = h/2;
% Set up initial matrix values for classes
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Jf=zeros(1,M+1); Sf=zeros(1,M+1); Pf=zeros(1,M+1); If=zeros(1,M+1);
Jm=zeros(1,M+1); Sm=zeros(1,M+1); Im=zeros(1,M+1);
Jf(1)=Jf0; Sf(1)=Sf0; Pf(1)=Pf0; If(1)=If0;
Jm(1)=Jm0; Sm(1)=Sm0; Im(1)=Im0;
% Set up initial values for adjoints
lambda1=zeros(1,M+1); lambda2=zeros(1,M+1); lambda3=zeros(1,M+1);
lambda4=zeros(1,M+1); lambda5=zeros(1,M+1); lambda6=zeros(1,M+1);
lambda7=zeros(1,M+1);
% Set up initial value for u
u=zeros(1,M+1); v=zeros(1,M+1);
% Convergence test
test2=1;
errlim=0.000001;
while test2>errlim
disp([’TEST = ’,num2str(test2)])
oldu = u; oldv = v;
oldJf = Jf; oldSf = Sf; oldPf = Pf; oldIf = If;
oldJm = Jm; oldSm = Sm; oldIm = Im;
oldlambda1 = lambda1; oldlambda2 = lambda2; oldlambda3 = lambda3;
oldlambda4 = lambda4; oldlambda5 = lambda5; oldlambda6 = lambda6;
oldlambda7 = lambda7;
% Setting up numerical solution of differential equations
for i = 1:M
m11 = jf*(Nf/phi)-(etaf+u(i)+1/phi)*Jf(i)+q*alpha*Pf(i);
m12 = (1-jf)*(Nf/phi)+etaf*Jf(i)+(1-q)*alpha*Pf(i)
-((z*beta)/(Nm-Jm(i)))*Sf(i)*Im(i)-(1/phi+v(i))*Sf(i)
+gammaf*If(i);
m13 = u(i)*Jf(i)+v(i)*Sf(i)-(alpha+1/phi)*Pf(i);
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m14 = ((z*beta)/(Nm-Jm(i)))*Sf(i)*Im(i)-(gammaf+1/phi)*If(i);
m15 = jm*(Nm/phi)-(etam+1/phi)*Jm(i);
m16 = (1-jm)*(Nm/phi)+etam*Jm(i)-((z*beta)/(Nf-Jf(i)))*Sm(i)*If(i)
-(1/phi)*Sm(i)+gammam*Im(i);
m17 = ((z*beta)/(Nf-Jf(i)))*Sm(i)*If(i)-(gammam+1/phi)*Im(i);
m21 = jf*(Nf/phi)-(etaf+0.5*(u(i)+u(i+1))+1/phi)*(Jf(i)+h2*m11)
+q*alpha*(Pf(i)+h2*m13);
m22 = (1-jf)*(Nf/phi)+etaf*(Jf(i)+h2*m11)+(1-q)*alpha*(Pf(i)+h2*m13)
-((z*beta)/(Nm-(Jm(i)+h2*m15)))*(Sf(i)+h2*m12)*(Im(i)+h2*m17)
-(1/phi+0.5*(v(i)+v(i+1)))*(Sf(i)+h2*m12)+gammaf*(If(i)+h2*m14);
m23 = 0.5*(u(i)+u(i+1))*(Jf(i)+h2*m11)
+0.5*(v(i)+v(i+1))*(Sf(i)+h2*m12)-(alpha+1/phi)*(Pf(i)+h2*m13);
m24 = ((z*beta)/(Nm-(Jm(i)+h2*m15)))*(Sf(i)+h2*m12)*(Im(i)+h2*m17)
-(gammaf+1/phi)*(If(i)+h2*m14);
m25 = jm*(Nm/phi)-(etam+1/phi)*(Jm(i)+h2*m15);
m26 = (1-jm)*(Nm/phi)+etam*(Jm(i)+h2*m15)
-((z*beta)/(Nf-(Jf(i)+h2*m11)))*(Sm(i)+h2*m16)*(If(i)+h2*m14)
-(1/phi)*(Sm(i)+h2*m16)+gammam*(Im(i)+h2*m17);
m27 = ((z*beta)/(Nf-(Jf(i)+h2*m11)))*(Sm(i)+h2*m16)*(If(i)+h2*m14)
-(gammam+1/phi)*(Im(i)+h2*m17);
m31 = jf*(Nf/phi)-(etaf+0.5*(u(i)+u(i+1))+1/phi)*(Jf(i)+h2*m21)
+q*alpha*(Pf(i)+h2*m23);
m32 = (1-jf)*(Nf/phi)+etaf*(Jf(i)+h2*m21)+(1-q)*alpha*(Pf(i)+h2*m23)
-((z*beta)/(Nm-(Jm(i)+h2*m25)))*(Sf(i)+h2*m22)*(Im(i)+h2*m27)
-(1/phi+0.5*(v(i)+v(i+1)))*(Sf(i)+h2*m22)+gammaf*(If(i)+h2*m24);
m33 = 0.5*(u(i)+u(i+1))*(Jf(i)+h2*m21)+0.5*(v(i)+v(i+1))*(Sf(i)+h2*m22)
-(alpha+1/phi)*(Pf(i)+h2*m23);
m34 = ((z*beta)/(Nm-(Jm(i)+h2*m25)))*(Sf(i)+h2*m22)*(Im(i)+h2*m27)
-(gammaf+1/phi)*(If(i)+h2*m24);
m35 = jm*(Nm/phi)-(etam+1/phi)*(Jm(i)+h2*m25);
m36 = (1-jm)*(Nm/phi)+etam*(Jm(i)+h2*m25)
-((z*beta)/(Nf-(Jf(i)+h2*m21)))*(Sm(i)+h2*m26)*(If(i)+h2*m24)
-(1/phi)*(Sm(i)+h2*m26)+gammam*(Im(i)+h2*m27);
m37 = ((z*beta)/(Nf-(Jf(i)+h2*m21)))*(Sm(i)+h2*m26)*(If(i)+h2*m24)
-(gammam+1/phi)*(Im(i)+h2*m27);
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m41 = jf*(Nf/phi)-(etaf+u(i+1)+1/phi)*(Jf(i)+h*m31)
+q*alpha*(Pf(i)+h*m33);
m42 = (1-jf)*(Nf/phi)+etaf*(Jf(i)+h*m31)+(1-q)*alpha*(Pf(i)+h*m33)
-((z*beta)/(Nm-(Jm(i)+h*m35)))*(Sf(i)+h*m32)*(Im(i)+h*m37)
-(1/phi+v(i+1))*(Sf(i)+h*m32)+gammaf*(If(i)+h*m34);
m43 = u(i+1)*(Jf(i)+h*m31)+v(i+1)*(Sf(i)+h*m32)
-(alpha+1/phi)*(Pf(i)+h*m33);
m44 = ((z*beta)/(Nm-(Jm(i)+h*m35)))*(Sf(i)+h*m32)*(Im(i)+h*m37)
-(gammaf+1/phi)*(If(i)+h*m34);
m45 = jm*(Nm/phi)-(etam+1/phi)*(Jm(i)+h*m35);
m46 = (1-jm)*(Nm/phi)+etam*(Jm(i)+h*m35)
-((z*beta)/(Nf-(Jf(i)+h*m31)))*(Sm(i)+h*m36)*(If(i)+h*m34)
-(1/phi)*(Sm(i)+h*m36)+gammam*(Im(i)+h*m37);
m47 = ((z*beta)/(Nf-(Jf(i)+h*m31)))*(Sm(i)+h*m36)*(If(i)+h*m34)
-(gammam+1/phi)*(Im(i)+h*m37);
Jf(i+1) = Jf(i) + (h/6)*(m11 + 2*m21 + 2*m31 + m41);
Sf(i+1) = Sf(i) + (h/6)*(m12 + 2*m22 + 2*m32 + m42);
Pf(i+1) = Pf(i) + (h/6)*(m13 + 2*m23 + 2*m33 + m43);
If(i+1) = If(i) + (h/6)*(m14 + 2*m24 + 2*m34 + m44);
Jm(i+1) = Jm(i) + (h/6)*(m15 + 2*m25 + 2*m35 + m45);
Sm(i+1) = Sm(i) + (h/6)*(m16 + 2*m26 + 2*m36 + m46);
Im(i+1) = Im(i) + (h/6)*(m17 + 2*m27 + 2*m37 + m47);
end
% Setting up adjoint equations
for i = 1:M
j = M + 2 - i;
m11 = -b*u(j)*u(j)+(etaf+u(j)+1/phi)*lambda1(j)-etaf*lambda2(j)
-u(j)*lambda3(j)
+((z*beta*If(j)*Sm(j))/(Nf-Jf(j))^2)*lambda6(j)
-((z*beta*If(j)*Sm(j))/(Nf-Jf(j))^2)*lambda7(j);
m12 = -c*v(j)*v(j)-v(j)*lambda3(j)
+(((z*beta*Im(j))/(Nm-Jm(j)))+v(j)+1/phi)*lambda2(j)
-((z*beta*Im(j))/(Nm-Jm(j)))*lambda4(j);
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m13 = -q*alpha*lambda1(j)-(1-q)*alpha*lambda2(j)
+(alpha+1/phi)*lambda3(j);
m14 = -A-gammaf*lambda2(j)+(gammaf+1/phi)*lambda4(j)
+((z*beta*Sm(j))/(Nf-Jf(j)))*lambda6(j)
-((z*beta*Sm(j))/(Nf-Jf(j)))*lambda7(j);
m15 = (etam+1/phi)*lambda5(j)-etam*lambda6(j)
+((z*beta*Sf(j)*Im(j))/((Nm-Jm(j))^2))*lambda2(j)
-((z*beta*Sf(j)*Im(j))/((Nm-Jm(j))^2))*lambda4(j);
m16 = (((z*beta*If(j))/(Nf-Jf(j)))+1/phi)*lambda6(j)
-((z*beta*If(j))/(Nf-Jf(j)))*lambda7(j);
m17 = ((z*beta*Sf(j))/(Nm-Jm(j)))*lambda2(j)
-((z*beta*Sf(j))/(Nm-Jm(j)))*lambda4(j)
-gammam*lambda6(j)+(gammam+1/phi)*lambda7(j);
m21 = -b*0.5*(u(j)+u(j-1))*0.5*(u(j)+u(j-1))
+(etaf+0.5*(u(j)+u(j-1))+1/phi)*(lambda1(j)-h2*m11)
-etaf*(lambda2(j)-h2*m12)-0.5*(u(j)+u(j-1))*(lambda3(j)-h2*m13)
+((z*beta*0.5*(If(j)+If(j-1))*0.5*(Sm(j)+Sm(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1)))^2)*(lambda6(j)-h2*m16)
-((z*beta*0.5*(If(j)+If(j-1))*0.5*(Sm(j)+Sm(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1)))^2)*(lambda7(j)-h2*m17);
m22 = -c*0.5*(v(j)+v(j-1))*0.5*(v(j)+v(j-1))
+(((z*beta*0.5*(Im(j)+Im(j-1)))/(Nm-0.5*(Jm(j)+Jm(j-1))))
+0.5*(v(j)+v(j-1))+1/phi)*(lambda2(j)-h2*m12)
-0.5*(v(j)+v(j-1))*(lambda3(j)-h2*m13)
-((z*beta*0.5*(Im(j)+Im(j-1)))/(Nm-0.5*(Jm(j)+Jm(j-1))))*...
...(lambda4(j)-h2*m14);
m23 = -q*alpha*(lambda1(j)-h2*m11)-(1-q)*alpha*(lambda2(j)-h2*m12)
+(alpha+1/phi)*(lambda3(j)-h2*m13);
m24 = -A-gammaf*(lambda2(j)-h2*m12)+(gammaf+1/phi)*(lambda4(j)-h2*m14)
+((z*beta*0.5*(Sm(j)+Sm(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))*...
...(lambda6(j)-h2*m16)
-((z*beta*0.5*(Sm(j)+Sm(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))*...
...(lambda7(j)-h2*m17);
m25 = (etam+1/phi)*(lambda5(j)-h2*m15)-etam*(lambda6(j)-h2*m16)
+((z*beta*0.5*(Sf(j)+Sf(j-1))*0.5*(Im(j)+Im(j-1)))/...
...((Nm-0.5*(Jm(j)+Jm(j-1)))^2))*(lambda2(j)-h2*m12)
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-((z*beta*0.5*(Sf(j)+Sf(j-1))*0.5*(Im(j)+Im(j-1)))/...
...((Nm-0.5*(Jm(j)+Jm(j-1)))^2))*(lambda4(j)-h2*m14);
m26 = (((z*beta*0.5*(If(j)+If(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1))))+1/phi)*...
...(lambda6(j)-h2*m16)-((z*beta*0.5*(If(j)+If(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1))))*(lambda7(j)-h2*m17);
m27 = ((z*beta*0.5*(Sf(j)+Sf(j-1)))/...
...(Nm-0.5*(Jm(j)+Jm(j-1))))*(lambda2(j)-h2*m12)
-((z*beta*0.5*(Sf(j)+Sf(j-1)))/...
...(Nm-0.5*(Jm(j)+Jm(j-1))))*(lambda4(j)-h2*m14)
-gammam*(lambda6(j)-h2*m16)+(gammam+1/phi)*(lambda7(j)-h2*m17);
m31 = -b*0.5*(u(j)+u(j-1))*0.5*(u(j)+u(j-1))
+(etaf+0.5*(u(j)+u(j-1))+1/phi)*(lambda1(j)-h2*m21)
-etaf*(lambda2(j)-h2*m22)-0.5*(u(j)+u(j-1))*(lambda3(j)-h2*m23)
+((z*beta*0.5*(If(j)+If(j-1))*0.5*(Sm(j)+Sm(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1)))^2)*(lambda6(j)-h2*m26)
-((z*beta*0.5*(If(j)+If(j-1))*0.5*(Sm(j)+Sm(j-1)))/...
...(Nf-0.5*(Jf(j)+Jf(j-1)))^2)*(lambda7(j)-h2*m27);
m32 = -c*0.5*(v(j)+v(j-1))*0.5*(v(j)+v(j-1))
+(((z*beta*0.5*(Im(j)+Im(j-1)))/(Nm-0.5*(Jm(j)+Jm(j-1))))
+0.5*(v(j)+v(j-1))+1/phi)*(lambda2(j)-h2*m22)
-0.5*(v(j)+v(j-1))*(lambda3(j)-h2*m23)
-((z*beta*0.5*(Im(j)+Im(j-1)))/...
...(Nm-0.5*(Jm(j)+Jm(j-1))))*(lambda4(j)-h2*m24);
m33 = -q*alpha*(lambda1(j)-h2*m21)-(1-q)*alpha*(lambda2(j)-h2*m22)
+(alpha+1/phi)*(lambda3(j)-h2*m23);
m34 = -A-gammaf*(lambda2(j)-h2*m22)+(gammaf+1/phi)*...
...(lambda4(j)-h2*m24)
+((z*beta*0.5*(Sm(j)+Sm(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))*...
...(lambda6(j)-h2*m26)
-((z*beta*0.5*(Sm(j)+Sm(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))*...
...(lambda7(j)-h2*m27);
m35 = (etam+1/phi)*(lambda5(j)-h2*m25)-etam*(lambda6(j)-h2*m26)
+((z*beta*0.5*(Sf(j)+Sf(j-1))*0.5*(Im(j)+Im(j-1)))/...
...((Nm-0.5*(Jm(j)+Jm(j-1)))^2))*(lambda2(j)-h2*m12)
-((z*beta*0.5*(Sf(j)+Sf(j-1))*0.5*(Im(j)+Im(j-1)))/...
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...((Nm-0.5*(Jm(j)+Jm(j-1)))^2))*(lambda4(j)-h2*m14);
m36 = (((z*beta*0.5*(If(j)+If(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))+...
...1/phi)*(lambda6(j)-h2*m26)
-((z*beta*0.5*(If(j)+If(j-1)))/(Nf-0.5*(Jf(j)+Jf(j-1))))*...
...(lambda7(j)-h2*m27);
m37 = ((z*beta*0.5*(Sf(j)+Sf(j-1)))/(Nm-0.5*(Jm(j)+Jm(j-1))))*...
...(lambda2(j)-h2*m22)
-((z*beta*0.5*(Sf(j)+Sf(j-1)))/(Nm-0.5*(Jm(j)+Jm(j-1))))*...
...(lambda4(j)-h2*m24)
-gammam*(lambda6(j)-h2*m26)+(gammam+1/phi)*(lambda7(j)-h2*m27);
m41 = -b*u(j-1)*u(j-1)
+(etaf+u(j-1)+1/phi)*(lambda1(j)-h*m31)-etaf*(lambda2(j)-h*m32)
-u(j-1)*(lambda3(j)-h*m33)
+((z*beta*If(j-1)*Sm(j-1))/(Nf-Jf(j-1))^2)*(lambda6(j)-h*m36)
-((z*beta*If(j-1)*Sm(j-1))/(Nf-Jf(j-1))^2)*(lambda7(j)-h*m37);
m42 = -c*v(j-1)*v(j-1)
+(((z*beta*Im(j-1))/(Nm-Jm(j-1)))+v(j-1)+1/phi)*(lambda2(j)-h*m32)
-v(j-1)*(lambda3(j)-h*m33)-((z*beta*Im(j-1))/(Nm-Jm(j-1)))*...
...(lambda4(j)-h*m34);
m43 = -q*alpha*(lambda1(j)-h*m31)-(1-q)*alpha*(lambda2(j)-h*m32)
+(alpha+1/phi)*(lambda3(j)-h*m33);
m44 = -A-gammaf*(lambda2(j)-h*m32)+(gammaf+1/phi)*(lambda4(j)-h*m34)
+((z*beta*Sm(j-1))/(Nf-Jf(j-1)))*(lambda6(j)-h*m36)
-((z*beta*Sm(j-1))/(Nf-Jf(j-1)))*(lambda7(j)-h*m37);
m45 = (etam+1/phi)*(lambda5(j)-h*m35)-etam*(lambda6(j)-h*m36)
+((z*beta*Sf(j-1)*Im(j-1))/((Nm-Jm(j-1))^2))*(lambda2(j)-h*m32)
-((z*beta*Sf(j-1)*Im(j-1))/((Nm-Jm(j-1))^2))*(lambda4(j)-h*m34);
m46 = (((z*beta*If(j-1))/(Nf-Jf(j-1)))+1/phi)*(lambda6(j)-h*m36)
-((z*beta*If(j-1))/(Nf-Jf(j-1)))*(lambda7(j)-h*m37);
m47 = ((z*beta*Sf(j-1))/(Nm-Jm(j-1)))*(lambda2(j)-h*m32)
-((z*beta*Sf(j-1))/(Nm-Jm(j-1)))*(lambda4(j)-h*m34)
-gammam*(lambda6(j)-h*m36)+(gammam+1/phi)*(lambda7(j)-h*m37);
lambda1(j-1) = lambda1(j) - (h/6)*(m11 + 2*m21 + 2*m31 + m41);
lambda2(j-1) = lambda2(j) - (h/6)*(m12 + 2*m22 + 2*m32 + m42);
lambda3(j-1) = lambda3(j) - (h/6)*(m13 + 2*m23 + 2*m33 + m43);
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lambda4(j-1) = lambda4(j) - (h/6)*(m14 + 2*m24 + 2*m34 + m44);
lambda5(j-1) = lambda5(j) - (h/6)*(m15 + 2*m25 + 2*m35 + m45);
lambda6(j-1) = lambda6(j) - (h/6)*(m16 + 2*m26 + 2*m36 + m46);
lambda7(j-1) = lambda7(j) - (h/6)*(m17 + 2*m27 + 2*m37 + m47);
end
% Characterising the optimal control functions
tempu=(lambda1-lambda3)./(2*b);
% tempu=0;
u1 = min(2.3,max(0,tempu)); %temporary u
u = 0.5*(u1 + oldu); % final control
tempv=(lambda2-lambda3)./(2*c);
% tempv=0;
v1 = min(2.3,max(0,tempv)); %temporary v
v = 0.5*(v1 + oldv);
%Convergence test parameters
temp1 = sum(abs(oldu - u));
temp2 = sum(abs(oldv - v));
temp3 = sum(abs(oldJf - Jf));
temp4 = sum(abs(oldSf - Sf));
temp5 = sum(abs(oldPf - Pf));
temp6 = sum(abs(oldIf - If));
temp7 = sum(abs(oldJm - Jm));
temp8 = sum(abs(oldSm - Sm));
temp9 = sum(abs(oldIm - Im));
temp10 = sum(abs(oldlambda1 - lambda1));
temp11 = sum(abs(oldlambda2 - lambda2));
temp12 = sum(abs(oldlambda3 - lambda3));
temp13 = sum(abs(oldlambda4 - lambda4));
temp14 = sum(abs(oldlambda5 - lambda5));
temp15 = sum(abs(oldlambda6 - lambda6));
temp16 = sum(abs(oldlambda7 - lambda7));
test2 = max([temp1 temp2 temp3 temp4 temp5 temp6 temp7
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temp8 temp9 temp10 temp11 temp12 temp13 temp14 temp15 temp16]);
end
%Final Values
y(1,:) = t;
y(2,:) = Jf;
y(3,:) = Sf;
y(4,:) = Pf;
y(5,:) = If;
y(6,:) = Jm;
y(7,:) = Sm;
y(8,:) = Im;
y(9,:) = u;
y(10,:) = v;
% Plot the optimal functions
figure(3)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot(y(1,:),y(9,:), ’k’,’LineWidth’,3)
hold on
plot(y(1,:),y(10,:), ’--k’,’LineWidth’,3)
hold on
xlabel(’t’,’FontSize’,14)
ylabel(’Optimal control’,’FontSize’,14)
legend(’u_{jf}(t)’,’u_{sf}(t)’)
% Plot the class profiles
figure(6)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot(y(1,:),y(2,:),’--k’,’LineWidth’,3)
hold on
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plot(y(1,:),y(3,:),’-.k’,’LineWidth’,3)
hold on
plot(y(1,:),y(4,:),’k’,’LineWidth’,3)
hold on
plot(y(1,:),y(5,:),’:k’,’LineWidth’,3)
hold on
plot(y(1,:),y(6,:),’--’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(y(1,:),y(7,:),’-.’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(y(1,:),y(8,:),’:’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
xlabel(’t’,’FontSize’,14)
ylabel(’Classes’,’FontSize’,14)
legend(’J_F(t)’,’S_F(t)’,’P_F(t)’,’I_F(t)’, ’J_M(t)’, ’S_M(t)’, ’I_M(t)’)
11.2 Age-dependent ODE code
[p,alpha,q,phi,Nf,Nfo,Nm,Nmo,z,beta,jf,jm,etaf,etam,gammaf,gammam,mu]
=paramgend;
% Setting up initial conditions
T=65;
Pf0=87500; Jf0=28125; Sf0=3125; If0=6250;
Jm0=106875; Sm0=11875; Im0=6250;
Nf0=125000; Nm0=125000;
% Set up values for some parameters
M = 1000; %M+1 is # nodes
t=linspace(0,T,M+1);
h=T/M;
h2 = h/2;
% Set up initial values for classes
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Pf=zeros(1,M+1); Jf=zeros(1,M+1); Sf=zeros(1,M+1); If=zeros(1,M+1);
Jm=zeros(1,M+1); Sm=zeros(1,M+1); Im=zeros(1,M+1);
Nf=zeros(1,M+1); Nm=zeros(1,M+1);
lambdaf(1,M+1)=1; lambdam(1,M+1)=1;
test2=1;
kk=0;
errlim=0.000000001;
while test2>errlim
kk=kk+1;
disp([’IT = ’,num2str(kk),’ TEST = ’,num2str(test2)])
Pf(1)=Pf0; Jf(1)=Jf0; Sf(1)=Sf0; If(1)=If0; Nf(1)=Nf0;
Jm(1)=Jm0; Sm(1)=Sm0; Im(1)=Im0; Nm(1)=Nm0;
oldPf = Pf; oldJf = Jf; oldSf = Sf; oldIf = If; oldNf = Nf;
oldJm = Jm; oldSm = Sm; oldIm = Im; oldNm = Nm;
oldlambdaf=lambdaf; oldlambdam=lambdam;
% Solving the model equations
for i = 1:M
j=(i)./(M./T);
%disp(i)
m11 = -(alpha+mu)*Pf(i);
m12 = -(etaf+mu)*Jf(i)+q*alpha*Pf(i) ;
m13 = (1-q)*alpha*Pf(i)+etaf*Jf(i)-(z*beta*Sf(i)*lambdaf(i))
+gammaf*If(i)-mu*Sf(i);
m14 = (z*beta*Sf(i)*lambdaf(i))-(gammaf+mu)*If(i);
m15 = -mu*Nf(i);
m16 = -(etam+mu)*Jm(i);
m17 = etam*Jm(i)-(z*beta*Sm(i)*lambdam(i))+gammam*Im(i)-mu*Sm(i);
m18 = (z*beta*Sm(i)*lambdam(i))-(gammam+mu)*Im(i);
m19 = -mu*Nm(i);
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m21 = -(alpha+mu)*(Pf(i)+h2*m11);
m22 = -(etaf+mu)*(Jf(i)+h2*m12)+q*alpha*(Pf(i)+h2*m11) ;
m23 = (1-q)*alpha*(Pf(i)+h2*m11)+etaf*(Jf(i)+h2*m12)
-(z*beta*(Sf(i)+h2*m13)*lambdaf(i))+gammaf*(If(i)+h2*m14)
-mu*(Sf(i)+h2*m13);
m24 = (z*beta*(Sf(i)+h2*m13)*lambdaf(i))-(gammaf+mu)*(If(i)+h2*m14);
m25 = -mu*(Nf(i)+h2*m15);
m26 = -(etam+mu)*(Jm(i)+h2*m16);
m27 = etam*(Jm(i)+h2*m16)-(z*beta*(Sm(i)+h2*m17)*lambdam(i))
+gammam*(Im(i)+h2*m18)-mu*(Sm(i)+h2*m17);
m28 = (z*beta*(Sm(i)+h2*m17)*lambdam(i))-(gammam+mu)*(Im(i)+h2*m18);
m29 = -mu*(Nm(i)+h2*m19);
m31 = -(alpha+mu)*(Pf(i)+h2*m21);
m32 = -(etaf+mu)*(Jf(i)+h2*m22)+q*alpha*(Pf(i)+h2*m21) ;
m33 = (1-q)*alpha*(Pf(i)+h2*m21)+etaf*(Jf(i)+h2*m22)
-(z*beta*(Sf(i)+h2*m23)*lambdaf(i))+gammaf*(If(i)+h2*m24)
-mu*(Sf(i)+h2*m23);
m34 = (z*beta*(Sf(i)+h2*m23)*lambdaf(i))-(gammaf+mu)*(If(i)+h2*m24);
m35 = -mu*(Nf(i)+h2*m25);
m36 = -(etam+mu)*(Jm(i)+h2*m26);
m37 = etam*(Jm(i)+h2*m26)-(z*beta*(Sm(i)+h2*m27)*lambdam(i))
+gammam*(Im(i)+h2*m28)-mu*(Sm(i)+h2*m27);
m38 = (z*beta*(Sm(i)+h2*m27)*lambdam(i))-(gammam+mu)*(Im(i)+h2*m28);
m39 = -mu*(Nm(i)+h2*m29);
m41 = -(alpha+mu)*(Pf(i)+h*m31);
m42 = -(etaf+mu)*(Jf(i)+h*m32)+q*alpha*(Pf(i)+h*m31) ;
m43 = (1-q)*alpha*(Pf(i)+h*m31)+etaf*(Jf(i)+h*m32)
-(z*beta*(Sf(i)+h*m33)*lambdaf(i))+gammaf*(If(i)+h*m34)
-mu*(Sf(i)+h*m33);
m44 = (z*beta*(Sf(i)+h*m33)*lambdaf(i))-(gammaf+mu)*(If(i)+h*m34);
m45 = -mu*(Nf(i)+h*m35);
m46 = -(etam+mu)*(Jm(i)+h*m36);
m47 = etam*(Jm(i)+h*m36)-(z*beta*(Sm(i)+h*m37)*lambdam(i))
+gammam*(Im(i)+h*m38)-mu*(Sm(i)+h*m37);
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m48 = (z*beta*(Sm(i)+h*m37)*lambdam(i))-(gammam+mu)*(Im(i)+h*m38);
m49 = -mu*(Nm(i)+h*m39);
Pf(i+1) = Pf(i) + (h/6)*(m11 + 2*m21 + 2*m31 + m41);
Jf(i+1) = Jf(i) + (h/6)*(m12 + 2*m22 + 2*m32 + m42);
Sf(i+1) = Sf(i) + (h/6)*(m13 + 2*m23 + 2*m33 + m43);
If(i+1) = If(i) + (h/6)*(m14 + 2*m24 + 2*m34 + m44);
Nf(i+1) = Nf(i) + (h/6)*(m15 + 2*m25 + 2*m35 + m45);
Jm(i+1) = Jm(i) + (h/6)*(m16 + 2*m26 + 2*m36 + m46);
Sm(i+1) = Sm(i) + (h/6)*(m17 + 2*m27 + 2*m37 + m47);
Im(i+1) = Im(i) + (h/6)*(m18 + 2*m28 + 2*m38 + m48);
Nm(i+1) = Nm(i) + (h/6)*(m19 + 2*m29 + 2*m39 + m49);
end
% Calculating mixing matrix
A=zeros(M+1,M+1);
for i=1:M+1;
for j=1:M+1;
if j==i;
A(i,j)=0.5;
elseif j==i+1;
A(i,j)=0.25-0.125;
elseif j==i-1;
A(i,j)=0.25-0.125;
elseif j==i+2;
A(i,j)=0.125;
elseif j==i-2;
A(i,j)=0.125;
end
end
end
A(1,2)=0.25; A(1,3)=0.25; A(2,1)=0.25;
158
A(M,M+1)=0.25; A(M+1,M-1)=0.25; A(M+1,M)=0.25;
% Calculating the integral part of the force of infection
for i=1:M+1;
lambdaf(i)=sum(A(i,:).*(Im)./(Nm-Jm));
lambdam(i)=sum(A(i,:).*(If)./(Nf-Jf));
end
temp1 = sum(abs(oldPf - Pf)); temp2 = sum(abs(oldJf - Jf));
temp3 = sum(abs(oldSf - Sf)); temp4 = sum(abs(oldIf - If));
temp5 = sum(abs(oldJm - Jm)); temp6 = sum(abs(oldSm - Sm));
temp7 = sum(abs(oldIm - Im)); temp8 = sum(abs(oldNf - Nf));
temp9 = sum(abs(oldNm - Nm));
temp10 = sum(abs(oldlambdaf - lambdaf));
temp11 = sum(abs(oldlambdam - lambdam));
test2 = max([temp1 temp2 temp3 temp4 temp5 temp6 ...
... temp7 temp8 temp9 temp10 temp11]);
end
y(1,:) = t;
y(2,:) = Pf; y(3,:) = Jf; y(4,:) = Sf; y(5,:) = If; y(6,:) = Nf;
y(7,:) = Jm; y(8,:) = Sm; y(9,:) = Im; y(10,:) = Nm;
y(11,:) = lambdaf; y(12,:) = lambdam;
figure(2)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot((y(1,:)+12),y(2,:)/125000,’LineWidth’,3)
hold on
plot((y(1,:)+12),y(3,:)/125000,’--k’,’LineWidth’,3)
hold on
plot((y(1,:)+12),y(4,:)/125000,’-.k’,’LineWidth’,3)
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hold on
plot((y(1,:)+12),y(5,:)/125000,’:k’,’LineWidth’,3)
hold on
plot((y(1,:)+12),y(6,:)/125000,’k’,’LineWidth’,3)
hold on
plot((y(1,:)+12),y(7,:)/125000,’--’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot((y(1,:)+12),y(8,:)/125000,’-.’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot((y(1,:)+12),y(9,:)/125000,’:’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot((y(1,:)+12),y(10,:)/125000, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
legend(’P_F’, ’J_F’, ’S_F’, ’I_F’, ’N_F’, ’J_M’, ’S_M’, ’I_M’, ’N_M’)
xlabel(’age’)
ylabel(’Population’)
figure(3)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot((y(1,:)+12),y(5,:)/125000,’k’,’LineWidth’,3)
hold on
plot((y(1,:)+12),y(9,:)/125000, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
xlabel(’age’)
ylabel(’Proportion Infected’)
11.3 Matlab Code for PDE Model
%This program will use the ENO UNO scheme (Essentially Non-Oscillatory
% Uniformly high Order) to do the advection.
%Ref Harten, A. and Osher, S.
%Uniformly High-Order Accurate Nonoscillatory Schemes. I.
%SIAM Journal on Numerical Analysis, 24, 2, 279-309. 1987
clear; clc;
% Set up grid
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n=148; da=1/n; a=(12:0.5:85.5); C=0.1; dt=C.*da; c=dt./da;
% Final Time
N1=n/C; % Final time is N2*dt*74
N2=800;
p=0.7;
Nf=125000;
phi=74;
% Initial Conditions
Pfstart(1:n)=0.0; Jfstart(1:n)=0.0; Sfstart(1:n)=0.0; Ifstart(1:n)=0.0;
Jmstart(1:n)=0.0; Smstart(1:n)=0.0; Imstart(1:n)=0.0;
Nfstart(1:n)=0.0; Nmstart(1:n)=0.0;
lambdaf=1; lambdam=1;
% Initial Conditions
Nfstart=exp(-(0.0000189*exp(0.1*(a))));
Nmstart=exp(-(0.0000354*exp(0.098*(a))));
L=da; l=7/64;
Pfstart=Nfstart.*(1-0.9./(1+exp(16.3-a))).*p.*...
...(cos((pi*((a-12)./74-L))/(2*l))).^3; j1=ceil((L+l)/da); Pfstart(j1:n)=0;
Jfstart=((1-0.9./(1+exp(16.3-a))).*Nfstart-Pfstart);
Ifstart=(0.23.*exp(-((a-21.8)./12.5).^2)).*(0.9./(1+exp(16.3-a))).*Nfstart;
Sfstart=(1-0.23.*exp(-((a-21.8)./12.5).^2)).*...
...(0.9./(1+exp(16.3-a))).*Nfstart;
Smstart=(1-0.23.*exp(-((a-21.8)./12.5).^2)).*...
...(0.9./(1+exp(13.3-0.8*a))).*Nmstart;
Jmstart=(1-0.9./(1+exp(13.3-0.8*a))).*Nmstart;
Imstart=(0.23.*exp(-((a-21.8)./12.5).^2)).*...
...(0.9./(1+exp(13.3-0.8*a))).*Nmstart;
Pfeno4=Pfstart; Jfeno4=Jfstart; Sfeno4=Sfstart; Ifeno4=Ifstart;
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Jmeno4=Jmstart; Smeno4=Smstart; Imeno4=Imstart;
Nfeno4=Nfstart; Nmeno4=Nmstart;
% Parameter values
beta=0.6; gammaf=0.8; gammam=0.8;
for j=1:N2;
Pfeno4star=enoadvection(Pfeno4,n,da,dt,2);
Jfeno4star=enoadvection(Jfeno4,n,da,dt,2);
Sfeno4star=enoadvection(Sfeno4,n,da,dt,2);
Ifeno4star=enoadvection(Ifeno4,n,da,dt,2);
Jmeno4star=enoadvection(Jmeno4,n,da,dt,2);
Smeno4star=enoadvection(Smeno4,n,da,dt,2);
Imeno4star=enoadvection(Imeno4,n,da,dt,2);
Nfeno4star=enoadvection(Nfeno4,n,da,dt,2);
Nmeno4star=enoadvection(Nmeno4,n,da,dt,2);
for i=2:n-1
k=(i).*da.*74;
if k <= 7
etaf=((exp((-((k+12)-16.95)^2)/(2*(1.33^2))))/(1.33*sqrt(2*pi)));
etam=((exp(-((k+12)-16.58)^2/(2*(1.14^2))))/(1.14*sqrt(2*pi)));
else
etaf=0.06; etam=0.06;
end
if k < 4
zm=0.1411*(k+12);
zf=0.1411*(k+12);
elseif k >= 4 && k <= 57;
zm=2.93-0.042*(k+12);
zf=2.93-0.042*(k+12);
else
zm=0;
zf=0;
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end
alpha=0.003*(k+12);
% Contact Matrix A
A=zeros(n,n);
for ii=1:n;
for jj=1:n;
if jj==ii;
A(ii,jj)=0.5;
elseif jj==ii+1;
A(ii,jj)=0.125;
elseif jj==ii-1;
A(ii,jj)=0.125;
elseif jj==ii+2;
A(ii,jj)=0.125;
elseif jj==ii-2;
A(ii,jj)=0.125;
end
end
end
A(1,2)=0.25; A(1,3)=0.25; A(2,1)=0.25;
A(n-1,n)=0.25; A(n,n-2)=0.25; A(n,n-1)=0.25;
% Integral part of lambda
lambdaf(i)=sum(A(i,:).*(Imeno4)./(Nmeno4-Jmeno4));
lambdam(i)=sum(A(i,:).*(Ifeno4)./(Nfeno4-Jfeno4));
% Solving the equations
Pfneweno4(i)=Pfeno4star(i)
+74.*( -dt.*(alpha+1.*0.0000189*exp(0.1*(k+12)))*Pfeno4(i) );
Jfneweno4(i)=Jfeno4star(i)
+74.*( +dt.*(-(etaf+1.*0.0000189*exp(0.1*(k+12)))*Jfeno4(i)+...
...(0.616*alpha+0.05)/(1+alpha)*alpha*Pfeno4(i)) );
Sfneweno4(i)=Sfeno4star(i)+
74.*( +dt.*((1-(0.616*alpha+0.05)/(1+alpha))*alpha*Pfeno4(i)+...
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...etaf*Jfeno4(i)-(zf*beta*lambdaf(i)+...
...1.*0.0000189*exp(0.1*(k+12)))*Sfeno4(i)+gammaf*Ifeno4(i)) );
Ifneweno4(i)=Ifeno4star(i)
+74.*( +dt.*(zf*beta*Sfeno4(i)*lambdaf(i)-...
...(gammaf+1.*0.0000189*exp(0.1*(k+12)))*Ifeno4(i)) );
Jmneweno4(i)=Jmeno4star(i)
+74.*( -dt.*((etam+(1.*0.0000347*exp(0.098*(k+12))))*Jmeno4(i)) );
Smneweno4(i)=Smeno4star(i)
+74.*( +dt.*(etam*Jmeno4(i)-(zm*beta*lambdam(i)+...
...(1.*0.0000347*exp(0.098*(k+12))))*Smeno4(i)+gammam*Imeno4(i)) );
Imneweno4(i)=Imeno4star(i)
+74.*( +dt.*(zm*beta*Smeno4(i)*lambdam(i)-...
...(gammam+(1.*0.0000347*exp(0.098*(k+12))))*Imeno4(i)) );
Nfneweno4(i)=Nfeno4star(i)
+74.*( -dt.*(1.*0.0000189*exp(0.1*(k+12)))*Nfeno4(i) );
Nmneweno4(i)=Nmeno4star(i)
+74.*( -dt.*(1.*0.0000347*exp(0.098*(k+12)))*Nmeno4(i) );
end
% Boundary Conditions
Nfneweno4(1)=1;
Nfneweno4(n)=Nfneweno4(n-1);
Nmneweno4(1)=1;
Nmneweno4(n)=Nmneweno4(n-1);
Pfneweno4(1)=p.*(1-0.9./(1+exp(16.3-12))).*Nfneweno4(1);
Pfneweno4(n)=Pfneweno4(n-1);
Ifneweno4(1)=(0.23.*exp(-((12-21.8)./12.5).^2)).*...
...(0.9./(1+exp(16.3-12))).*Nfneweno4(1);
Ifneweno4(n)=Ifneweno4(n-1);
Sfneweno4(1)=(1-0.23.*exp(-((12-21.8)./12.5).^2)).*...
...(0.9./(1+exp(16.3-12))).*Nfneweno4(1);
Sfneweno4(n)=Sfneweno4(n-1);
Jfneweno4(1)=((1-0.9./(1+exp(16.3-12))).*Nfneweno4(1)-Pfneweno4(1));
Jfneweno4(n)=Jfneweno4(n-1);
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Imneweno4(1)=(0.23.*exp(-((12-21.8)./12.5).^2)).*...
...(0.9./(1+exp(13.3-0.8*12))).*Nmneweno4(1);
Imneweno4(n)=Imneweno4(n-1);
Smneweno4(1)=(1-0.23.*exp(-((12-21.8)./12.5).^2)).*...
...(0.9./(1+exp(13.3-0.8*12))).*Nmneweno4(1);
Smneweno4(n)=Smneweno4(n-1);
Jmneweno4(1)=(1-0.9./(1+exp(13.3-0.8*12))).*Nmneweno4(1);
Jmneweno4(n)=Jmneweno4(n-1);
Pfeno4=Pfneweno4; Jfeno4=Jfneweno4; Sfeno4=Sfneweno4;
Ifeno4=Ifneweno4;
Jmeno4=Jmneweno4; Smeno4=Smneweno4; Imeno4=Imneweno4;
Nfeno4=Nfneweno4; Nmeno4=Nmneweno4;
% Class sizes over time
Pfsum(j)=sum(Pfeno4); Jfsum(j)=sum(Jfeno4); Sfsum(j)=sum(Sfeno4);
Ifsum(j)=sum(Ifeno4);
Jmsum(j)=sum(Jmeno4); Smsum(j)=sum(Smeno4); Imsum(j)=sum(Imeno4);
Nfsum(j)=sum(Nfeno4); Nmsum(j)=sum(Nmeno4);
end
% Plot the classes after final time;
the difference between the classes initially and after final time;
the class sizes over time and the initial conditions.
figure(1)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot(a,Pfeno4,’LineWidth’,3)
hold on
plot(a,Jfeno4,’--k’,’LineWidth’,3)
hold on
plot(a,Sfeno4,’-.k’,’LineWidth’,3)
hold on
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plot(a,Ifeno4,’:k’,’LineWidth’,3)
hold on
plot(a,Nfeno4,’k’,’LineWidth’,3)
hold on
plot(a,Jmeno4,’--’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Smeno4,’-.’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Imeno4,’:’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Nmeno4, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
legend(’P_F’, ’J_F’, ’S_F’, ’I_F’, ’N_F’, ’J_M’, ’S_M’, ’I_M’, ’N_M’)
xlabel(’age’)
ylabel(’Population’)
disp(74.*dt.*N2)
figure(2)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot(74.*dt.*(1:N2),Pfsum,’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Jfsum,’--k’,’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Sfsum,’-.k’,’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Ifsum,’:k’,’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Nfsum,’k’,’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Jmsum,’--’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Smsum,’-.’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(74.*dt.*(1:N2),Imsum,’:’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
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plot(74.*dt.*(1:N2),Nmsum,’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
legend(’P_F’, ’J_F’, ’S_F’, ’I_F’, ’N_F’, ’J_M’, ’S_M’, ’I_M’, ’N_M’)
xlabel(’time’)
ylabel(’Population’)
figure(3)
set(gca,’FontSize’,14)
set(legend,’FontSize’,14)
plot(a,Pfstart,’LineWidth’,3)
hold on
plot(a,Jfstart,’--k’,’LineWidth’,3)
hold on
plot(a,Sfstart,’-.k’,’LineWidth’,3)
hold on
plot(a,Ifstart,’:k’,’LineWidth’,3)
hold on
plot(a,Nfstart,’k’,’LineWidth’,3)
hold on
plot(a,Jmstart,’--’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Smstart,’-.’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Imstart,’:’, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
plot(a,Nmstart, ’Color’,[0.8, 0.8, 0.8],’LineWidth’,3)
hold on
legend(’P_F’, ’J_F’, ’S_F’, ’I_F’, ’N_F’, ’J_M’, ’S_M’, ’I_M’, ’N_M’)
xlabel(’age’)
ylabel(’Population’)
%sum(Jfstart)
figure; plot((a),Pfstart,’k’,(a),Pfeno4,’b’)
figure; plot((a),Jfstart,’k’,(a),Jfeno4,’r’)
figure; plot((a),Sfstart,’k’,(a),Sfeno4,’b’)
figure; plot((a),Ifstart,’k’,(a),Ifeno4,’r’)
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figure; plot((a),Jmstart,’k’,(a),Jmeno4,’b’)
figure; plot((a),Smstart,’k’,(a),Smeno4,’r’)
figure; plot((a),Imstart,’k’,(a),Imeno4,’b’)
figure; plot((a),Nfstart,’k’,(a),Nfeno4,’r’)
figure; plot((a),Nmstart,’k’,(a),Nmeno4,’b’)
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